Document:

EX-10.1

 Exhibit 10.1 

***Text Omitted and Filed Separately with 

the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. 

EXECUTION VERSION 

LICENSE AND COLLABORATION AGREEMENT 

This LICENSE AND COLLABORATION AGREEMENT (the
“Agreement”) is entered into as of August 11, 2014 (the “Execution Date”) between MANNKIND CORPORATION, a Delaware corporation,
having a principal place of business at 28903 North Avenue Paine, Valencia, California 91355, USA (“MannKind”), TECHNOSPHERE INTERNATIONAL C.V., a Dutch limited partnership,
having a principal place of business at 1097 JB Amsterdam, Prins Bernhardplein 200, Netherlands (“TICV”), MANNKIND NETHERLANDS B.V., a Dutch limited liability
company, having a principal place of business at 1097 JB Amsterdam, Prins Bernhardplein 200, Netherlands (“BV” and together with MannKind and TICV, jointly and severally, the “Licensors”), and
SANOFI-AVENTIS DEUTSCHLAND GMBH, a company organized and existing under the laws of Germany with a place of business at 65926 Frankfurt am Main, Germany (“Sanofi”). 

RECITALS 

WHEREAS, MannKind has developed and has obtained regulatory approval in the United States (as defined below) of Product
(as defined below) for improvement of glycemic control in adult patients with diabetes and owns or controls certain patents, know-how and other intellectual property related to Product; 

WHEREAS, Sanofi is engaged in the development and commercialization of pharmaceutical products; and 

WHEREAS, Sanofi desires to obtain from the Licensors, and the Licensors desire to grant to Sanofi, certain exclusive
rights and licenses to develop and commercialize Product in the Territory subject to the terms and conditions of this Agreement. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 

DEFINITIONS 
 As
used in this Agreement, the following terms shall have the meanings set out in this Article I unless otherwise specifically provided herein. 

1.1 “Adverse Ruling” shall have the meaning set forth in Section 12.2(a). 

1.2 “Affiliate” of a Party shall mean any Person that, directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used in this Section 1.2, 

  
 1. 

 CONFIDENTIAL 
  

“control” shall mean: (a) direct or indirect beneficial ownership of at least 50% (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) of the voting share capital or other equity interest in such Person; or (b) any other arrangement whereby a Person, acting alone, or a “group,” as defined in Rule 13d-3 of the Securities Exchange Act of
1934, as amended, of Third Parties (a “Group”), (i) controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or (ii) has the ability to cause the
direction of the management or policies of a corporation or other entity. For clarity, TICV and BV are Affiliates of MannKind. 
 1.3
“Alliance Manager” shall have the meaning set forth in Section 3.2. 
 1.4 “Allowable
Expenses” shall have the meaning set forth on EXHIBIT B hereto. 
 1.5
“[...***...]” shall mean [...***...] 
 1.6 “Antitrust Laws” shall mean the Clayton
Act, as amended, the HSR Act, and all other applicable laws and regulations issued by a Governmental Authority, whether domestic or foreign, that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of
monopolization or restraint of trade or lessening of competition. 
 1.7 “Applicable Laws” shall mean the
applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including
Marketing Approvals) of or from any court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item. 

1.8 “Audited Party” shall have the meaning set forth in Section 7.5. 

1.9 “Auditing Party” shall have the meaning set forth in Section 7.5. 

1.10 “Auditor” shall have the meaning set forth in Section 7.5. 

1.11 “Bankruptcy Laws” shall have the meaning set forth in Section 13.6. 

1.12 “Biosimilar Application” shall have the meaning set forth in Section 9.8(a). 

1.13 “Breaching Party” shall have the meaning set forth in Section 12.2(a). 

1.14 “[...***...] Country” shall mean any of the following countries: [...***...]. 

1.15 “Budget(s)” shall mean the Development Budget, and the Commercialization Budget. 

1.16 “Business Day” shall mean a day other than a Saturday or Sunday or any public holiday in the United States,
France or Germany. 

  
 ***Confidential Treatment
Requested 
 2. 

 CONFIDENTIAL 
  

1.17 “Calendar Quarter” shall mean a period of three consecutive months during a Calendar Year beginning on and
including January 1st, April 1st, July 1st or October 1st. 
 1.18 “Calendar Year” shall mean a period of 12
consecutive months beginning on and including January 1st. 
 1.19
“Challenge” shall have the meaning set forth in Section 12.4. 
 1.20 “Change of
Control” means, with respect to a Party (or in the case of Licensors and solely for purposes of this definition, any of MannKind, TICV or BV separately): 

(a) (i) the acquisition by a Third Party or Group, in one transaction or a series of related transactions, of direct or indirect
beneficial ownership of more than fifty percent (50%) of the outstanding voting equity securities of a Party; (ii) a merger or consolidation involving a Party, as a result of which a Third Party or a Group acquires direct or indirect
beneficial ownership of more than fifty percent (50%) of the voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (iii) a sale of all or substantially all of the assets of a Party in one
transaction or a series of related transactions to a Third Party or a Group; or 
 (b) the acquisition by a [...***...], in one
transaction or a series of related transactions, of: (i) majority control of the board of directors or equivalent governing body of such Party; or (ii) direct or indirect beneficial ownership of more than [...***...] percent
([...***...]%) of the outstanding voting equity securities of a Party; or (iii) the ability to cause the direction of the management or allocation of corporate resources of such Party (provided that [...***...], shall not be deemed
to be a Change of Control under this sub-clause (iii) so long as [...***...]; or (iv) all or substantially all of the assets of such Party related to the transactions contemplated by this Agreement. 

1.21 “CMC” shall mean chemistry, manufacturing and controls. 

1.22 “Commercialize” (including any variations such as “Commercialization” or
“Commercializing”) shall mean, with respect to a Product, to promote, market, distribute, sell (and offer for sale or contract to sell), import, or otherwise commercially exploit or provide product support for such Product.

 1.23 “Commercialization Budget” shall mean the budget for activities within the Commercialization Plan for
conducting Commercialization activities with respect to Product in the Field in the Territory established on a Calendar Year basis by Sanofi for review and approval by the JAC. 

  
 ***Confidential Treatment
Requested 
 3. 

 1.24 “Commercialization Plan” shall have the meaning set forth in
Section 5.1(b). 
 1.25 “Commercially Reasonable Efforts” shall mean: 

(a) With respect to efforts of Sanofi as measured on a country by country basis: that measure of efforts and resources consistent with
Sanofi’s and its Affiliates’ own efforts and resources applied to its and their own compounds, devices and products of a similar value, stage of development, life cycle and commercial potential, taking into account all relevant factors
including issues of safety and efficacy, product profile, difficulty in developing or manufacturing the applicable Product or sourcing raw materials necessary therefor, competitiveness of alternative third party products in the marketplace,
regulatory approvals (including pricing approvals), pricing and reimbursement, the patent or other proprietary position of the applicable Product, the regulatory requirements involved and the potential profitability of the applicable Product for
Sanofi and its Affiliates as compared to the expected profitability of other products of its then current or in development product portfolios; and 

(b) With respect to efforts of the Licensors: the use of reasonable efforts and resources, in good faith, consistent with the efforts
and resources that a pharmaceutical or biotechnology company of similar size and situation to the Licensors, in the exercise of prudent legal, medical, scientific and business judgment, would commonly apply to its own compounds, devices and products
of a similar value, stage of development, life cycle and commercial potential to the applicable Product. 
 1.26
“Commercial Strategy” shall have the meaning set forth in Section 5.1(a). 
 1.27
“Competing Product” shall mean any product (other than Product) containing or comprising any formulation of Insulin that is or is intended to be primarily administered in or through the lungs. 

1.28 “Complaining Party” shall have the meaning set forth in Section 12.2(a). 

1.29 “Confidential Information” shall have the meaning set forth in Section 8.1. 

1.30 “Confidentiality Agreement” shall mean that certain confidentiality agreement, dated May 31, 2013,
between MannKind and Sanofi, as amended. 
 1.31 “Control” (including any variations such as
“Controlled” and “Controlling”), in the context of intellectual property rights and Information, shall mean possession by a Party (whether by ownership or license, other than pursuant to this
Agreement) of the ability to grant the applicable license under this Agreement, without violating the terms of an agreement with a Third Party. 

1.32 “Data” shall mean any and all scientific, technical or test data pertaining to Product that is generated by
or on behalf of Sanofi or its Affiliates or by or on behalf of MannKind or a MannKind Affiliate in the course of performance of studies or activities contemplated by the Development Plan or this Agreement, including research data, clinical
pharmacology data, CMC data (including analytical and quality control data and stability data), 

  
 4. 

 CONFIDENTIAL 
  

pre-clinical data, clinical data and pharmacoeconomic data, including any and all such data in publications, presentations or submissions made in association with a Regulatory Filing with respect
to Product. 
 1.33 “Development” or “Develop” shall mean, with respect to a Product,
those pre-clinical and clinical drug development activities that are necessary or useful to obtain or maintain Marketing Approval, including activities directed to label expansion after obtaining Marketing Approval that are set forth in the
Development Plan, in the applicable regulatory jurisdiction, whether alone or for use together, or in combination, with another active agent or pharmaceutical product, including discovery, test method development, stability testing, toxicology
(including [...***...] toxicology studies), formulation or process development, CMC development, analytical method validation, manufacturing process validation, cleaning validation, post-Marketing Approval changes, statistical analysis,
development report writing, preclinical and clinical studies, regulatory filing submission and approval, all activities of the medical affairs, pharmacoviligance, regulatory, medical liaison and health outcome liaison groups with respect to the
activities contemplated under this Agreement, and any other activities set forth in any Development Plan. 
 1.34
“Development Budget” shall mean the budget, established on a Calendar Year basis and reviewed and approved by the JAC, for activities within the Development Plan for conducting Development activities with respect to
Product in the Field in the Territory, established on a Calendar Year basis by Sanofi for review and approval by the JAC. 
 1.35
“Development Plan” shall mean the written plan setting forth the studies and other activities to be performed by the Parties with respect to the Development of Product in the Field in the Territory, established by Sanofi
and reviewed and approved by the JAC, as may be amended. A summary of the initial Development Plan has been separately delivered by letter as of the Execution Date. 

1.36 “Development Term” shall mean the period during which the Parties are conducting studies and activities
with respect to Product in the Field in the Territory under the Development Plan, commencing on the Effective Date and ending upon the completion of all studies and activities specified in the Development Plan or earlier termination of this
Agreement. 
 1.37 “Device” shall mean any device through which a Formulation may be administered by
inhalation, including the devices Controlled by the Licensors, such as the DreamboatTM, MedTone® and CricketTM inhalers. 

1.38 “Diabetes” shall mean diabetes mellitus, regardless of type. 

1.39 “[...***...] shall mean, [...***...]. 

  
 ***Confidential Treatment
Requested 
 5. 

 CONFIDENTIAL 
  

1.40 “Disclosing Party” shall have the meaning set forth in Section 8.1. 

1.41 “Effective Date” shall have the meaning set forth in Section 15.16. 

1.42 “Export Control Laws” shall mean all applicable laws and regulations relating to (a) sanctions and
embargoes imposed by any governmental authority in the Territory or (b) the export or re-export of commodities, technologies, or services, including, but not limited to, the Export Administration Act of 1979, 24 U.S.C. §§ 2401-2420,
the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et seq., the Arms Export Control Act, 22 U.S.C. §§ 2778 and 2779, and the International
Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 
 1.43 “FCPA”
shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. § 78dd-1, et seq.) as amended. 
 1.44 “FDA”
shall mean the United States Food and Drug Administration, or any agency that is responsible for approving the sale of pharmaceutical products in the United States. 

1.45 “Field” shall mean the prevention or treatment of diseases and other conditions in all indications in
humans and animals. 
 1.46 “Filings” shall have the meaning set forth in Section 15.16. 

1.47 “First Commercial Sale” shall mean, on a Competing Product-by-Competing Product and country-by-country
basis, the first bona fide, arm’s length sale by, on behalf of or under the authority of Sanofi, its Affiliates or sublicensees to a Third Party, of Competing Product in a country in the Field in the Territory following receipt of
Marketing Approval in such country. Sales of a Competing Product for registration samples, clinical trials, compassionate use, named patient use and inter-company transfers to Affiliates of a Party will not constitute a First Commercial Sale. 

1.48 “Formulation” shall mean a formulation of an active pharmaceutical ingredient suitable for pulmonary
administration based upon or incorporating the drug delivery technology Controlled by the Licensors that involves amorphous or crystalline diketopiperazine microparticles. 

1.49 “[...***...] Milestone” shall mean [...***...]. 

  
 ***Confidential Treatment
Requested 
 6. 

 CONFIDENTIAL 
  

[...***...] For the avoidance of doubt, if [...***...]. 

1.50 “Governmental Authority” shall mean any national, international, federal, state, provincial or local
government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any
court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 
 1.51
“Government Health Care Program” shall mean the Medicare Part D Coverage Gap Discount program (as defined in 42 U.S.C. 1395w-114A, as amended), the Medicaid program (Title XIX of the Social Security Act), the Department
of Veterans Affairs FSS Program, TRICARE, and the Public Health Service 340B Program, and any similar federal, state, and local governmental health care plans and programs. 

1.52 “Government Health Care Program Contract” shall mean, with respect to Product, any agreements that are
necessary to give effect to any Government Health Care Program (whether or not such agreements constitute “government contracts” as such term is used in connection with government procurement, e.g. 340B Pharmaceutical Pricing Agreements
and Medicaid Drug Rebate Agreements). 
 1.53 “HSR Act” shall have the meaning set forth in
Section 15.16. 
 1.54 “HSR Filing Date” shall have the meaning set forth in Section 15.16. 

1.55 “ICH” shall mean the International Conference on Harmonization (of Technical Requirements for
Registration of Pharmaceuticals for Human Use). 
 1.56 “IFRS” shall mean the international financial
reporting standards. 
 1.57 “IND” shall mean an Investigational New Drug Application (including any
amendments thereto) filed with the FDA pursuant to 21 C.F.R. §312 before commencement of clinical trials of a pharmaceutical product, including clinical trial applications, or any comparable filing with any Regulatory Authority in any country
or jurisdiction in the Territory other than the United States. 
 1.58 “Indemnitee” shall have the meaning set
forth in Section 11.3. 
 1.59 “Indemnitor” shall have the meaning set forth in Section 11.3. 

1.60 “Information” shall mean all technical, scientific, marketing, financial, commercial and other know-how and
information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs,

  
 ***Confidential Treatment
Requested 
 7. 

 CONFIDENTIAL 
  

apparatuses, prototypes, specifications, data, including raw data, results, customer lists, marketing materials, and other material, including: drug discovery and development technology;
biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols; assays and biological
methodology; manufacturing and quality control procedures and data, including test procedures; and synthesis, purification and isolation techniques (whether or not confidential, proprietary, patented or patentable) in written, electronic or any
other form now known or hereafter developed. 
 1.61 “Insulin” shall mean human insulin and analogs and
derivatives thereof. 
 1.62 “[...***...] Milestone” shall mean [...***...]. 

1.63 “[...***...] Milestone” shall mean [...***...]. 

1.64 “Intervening Event” shall have the meaning set forth in Section 15.1. 

1.65 “Inventions” shall mean any and all inventions, discoveries, improvements, processes and techniques
invented in the course of performance of studies or activities contemplated by the Development Plan or this Agreement, whether or not patentable or included in any claim of Patents and Patent applications, constituting an improvement or line
extension associated with Product. 
 1.66 “JAC” shall have the meaning set forth in Section 3.1(a). 

1.67 “Joint Inventions” shall mean any and all Inventions invented by one or more employees or contractors of
Sanofi or any of its Affiliates and one or more employees or contractors of the Licensors or any MannKind Affiliate. 
 1.68
“Joint Patents” shall mean all Patents claiming any Joint Invention. 
 1.69
“Losses” shall have the meaning set forth in Section 11.1. 
 1.70 “MAA”
shall mean a New Drug Application as defined in Title 21 of the U.S. Code of Federal Regulations, Section 314.80, et seq., or comparable filing with any Regulatory Authority in any country or jurisdiction in the Territory other than the United
States, and all amendments and supplements thereto, which is filed with the FDA, including all documents, 

  
 ***Confidential Treatment
Requested 
 8. 

 CONFIDENTIAL 
  

data, and other information concerning a pharmaceutical product which are necessary for gaining Marketing Approval in the Territory. 

1.71 “Major Market” shall mean any of the following countries: [...***...]. 

1.72 “MannKind Affiliate” shall mean any Affiliate of the Licensors that is controlled (as such term is defined
in Section 1.2) by any of the Licensors. For clarity, TICV and BV are MannKind Affiliates. 
 1.73 “MannKind
Indemnitees” shall have the meaning set forth in Section 11.1. 
 1.74 “MannKind Know-How”
shall mean all Information not included in the MannKind Patents Controlled by the Licensors or any MannKind Affiliate as of the Effective Date or during the Term that is necessary or useful for the Development, Manufacture, use or Commercialization
of Product in the Field, including all such Information related to the design and utility of the Device and to the creation of a Formulation, and any replication or any part of such Information. 

1.75 “MannKind Patents” shall mean all Patents Controlled by MannKind or any MannKind Affiliate as of the
Effective Date or during the Term that claim or disclose Product or its components, or are necessary or useful for the Development, Manufacture, use or Commercialization of Product in the Field in the Territory, including all such Patents claiming
or covering the design or utility of a Device or a Formulation, but excluding any Joint Patents. The MannKind Patents existing as of the Execution Date are listed in EXHIBIT C. 

1.76 “MannKind Technology” shall mean all MannKind Know-How, MannKind Patents and MannKind’s or a MannKind
Affiliate’s interest in Joint Patents and Joint Inventions. 
 1.77 “MannKind Trademarks” shall have the
meaning set forth on EXHIBIT A. 
 1.78 “Manufacture” or
“Manufacturing” shall mean all activities related to the manufacturing, packaging and supply of a pharmaceutical product, or any component thereof, including manufacturing product, components thereof or supplies for
Development, clinical trials, and/or commercial sale; in-process and semi-finished product testing; release of product or any components thereof; quality assurance activities related to manufacturing and release of product; ongoing stability tests
and regulatory activities related to any of the foregoing, and packaging of products ready for distribution and sale. 
 1.79
“Marketing Approval” shall mean all approvals, licenses, registrations or authorizations of Regulatory Authorities in a country necessary for the Manufacture, use, storage and Commercialization of Product in such country.
For countries where governmental approval is required for pricing or reimbursement for Product to be reimbursed by national health insurance (or its local equivalent), “Marketing Approval” shall not be deemed to occur until such pricing or
reimbursement approval is obtained. 

  
 ***Confidential Treatment
Requested 
 9. 

 1.80 “Master Files” shall mean all drug master files and device
master files relating to Product filed or that may be filed with any Regulatory Authority in any country or jurisdiction in the Territory. 

1.81 “Materials” shall have the meaning set forth in Section 4.5. 

1.82 “NDC” shall have the meaning set forth in Section 13.3(c). 

1.83 “Net Sales” shall mean, with respect to a Product for any period, the gross amount billed or invoiced by
Sanofi or its Affiliates for the sale of a Product to Third Parties, less the following deductions from such gross amounts, solely to the extent allocable to such Product and actually incurred, allowed or accrued (and not previously deducted in
calculating the amount invoiced): 
 (a) normal and customary trade, quantity and prompt settlement discounts (including chargebacks
and allowances) actually allowed; 
 (b) amounts repaid or credited by reason of rejection, return or recall of Product; 

(c) rebates or bona fide retroactive price reductions; 

(d) freight, postage, shipping and insurance expenses to the extent that such items are included in the gross amount invoiced; 

(e) customs and excise duties and other taxes or duties related to the sales to the extent that such items are included in the gross
amount invoiced; 
 (f) rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority
such as, by way of illustration, federal or state Medicaid, Medicare or similar state program or equivalent foreign governmental program; 

(g) the portion of administrative fees paid during the relevant time period to group purchasing organizations or pharmaceutical benefit
managers relating to such product; and 
 (h) bad debts and uncollectable invoiced amounts relating to sales of Product that are
actually written off in accordance with IFRS, consistently applied throughout Sanofi and its Affiliates, provided that any such amounts subsequently collected will be included in Net Sales. 

For purposes of determining Net Sales, a Product shall be deemed to be sold when invoiced and a “sale” shall not include
transfers or dispositions of such Product for pre-clinical or clinical purposes, compassionate use or as samples, in each case, without charge. Sanofi’s or its Affiliates’ transfer of any Product to an Affiliate or sublicensee shall not
result in any Net Sales unless the transferee is an end user. In the event of any sale or other disposition of a Product for any consideration other than exclusively monetary consideration on bona fide arm’s-length terms, then for
purposes of calculating Net Sales under this Agreement, such Product shall  

  
 10. 

 CONFIDENTIAL 
  

be deemed to be sold exclusively for money at the weighted (by sales volume) average sale price of such Product in bona fide arm’s-length transactions (when sold alone, and not
with other products) during the applicable Calendar Quarter in the country in which such sale or other disposition occurred.  
 To
the extent that Sanofi or its Affiliate provides to any Third Party purchaser of Product rebates, discounts or other forms of reimbursements within the permissible deductions described in clauses (a), (c) and (f) above that, in each
case, are applicable both to Product and one or more other products, such rebates, discounts and reimbursements shall be allocated (for purposes of the deductions used in calculating Net Sales as above) between the Product and such other product(s)
in a manner such that the reimbursements, discounts and reimbursements allocated to the Product are the lesser of: (x) a pro rata allocation between the Product and such other product(s) that does not unfairly or inappropriately bias the
level of discounting against the Product (as compared to the other product(s)), or (y) the weighted average of rebates, discounts and reimbursements that are granted by Sanofi or its Affiliate with respect to Product (during the applicable
Calendar Quarter) when Product is sold outside of any such arrangement. 
 All adjustments for any of clauses (a) to (h) above
will be made in a manner consistent with adjustments applied to comparable products of Sanofi and its Affiliates and will not be applied disproportionately with respect to Product. In no event shall any particular amount described in
clauses (a) to (h) above, be deducted more than once in calculating Net Sales (i.e., no double-counting of deductions), and no such amount deducted in calculating Net Sales shall be considered an Allowable Expense. 

Except as expressly set forth above in this Section 1.83, Net Sales shall be calculated in accordance with the standard internal policies
and procedures of Sanofi and its Affiliates, consistently applied across all comparable products of Sanofi and its Affiliates, which must be in accordance with IFRS. 

1.84 “Notice Period” shall have the meaning set forth in Section 12.2(a). 

1.85 “Partial Termination” shall have the meaning set forth in Section 13.1. 

1.86 “Party” shall mean the Licensors (considered together as one “Party”) or Sanofi
individually, and “Parties” shall mean the Licensors (considered together as one “Party”) and Sanofi collectively. 

1.87 “Patent(s)” shall mean (a) all patents, certificates of invention, applications for certificates of
invention, priority patent filings and patent applications, and (b) any renewal, division, continuation (in whole or in part), or request for continued examination of any of such patents, certificates of invention and patent applications, and
any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the
foregoing. 

  
 11. 

 CONFIDENTIAL 
  

1.88 “Person” shall mean any individual, corporation, partnership, limited liability company, trust,
governmental entity, or other legal entity of any nature whatsoever. 
 1.89 “PHSA” shall have the meaning set
forth in Section 9.8(a). 
 1.90 “Platform MannKind Patent” shall mean any MannKind Patent that is not a
Product-Specific MannKind Patent. The Platform MannKind Patents in existence as of the Execution Date are identified in EXHIBIT C. The categorization of any future MannKind Patent as a Platform MannKind Patent shall be
determined in good faith by mutual agreement of the Parties. 
 1.91 “Product” shall mean any product in a
form suitable for human applications consisting of (a) a Formulation that contains Insulin as the sole active pharmaceutical ingredient, without any other active ingredients, for use in a Device, (b) a Device, but only to the extent that
it is sold (or intended to be sold) for use with such a Formulation described in clause (a), or (c) both a Device and such a Formulation described in clause (a) for use together, in each case, including all improvements thereof. For
clarification, Product shall not include a Device to the extent that it is sold (or intended to be sold) for administration of a Formulation that contains an active pharmaceutical ingredient other than solely Insulin. 

1.92 “Product-Specific MannKind Patent” shall mean a MannKind Patent that claims or covers no other product or
product candidate in addition to Product. The Product-Specific MannKind Patents in existence as of the Execution Date are identified in EXHIBIT C. The categorization of any future MannKind Patent as a Product-Specific
MannKind Patent shall be determined in good faith by mutual agreement of the Parties. 
 1.93 “Profit” shall
have the meaning set forth on EXHIBIT B hereto. 
 1.94 “Public Official or Entity”
shall mean (a) any officer, employee (including physician, hospital administrator, or other healthcare professional), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision
of any government, military or international organization, including, but not limited to, any ministry or department of health or any state-owned or affiliated company or hospital, or (b) any candidate for political office, any political party
or any official of a political party. 
 1.95 “Receiving Party” shall have the meaning set forth in
Section 8.1. 
 1.96 “Regulatory Authority” shall mean any Governmental Authority whose review or
approval is necessary for the Manufacture, packaging, use, storage and Commercialization of Product in a given country in the Territory. Where governmental approval is required for pricing or reimbursement for Product to be reimbursed by national
health insurance (or its local equivalent), “Regulatory Authority” shall also include any Governmental Authority whose review or approval of pricing or reimbursement is required. 

1.97 “Regulatory Filing” shall mean all approvals, licenses, registrations, submissions and authorizations made
to or received from a Regulatory Authority necessary for the 

  
 12. 

 CONFIDENTIAL 
  

Development, Manufacture or Commercialization of the Product, including any INDs, MAAs and Marketing Approvals, excluding Master Files. 

1.98 “Responsible Party” shall mean the Party designated as responsible for conducting the applicable clinical
or non-clinical studies or other activities under the Development Plan or designated by the JAC as responsible for filing and securing Marketing Approval for Product in the Field in the Territory, as
applicable. 
 1.99 “Sanofi Indemnitees” shall have the meaning set forth in Section 11.2. 

1.100 “Sanofi Know-How” shall mean all Information that (a) is Controlled by Sanofi or any of its
Affiliates as of the Effective Date or during the Term and (b) is necessary or useful for the Development, Manufacture, use or Commercialization of Product in the Field, expressly excluding any Know-How pertaining to the Manufacture of Insulin.

 1.101 “Sanofi Patents” shall mean all Patents Controlled by Sanofi or any of its Affiliates as of the
Effective Date or during the Term that are necessary for, or useful for and actually used in, the Development, Manufacture, use or Commercialization of Product in the Field, but excluding any Joint Patents. 

1.102 “Sanofi Technology” shall mean all Sanofi Know-How, Sanofi Patents and Sanofi’s or its
Affiliate’s interest in Joint Patents and Joint Inventions. 
 1.103 “SEC” shall mean the U.S. Securities
and Exchange Commission, or any successor agency. 
 1.104 “Service Provider” shall mean any Third Party
service provider such as a contract research organization, clinical research organization, contract manufacturing organization, consultant, subcontractor or other independent contractor performing on behalf of a Party such Party’s obligations
under this Agreement, but excluding any Third Party to whom a sublicense or license under any MannKind Technology, MannKind Trademarks or Sanofi Technology is granted. 

1.105 “Standstill Period” shall have the meaning set forth in Section 15.12. 

1.106 “Supply Agreement” shall mean that certain Supply Agreement, effective as of the Effective Date, by and
between MannKind and Sanofi-Aventis Deutschland GmbH. 
 1.107 “Term” shall have the meaning set forth in
Section 12.1. 
 1.108 “Terminated Country” shall have the meaning set forth in Section 13.1. 

1.109 “Territory” shall mean all countries of the world, excluding any Terminated Country. 

1.110 “Third Party” shall mean any Person other than the Licensors, Sanofi and their respective Affiliates. 

  
 13. 

 CONFIDENTIAL 
  

1.111 “Third Party Claims” shall have the meaning set forth in Section 11.1. 

1.112 “United States” or “U.S.” shall mean the United States of America, including its
territories and possessions and the District of Columbia. 
 1.113 “Wind-down Period” shall mean any period
after the date of termination of this Agreement during which, pursuant to Section 13.3(a), Sanofi is required to continue to perform certain activities. 

1.114 “Withdrawal Notice” shall have the meaning set forth in Section 3.4. 

ARTICLE 2 
 GRANT OF
LICENSE 
 2.1 Development Licenses. Subject to the terms and conditions of this Agreement: (a) the Licensors hereby
grant to Sanofi an exclusive (except as to MannKind with respect to Development activities to be performed by MannKind pursuant to the Development Plan and subject to the rights reserved by the Licensors pursuant to Section 2.5), worldwide,
royalty-free license, with the right to grant sublicenses as provided in Section 2.4, under the MannKind Technology to Develop Product in the Field in accordance with this Agreement; and (b) Sanofi hereby grants to the Licensors a non-exclusive, worldwide, royalty-free license under the Sanofi Technology as is necessary solely for the Licensors to Develop Product in the Field in accordance with this Agreement. 

2.2 Commercialization License. Subject to the terms and conditions of this Agreement, the Licensors hereby grant to Sanofi an exclusive,
payment-bearing license, with the right to grant sublicenses as provided in Section 2.4, under the MannKind Technology to (a) Manufacture and have Manufactured Product in the Field in the Territory, subject to the terms of and as permitted
by the Supply Agreement, and (b) use, Commercialize and have Commercialized Product in the Field in the Territory. The license granted in this Section 2.2 shall be exclusive even as to the Licensors, subject to the rights reserved by the
Licensors pursuant to Section 2.5. 
 2.3 License to MannKind Trademarks. Subject to the terms and conditions of this Agreement,
MannKind grants Sanofi the license to the MannKind Trademarks on the terms set forth in EXHIBIT A. 
 2.4
Sublicenses. Sanofi shall have the right to grant sublicenses of the rights granted to it under this Article 2 to any of its Affiliates or Third Parties for the purposes of Development, regulatory, Manufacture and Commercialization
activities with respect to Product in the Field in the Territory; provided, however, that (a) the prior written consent of MannKind shall be required for sublicenses to any Third Party that include a right of Commercialization in any or
all of the Major Markets, such consent not to be unreasonably withheld, conditioned or delayed, and (b) the prior approval of the JAC shall be required for sublicenses to any Third Party that include a right of Commercialization outside the
Major Markets. Any sublicense shall be in writing and 

  
 14. 

 
on substantially the same (or narrower) license terms as those contained in this Agreement (except that such sublicensee shall not have the right to further sublicense). Sanofi shall be
responsible for the acts or omissions of its sublicensees in exercising rights under the sublicense which would constitute a breach hereunder. 

2.5 Reserved Rights; No Implied Licenses. Except for the rights and licenses expressly granted in this Agreement, the Licensors retain
all rights under their respective intellectual property, including the MannKind Technology and MannKind Trademarks, and Sanofi retains all rights under its intellectual property, including the Sanofi Technology, and no rights shall be deemed granted
by one Party to the other Party by implication, estoppel or otherwise. Without limiting the foregoing, the Licensors reserve and retain the right under the MannKind Technology, subject to the terms and conditions of this Agreement (i) to
perform Development under the Development Plan pursuant to Article 4, (ii) to Manufacture, have Manufactured and supply Product to Sanofi pursuant to Section 5.2 and the Supply Agreement and (iii) to submit, obtain and maintain
Master Files. 
 2.6 Sanofi Acknowledgment and Negative Covenant.  

(a) Sanofi hereby acknowledges that the licenses granted by the Licensors to Sanofi under the MannKind Technology pursuant to this
Agreement are expressly limited to the Development, Manufacture and Commercialization of Product in the Field in the Territory. 
 (b)
Sanofi hereby covenants, on behalf of itself and its Affiliates, that neither Sanofi nor any of its Affiliates will: (i) either during or after the Term, infringe any MannKind Patents; (ii) either during, or within the first ten
(10) years after the end of, the Term, use any MannKind Know-How (other than MannKind Know-How that is or becomes generally available to the public or otherwise part of the public domain other than through any act or omission of Sanofi or any
of its Affiliates in breach of this Agreement) outside the scope of the licenses granted hereunder; or (iii) license or authorize any Third Party to engage in any of the actions described in the preceding clauses (i) and (ii) of this
Section 2.6(b). 
 2.7 [...***...] Product. 

(a) During the Term, if any of the Licensors or any MannKind Affiliate proposes to grant any Third Party (which, solely for purposes of
this Section 2.7, shall mean any Person other than a MannKind Affiliate), a license or other rights to develop or commercially exploit any product [...***...] (each, a “[...***...] Product”), then,
prior to granting any such license or other rights, MannKind shall so notify Sanofi in writing and shall promptly establish and provide Sanofi with access to an electronic data room containing any study results and data generated by or on behalf of
the Licensors or MannKind Affiliates with respect to such [...***...] Product (the “Data Room”). Subject to the terms and conditions of this Agreement, MannKind hereby grants to Sanofi, during the [...***...]-day period beginning on the date the Data Room is first accessible by Sanofi (the “Initial Election Period”), the first right to negotiate with the Licensors for the grant
to Sanofi or any of its Affiliates of a license under all intellectual property of the Licensors or the MannKind 

  
 ***Confidential Treatment
Requested 
 15. 

 CONFIDENTIAL 
  

Affiliates pertaining to such [...***...] Product (a “Transaction”), and the Licensors agree not to grant and cause the MannKind Affiliates not to grant any Third
Party access to the Data Room, or a license or other rights to develop or commercially exploit such [...***...] Product during the Initial Election Period. 

(b) If Sanofi or any of its Affiliates is interested in negotiating a Transaction with the Licensors, then Sanofi shall so notify the
Licensors in writing prior to expiration of the Initial Election Period (such notice, an “Indication of Interest”). If Sanofi delivers an Indication of Interest to the Licensors prior to expiration of the Initial Election
Period, then Sanofi shall have an additional
 [...***...] days from expiration of the Initial Election Period (the “Due Diligence Period”) in which to complete due diligence regarding the [...***...]
Product and, if Sanofi or any of its Affiliates in good faith wishes to negotiate with the Licensors regarding a Transaction, to deliver to the Licensors a written non-binding offer letter setting forth the
principal terms and conditions upon which Sanofi or its Affiliate would be willing to enter into such Transaction (an “NBO”). If Sanofi delivers an NBO to the Licensors prior to expiration of the Due Diligence Period, then
the Parties shall negotiate in good faith a definitive agreement regarding the Transaction for up to an additional [...***...] days from expiration of the Due Diligence Period (the “Negotiation Period”);
provided, however, that the Licensors shall have no obligation to enter into a Transaction with Sanofi or its Affiliates. 
 (c)
If Sanofi (whether on its own behalf or on behalf of its Affiliate) (i) fails to deliver an Indication of Interest to the Licensors prior to expiration of the Initial Election Period, or (ii) delivers an Indication of Interest prior to
expiration of the Initial Election Period but fails to deliver an NBO to the Licensors prior to expiration of the Due Diligence Period, or (iii) delivers an Indication of Interest prior to expiration of the Initial Election Period and an NBO
prior to expiration of the Due Diligence Period, but the Parties have not entered into a definitive agreement for a Transaction prior to expiration of the Negotiation Period, then, in each case, upon the expiration of the Initial Election Period,
Due Diligence Period or Negotiation Period, respectively, the Licensors shall be free to grant one or more Third Parties a license or other right to develop or commercially exploit a [...***...] Product, without further obligation to Sanofi
(or any of its Affiliates), provided that, for a period of [...***...] months following the expiration of the Initial Election Period, the Due Diligence Period or the Negotiation Period, as applicable, the Licensors shall not grant any such
license or other right to any Third Party on terms that are materially less favorable, taken as a whole, to the Licensors than the terms last offered by Sanofi to the Licensors during the Parties’ negotiations. If the Licensors have not entered
into a definitive agreement with a Third Party granting a license or other right to develop or commercially exploit a [...***...] Product within such [...***...] month period pursuant to the foregoing sentence, Sanofi’s rights under
this Section 2.7 and all applicable time periods for exercise of such rights shall reset, provided that the Negotiation Period shall be an additional [...***...] days from expiration of the Due Diligence Period. 

(d) For the avoidance of doubt, nothing in this Section 2.7 shall be construed to give Sanofi or any of its Affiliates any rights
whatsoever with respect to any proposed sale of all or substantially all of the business or assets of the Licensors, or of a substantial portion of the business or assets of the Licensors that relates to two or more bona fide development
programs 

  
 ***Confidential Treatment
Requested 
 16. 

 
or products of the Licensors, including [...***...] Products, in each case, whether by merger, sale of stock, sale of assets or otherwise. 

2.8 Covenants. 
 (a)
MannKind Non-Compete. During the Term, the Licensors covenant to Sanofi that the Licensors and MannKind Affiliates shall not either themselves or with, for the benefit of, or sponsored by any Third Party, (i) conduct any activity directed
to the Development (mutatis mutandis) or registration of a Competing Product in the Territory, (ii) Manufacture a Competing Product that is intended for sale in the Territory, (iii) Commercialize (mutatis mutandis) a
Competing Product in the Territory, or (iv) license or authorize, under any MannKind Technology, MannKind Trademarks or Data, any entity other than a MannKind Affiliate to engage in any of the activities described in the preceding
clauses (i), (ii) and (iii). 
 (b) Sanofi Non-Compete. During the Term, Sanofi covenants to the Licensors that Sanofi and
its Affiliates shall not either themselves or with, for the benefit of, or sponsored by any Third Party, (i) conduct any activity directed to the Development (mutatis mutandis) or registration of a Competing Product in the Territory,
(ii) Manufacture a Competing Product that is intended for sale in the Territory, (iii) Commercialize (mutatis mutandis) a Competing Product in the Territory, or (iv) license, sublicense or authorize, under any MannKind
Technology, MannKind Trademarks, Sanofi Technology or Data, any Third Party to engage in any of the activities described in the preceding clauses (i), (ii) and (iii). Notwithstanding the foregoing: 

(i) Starting on the fifth (5th) anniversary of the Effective Date, Sanofi
may, at its sole cost and expense, Develop (mutatis mutandis) internally at Sanofi or one of its Affiliates a Competing Product generated solely from Sanofi’s or its Affiliate’s internal research efforts; provided, however,
that Sanofi and its Affiliates shall not use any MannKind Technology in connection therewith. For the avoidance of doubt, Sanofi shall bear all costs and expenses of Development (mutatis mutandis) of such Competing Product and such costs and
expenses shall not be Allowable Expenses and shall not otherwise be subject to EXHIBIT B, except to the extent incurred after the First Commercial Sale of such Competing Product pursuant to approval by the JAC in
accordance with the immediately succeeding sentence. The Commercialization (mutatis mutandis) of any such Competing Product during the Term shall require the prior written approval of the JAC. Upon approval by the JAC of such
Commercialization, (A) subject to EXHIBIT B, Sanofi shall bear all Commercialization costs and expenses with respect to any such Competing Product, (B) except as expressly set forth below, such Competing Product
shall be deemed a “Product” for purposes of Section 6.3 and EXHIBIT B, and (C) payment of Allowable Expenses and calculation and sharing of Profit and Loss with respect to such Competing Product shall
be subject to EXHIBIT B; provided, however, that no Development Costs (mutatis mutandis) incurred prior to the First Commercial Sale of such Competing Product shall be included in Allowable Expenses or in the
calculation of Profit or Loss. 
 (ii) Starting on the tenth
(10th) anniversary of the Effective Date, Sanofi may in-license or acquire a Competing Product from a Third Party and the Development (mutatis mutandis) and Commercialization
(mutatis mutandis) of such in-licensed or acquired 

  
 ***Confidential Treatment
Requested 
 17. 

 CONFIDENTIAL 
  

Competing Product shall not be governed by the terms of this Agreement. For clarity, Sanofi shall be exclusively responsible for any and all costs and expenses with respect to such Development
(mutatis mutandis) and Commercialization (mutatis mutandis) and all costs and expenses with respect to such Development (mutatis mutandis) and Commercialization (mutatis mutandis) and, as between the Parties, shall be
entitled to all revenues with respect to such Competing Product. 
 (c) Acknowledgment. The Parties acknowledge (i) that this
Section 2.8 has been negotiated by the Parties, (ii) the geographical and time limitations on activities contained in this Section 2.8 are reasonable, valid and necessary for the adequate protection of the Product business, and
(iii) that the Parties would not have entered into this Agreement without the protection afforded by this Section 2.8. Notwithstanding the foregoing, if a court of competent jurisdiction determines that the restrictions set forth in this
Section 2.8 are too broad or are otherwise unreasonable under Applicable Law, including with respect to duration, geographic scope, or field, the court is hereby requested and authorized by the Parties to revise the foregoing restrictions to
include the maximum restrictions allowable under Applicable Law. 
 (d) Acquiring Party Business Combination. Neither Party shall be
in breach of the provisions of Section 2.8 by reason of its acquisition of a Third Party or its assets or by a Third Party if: (a) within sixty (60) days following the closing of such acquisition, the acquiring Party (or acquiring
Third Party) commits in writing to the other Party that such acquirer will promptly divest itself of the Competing Product of such Third Party (whether through sale of business or assets or discontinuation of all activities with respect to the
Competing Product); and (b) such divestiture is completed within twelve (12) months after the closing of such acquisition. 

ARTICLE 3 

GOVERNANCE 
 3.1
Joint Afrezza Committee. 
 (a) Establishment. Within 30 days following the Effective Date, MannKind and Sanofi shall establish a
Joint Afrezza Committee (the “JAC”) to oversee, review and coordinate the activities of the Parties under this Agreement with regard to the Development, regulatory and other activities relating to Product in the Field in the
Territory. 
 (b) Membership. Subject to Section 3.4, the JAC shall be composed of eight members (or such other even number
agreed to in writing by the Parties so long as each Party has an equal number of members on the JAC). One-half of the total number of members on the JAC shall be nominated by MannKind and one-half of the total number of members on the JAC shall be
nominated by Sanofi, which members shall be employees of the applicable Party with the requisite experience and seniority to make decisions on behalf of the Parties with respect to responsibilities within the jurisdiction of the JAC. Each Party will
notify the other Party of its initial JAC members within 30 days after the Effective Date. Each Party shall designate one of its representatives on the JAC as the co-chair of the JAC, whose roles shall be to convene and

  
 18. 

 CONFIDENTIAL 
  

preside at meetings of the JAC, but the co-chairs shall not be entitled to prevent items from being discussed or, subject to Section 3.1(f), to cast any tie-breaking vote. Each Party may
change its JAC members at any time by written notice to the other Party. Any member of the JAC may designate a substitute to attend and perform the functions of that member at any meeting of the JAC. 

(c) Meetings. The JAC will hold meetings at such frequency as determined by the JAC members, but no less than once per Calendar Quarter.
Such meetings may be conducted by videoconference, teleconference or in person, as agreed by the Parties; provided, that at least one JAC meeting per year shall be held in person and the location of such in-person meeting shall alternate between
MannKind’s and Sanofi’s offices, unless the Parties otherwise agree. Each Party may invite a reasonable number of non-member, non-voting representatives of such Party to attend meetings of the JAC. Minutes will be kept of all JAC meetings
and will reflect material decisions made at such meetings. The responsibility to prepare minutes of JAC meetings will be Sanofi’s. Meeting minutes will be sent to each member of the JAC for review and approval promptly following each meeting.
Minutes will be deemed approved unless a member of the JAC objects to the accuracy of such minutes within 15 days of receipt. Any costs and expenses incurred by a Party related to a JAC meeting, including, if applicable, travel and/or
telecommunication expenses, shall be borne by such Party. 
 (d) JAC Responsibilities. The JAC shall have the following
responsibilities: 
 (i) providing a forum for the Parties to exchange information and coordinate their respective activities with
respect to Development, regulatory and Manufacturing matters pertaining to Product in the Territory; 
 (ii) reviewing and approving
the Development Plan and material changes to the Development Plan, including any Development Budget (which Budget shall be reviewed and approved on an annual basis); 

(iii) reviewing and approving the regulatory strategy for Product in the Territory; 

(iv) reviewing and approving Commercialization Plan(s), Commercialization Budget(s), and updates and amendments thereto; 

(v) reviewing and approving revisions to the Paid Price set forth in the Supply Agreement; 

(vi) providing a forum for discussion as to whether the content of a Commercialization Plan (or any such plan as proposed to be updated
or amended) is sufficient to satisfy Sanofi’s obligations to use Commercially Reasonable Efforts in accordance with Section 5.1(c); 

(vii) receiving periodic updates on material Development and regulatory activities conducted or proposed to be conducted with respect
to Product in the Territory, including the submission and prosecution of applications for Marketing Approval; 

  
 19. 

 CONFIDENTIAL 
  

(viii) reviewing safety and compliance reports for Product in the Territory; 

(ix) overseeing the activities managed by the Manufacturing working group of the JAC as described in Section 3.1(e); 

(x) providing a forum for coordinating the Parties’ activities in response to crises with respect to Product, including unexpected
disruptions to the supply of Product, safety issues, and recalls or withdrawals of Product; 
 (xi) establishing and overseeing
working groups of the JAC as necessary to implement the responsibilities delegated to the JAC pursuant to this Agreement or by written agreement of the Parties; 

(xii) reviewing and approving potential sublicensees outside the Major Markets; 

(xiii) reviewing and approving the filing of an IND for Product using an amorphous Formulation; and 

(xiv) making such other decisions as may be delegated to the JAC pursuant to this Agreement or the Supply Agreement or by written
agreement of the Parties. 
 (e) Working Groups of the JAC. From time to time, the JAC may establish working groups to oversee
particular projects or activities within the scope of authority of the JAC, as it deems necessary or advisable. Each working group shall consist of such number of representatives of each Party as the JAC determines is appropriate from time to time
and shall meet with such frequency as the JAC shall determine. All decisions of each working group shall be made by unanimous vote or written consent, with the MannKind members of the working group collectively having one vote and the Sanofi members
of the working group collectively having one vote in all decisions of the working group. If, with respect to a matter that is subject to a working group’s decision-making authority, the working group cannot reach agreement, the matter shall be
referred to the JAC, which shall resolve such matter in accordance with Section 3.1(f). The Manufacturing working group of the JAC shall be responsible for (i) overseeing the forecasting, Manufacture and supply of Product, and any
regulatory activities with respect thereto, and (ii) discussing and overseeing the Parties’ efforts to reduce Cost of Goods and approving in advance any costs to be incurred by MannKind for such efforts. 

(f) JAC Decision-Making. All decisions within the authority of the JAC shall be made by unanimous vote or written consent, with the
MannKind members of the JAC collectively having one vote and the Sanofi members of the JAC collectively having one vote in all decisions of the JAC. The members of the JAC shall use reasonable efforts to reach agreement on all matters. If, despite
such efforts, agreement on a particular matter cannot be reached by the JAC within 15 days after the JAC first considers such matter (or such shorter or longer time as may be agreed by the Parties), then either Party may, by written notice to the
other Party, have such matter referred to, on behalf of MannKind, the President of MannKind and, on 

  
 20. 

 CONFIDENTIAL 
  

behalf of Sanofi, the Senior Vice President – Global Diabetes of Sanofi. Such executives shall use reasonable efforts to resolve the matter referred to them within 10 days after such
referral. If, despite such efforts, such executives are unable to resolve such matter within 10 days after such referral (or such shorter or longer time as may be agreed by the Parties), then the Sanofi co-chair on the JAC shall have the right to
make the final decision with regard to the disputed matter following good faith consideration of MannKind’s comments, subject to Section 3.4 and provided that the Sanofi co-chair on the JAC shall not have power to resolve a dispute:
(i) in a manner that would require MannKind to perform activities (A) for which Sanofi will not reimburse MannKind’s costs (except as expressly set forth in this Agreement or the Supply Agreement) or (B) which MannKind has not
agreed to perform as set forth in this Agreement or otherwise in writing; (ii) in a manner that would conflict with the terms of this Agreement or the Supply Agreement, including all Exhibits and Schedules hereto and thereto; (iii) by
unilaterally determining that it has fulfilled any diligence obligations hereunder; (iv) in a manner that would modify or increase MannKind’s responsibilities under the Development Plan; or (v) regarding changes to any Budget, except
as may be required to reflect activities required by a Regulatory Authority or Applicable Laws. For all purposes under this Agreement, any decision made pursuant to this Section 3.1(f) shall be deemed to be the decision of the JAC. 

3.2 Alliance Managers. Promptly after the Effective Date, each Party shall appoint an individual to act as the alliance manager for such
Party (the “Alliance Manager”). Each Alliance Manager shall be permitted to attend meetings of the JAC. The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this
Agreement and shall facilitate all such activities hereunder. Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party. 

3.3 Scope of Governance. Notwithstanding the creation of the JAC, each Party shall retain the rights, powers and discretion granted to
it hereunder, and the JAC shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly agree in writing. The JAC shall not have the power to amend or
modify this Agreement, and no decision of the JAC shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JAC are only those specific issues that are expressly
provided in this Agreement to be decided by the JAC. Any dispute regarding the interpretation of this Agreement or any alleged breach of this Agreement will be resolved in accordance with the terms of Article 14. 

3.4 Withdrawal from the JAC. At any time during the Term and for any reason, MannKind shall have the right to withdraw from the JAC upon
written notice to Sanofi, which notice shall be effective immediately upon receipt (“Withdrawal Notice”). Following the issuance of a Withdrawal Notice and subject to this Section 3.4, the JAC shall be suspended and
Sanofi shall have the right to make the final decision on all matters within the scope of authority of the JAC. If, at any time, following the issuance of a Withdrawal Notice, MannKind wishes to resume participation in the JAC, MannKind shall notify
Sanofi in writing and, thereafter, MannKind’s representatives to the JAC, shall be entitled to attend any subsequent meeting of the 

  
 21. 

 CONFIDENTIAL 
  

JAC, and to participate in the activities of, and decision-making by the JAC as provided in this Article 3 as if a Withdrawal Notice had not been issued by MannKind. 

ARTICLE 4 

DEVELOPMENT AND REGULATORY ACTIVITIES 

4.1 Development Activities. 

(a) Development Responsibility. Sanofi shall have the exclusive right and responsibility to Develop Product in the Field in the
Territory during the Term (other than the Development activities assigned to MannKind by the JAC in the Development Plan), subject to the terms and conditions of this Agreement and in accordance with a Development Plan established by Sanofi and
approved by the JAC, which shall specify the Development activities to be performed by or on behalf of the Parties, and shall set forth a proposed Development Budget for such activities. Subject to EXHIBIT B, each Party
shall be responsible for bearing the costs and expenses of the Development activities assigned to such Party in the Development Plan; provided, however, that prior to the filing of an IND in respect of an amorphous Formulation, MannKind shall
be solely responsible for the expenses associated with the Development of such Formulation and such expenses shall not be considered Allowable Expenses for purposes of EXHIBIT B, but all expenses associated with the Development
of an amorphous Formulation incurred after the filing of such IND shall be considered Allowable Expenses for purposes of EXHIBIT B. The Development Plan shall be subject to the terms and conditions of this Agreement, in
addition to the specific details set forth in the Development Plan. To the extent any terms or provisions of a Development Plan conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control. Any
changes to the Development Plan shall be in writing and approved by the JAC. 
 (b) Development Budget. Each Development Budget shall
set forth the budget associated with the various Development activities to be performed under the Development Plan. Each Party shall, on an annual basis during the fourth Calendar Quarter of each Calendar Year during the Development Term, prepare
and submit to the JAC for review, discussion and approval a draft Development Budget for activities planned to be performed by such Party under the Development Plan during the forthcoming Calendar Year. Subject to Section 3.1(f), the JAC shall
have the right to amend each annual Development Budget from time to time. In the event that any Regulatory Authority requires a modification to any Development Plan, the JAC may not limit or prevent any corresponding revision to a Development Budget
as necessary to accommodate and comply with such Regulatory Authority requirements. The Development Budget for the initial Development Plan shall be submitted to the JAC concurrently therewith. 

(c) Conduct of Development Activities. All Development activities in support of Product in the Field in the Territory will be conducted
by or on behalf of the Parties in accordance with the Development Plan and the other provisions of this Agreement. Each Party shall conduct those activities for which it is the Responsible Party under the Development Plan in compliance in all
material respects with all Applicable Laws and in accordance with good 

  
 22. 

 CONFIDENTIAL 
  

scientific and clinical practices, applicable under the Applicable Laws of the country in which such activities are conducted. 

(d) Information Regarding Development Activities. Each Party shall maintain records, in sufficient detail and in good scientific manner
appropriate for Patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved by or on behalf of such Party in the performance of its Development activities under this Agreement. Each Party shall keep the
JAC appropriately informed of the status of studies and other activities with respect to Product in the Field in the Territory conducted under the Development Plan. Upon request by the JAC, without limiting the foregoing, each Party shall promptly
provide the JAC with summaries in reasonable detail of all Data and results generated or obtained in the course of such Party’s performance of studies and activities under the Development Plan. 

4.2 Regulatory Activities. 

(a) Regulatory Strategy. Sanofi shall be solely responsible for developing the regulatory strategy for Product in the Field in the
Territory for review and approval by the JAC. Such strategy shall include the strategy with respect to any data, market or other regulatory exclusivity periods that may be applicable to Product in the Field in the Territory, including with respect
to any such periods listed in the FDA’s Orange Book. 
 (b) Regulatory Responsibilities. Within 30 days after the Effective Date,
MannKind will transfer to Sanofi the MAA and, at Sanofi’s option, the IND for Product in the Field in the United States to enable Sanofi to manage the Commercialization and any additional Development of Product in the Field in the United States
and Sanofi shall thereafter be responsible with respect to filing for, obtaining and maintaining Marketing Approval for Product in the Field in the United States with oversight by the JAC. Sanofi shall be responsible with respect to filing for,
obtaining and maintaining Marketing Approval for Product in the Field in all other countries in the Territory with oversight by the JAC. Subject to EXHIBIT B, Sanofi shall be responsible for bearing the costs and expenses
associated with performing the activities contemplated by this Section 4.2(b). 
 (c) Conduct of Regulatory Activities. All
regulatory activities with respect to Product in the Field in the Territory will be conducted by or on behalf of Sanofi in accordance with the provisions of this Agreement and the regulatory strategy developed by Sanofi and approved by the JAC;
provided, however, that MannKind reserves the exclusive right, as manufacturer of Product, to submit, obtain and maintain Master Files in MannKind’s name in the Territory, provided, further, that, solely to the extent and for so
long as the licenses granted by the Licensors to Sanofi under Sections 2.1 and 2.2 remain in full force and effect, Sanofi shall have the irrevocable right to refer to the Master Files with respect to the Product in the Territory solely for the
purposes of (i) Developing Product in the Field in accordance with this Agreement, (ii) Manufacturing and having Manufactured Product in the Field in the Territory, subject to the terms of and as permitted by the Supply Agreement, and
(iii) using, Commercializing and having Commercialized Product in the Field in the Territory. For the avoidance of doubt, and notwithstanding the foregoing or any other provision of this Agreement to the contrary, Sanofi

  
 23. 

 
shall have no right to refer to the Master Files with respect to the Product in the Territory for the purpose of developing, manufacturing, having manufactured, using, commercializing or having
commercialized any Competing Product. Sanofi shall conduct those regulatory activities in compliance in all material respects with all Applicable Laws. Sanofi shall use Commercially Reasonable Efforts to file for, obtain and maintain Marketing
Approvals for Product in the Field in all Major Markets and all
 [...***...] Countries, it being understood that the application of Commercially Reasonable Efforts may include a consideration of
 [...***...] and may result in
Sanofi deciding not to pursue or maintain Marketing Approval in a particular Major Market or [...***...] Country. From time to time after the [...***...] anniversary of the Effective Date, at MannKind’s request, Sanofi shall present
an analysis to the JAC of the commercial viability of Product in countries in the Territory that are not Major Markets or [...***...] Countries and where Sanofi has not at such time filed for or obtained Marketing Approvals for Product in
order to assess the opportunities for sublicensing or otherwise Commercializing Product in such countries, it being understood that MannKind can request such analysis for no more than one such country per Calendar Quarter. MannKind acknowledges and
agrees that, irrespective of the results of such analysis, Sanofi shall have no obligation to take any efforts to file for, obtain or maintain Marketing Approvals for Product in the Field in any such country. For the avoidance of doubt, all expenses
associated with any such analysis requested by MannKind shall be considered Allowable Expenses for purposes of EXHIBIT B. 

(d) Data. All Data generated by or on behalf of a Party or the Parties shall be owned jointly by MannKind and Sanofi. MannKind shall
have the right to use, make reference to and incorporate the Data in regulatory filings with regulatory authorities for products (other than Product and Competing Products) outside of the field of Diabetes without Sanofi’s consent and without
obligation to Sanofi. Should MannKind wish to use, make reference to or incorporate the Data in regulatory filings with regulatory authorities for products (other than Product) in the field of Diabetes, MannKind shall obtain the prior written
consent of Sanofi prior to such use, reference to or incorporation of the Data, which Sanofi may grant or withhold in its sole discretion. Sanofi shall have the right to use, make reference to and incorporate the Data in regulatory filings with
regulatory authorities for products in the Field without MannKind’s consent and without obligation to MannKind. 
 (e) Regulatory
Reporting. During the Term, Sanofi will keep MannKind updated regarding all Regulatory Filings and, upon request, shall (i) provide MannKind with copies of all submissions to Regulatory Authorities related to the Manufacture or
Commercialization of Product (other than ministerial submissions which do not involve safety or efficacy issues), and (ii) promptly disclose to MannKind all Regulatory Filings, and any Data included or referenced therein, made by or on behalf
of Sanofi, with respect to Product in the Field in the Territory. During the Term, MannKind will keep Sanofi updated regarding any submission with respect to the Master Files related to the Product and, upon request, shall (i) provide Sanofi
with copies of all submissions to Regulatory Authorities related to such Master Files, and (ii) promptly disclose to Sanofi all such Master Files, and any Data included or referenced therein. Each Party will notify the other Party promptly (and
in any event within two Business Days) of its receipt of information from any Governmental or Regulatory Authority, that: (A) raises any material concerns regarding the safety or efficacy of Product or would affect

  
 ***Confidential Treatment
Requested 
 24. 

 
Product labeling, (B) indicates a potential material liability for either Party arising in connection with Product, or (C) is reasonably likely to lead to a recall or market withdrawal
of Product. 
 (f) Device Vigilance; Pharmacovigilance. Representatives from competent departments of each Party shall, within three
(3) months following the Effective Date, negotiate and implement detailed device vigilance and/or pharmacovigilance agreement(s) or safety data exchange procedures defining the respective responsibilities of the Parties to ensure worldwide
safety surveillance of Product and to comply with all applicable device and safety reporting obligations as amended from time to time. Such agreement(s) shall be on terms no less stringent than those required by ICH guidelines, including:
(i) providing detailed procedures regarding the maintenance of core safety information and the exchange of safety data relating to Product worldwide within appropriate timeframes and in an appropriate format to enable each Party to meet both
expedited and periodic regulatory reporting requirements; and (ii) ensuring compliance with the reporting requirements of all applicable Regulatory Authorities on a worldwide basis for the reporting of safety data in accordance with standards
stipulated in the ICH guidelines, and all applicable regulatory and legal requirements regarding the management of safety data. Notwithstanding the foregoing, the Licensors shall reasonably assist Sanofi during the term of this Agreement to answer
any query of Sanofi or any Regulatory Authority in the Territory. 
 (g) Cooperation. Sanofi shall, at MannKind’s request,
reasonably cooperate with MannKind by (i) updating MannKind on a regular basis regarding Sanofi’s regulatory activities in the Territory and (ii) providing MannKind with summaries of its communications and correspondence with
Regulatory Authorities with respect to Product in the Territory. 
 4.3 Transfer of Know-How.
Promptly following the Effective Date, the Licensors will make available to Sanofi, at no additional cost or expense to Sanofi, the MannKind Know-How that exists as of the Effective Date. Subject to the Supply
Agreement, MannKind shall cooperate with Sanofi to provide such reasonable technical assistance as may be necessary in connection with the transfer to Sanofi of the Development and Manufacture of the Product. MannKind shall furnish, at Sanofi’s
request and expense, a representative to attend regulatory meetings with the FDA regarding Product and/or participate in activities related to such regulatory meetings. During the Term, the Licensors shall provide to Sanofi, at no additional cost or
expense to Sanofi, all MannKind Know-How that has not previously been provided hereunder promptly upon such MannKind Know-How being obtained or generated by MannKind. During the Term, Sanofi shall provide to MannKind, at no additional cost or
expense to MannKind, all Sanofi Know-How that is necessary for MannKind to perform its obligations hereunder and has not previously been provided hereunder promptly upon such Sanofi Know-How being obtained or generated by Sanofi. For the avoidance
of doubt, nothing in this Agreement or the Supply Agreement shall oblige Sanofi to disclose proprietary information about its Insulin manufacturing process. 

4.4 Use of Subcontractors. Sanofi may perform some of its Development or regulatory activities under this Agreement through one or more
Service Providers, provided that the Service Provider undertakes in writing obligations of confidentiality and non-use regarding Confidential Information which are substantially the same as those undertaken by the

  
 25. 

 CONFIDENTIAL 
  

Parties pursuant to Article 8. In the event Sanofi performs any of its Development or regulatory activities hereunder through a Service Provider, then Sanofi will at all times be fully
responsible for the performance and payment of such Service Provider. 
 4.5 Materials Transfer. In order to facilitate the
Development or regulatory activities contemplated by this Agreement, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, “Materials”)
for use by the other Party in furtherance of such Development activities. Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying Party, will be used only
in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any Third Party, except for Service Providers pursuant to Section 4.4 or, in the case of Sanofi
only, sublicensees, without the prior written consent of the supplying Party, and will be used in compliance with all Applicable Laws. The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental
work because not all of their characteristics may be known. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT OR THE SUPPLY AGREEMENT, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 

ARTICLE 5 

COMMERCIALIZATION; MANUFACTURE AND SUPPLY 

5.1 Commercialization of Product. 

(a) Sanofi Responsibilities. Sanofi shall have the exclusive right to Commercialize Product in the Field in the Territory during the
Term, subject to the terms and conditions of this Agreement. Without limiting the foregoing, during the Term, Sanofi will have the exclusive right and responsibility, at Sanofi’s sole expense (but subject to
EXHIBIT B), for the following with respect to Product in the Field in the Territory: 
 (i) establish the
Commercialization and marketing strategy and tactics (the “Commercial Strategy”); 
 (ii) establishing
pricing and reimbursement, including payment of applicable rebates and chargebacks; 
 (iii) managed care and government contracting
(including contracting for the Product to be available under the Government Health Care Programs); 
 (iv) receiving, accepting and
filling orders; 
 (v) distribution to customers; 

  
 26. 

 (vi) controlling invoicing, order processing and collecting accounts receivable for
sales; 
 (vii) recording sales in its books of account for sales; and 

(viii) tracking and reporting transfers of value in connection with Product under applicable state and federal “aggregate
spend”/“sunshine” reporting laws (except to the extent legally the responsibility of the Licensors). 
 (b)
Commercialization Plan. Within a reasonable time prior to anticipated launch of Product in any Major Market and
 [...***...] Country, Sanofi shall prepare and submit to the JAC a three-year, non-binding plan for the marketing, promotion
and pricing of Product in such Major Market or [...***...] Country, which plan shall be reasonable in scope and detail and may be amended by Sanofi (each, a “Commercialization Plan”). In addition, Sanofi shall prepare
and submit to the JAC for approval an initial Commercialization Budget to be included in each Commercialization Plan that specifies amounts to be spent on Product launch, detailing, meetings, symposiums, Congressional support, clinical support,
brand support and other items during the first year of such Commercialization Plan. Thereafter, in the fourth Calendar Quarter of each Calendar Year during the Term, Sanofi shall prepare and submit to the JAC for review, discussion and approval an
initial draft of the Commercialization Budget for planned activities to be performed under such Commercialization Plan during the forthcoming Calendar Year. The JAC shall have the right to amend each annual Commercialization Budget from time to
time. Sanofi shall promptly provide any material amendments to a Commercialization Plan to the JAC. 
 (c) Diligence. Sanofi shall use
Commercially Reasonable Efforts to market, promote and Commercialize Product in the Field in countries in the Territory where regulatory approval has been received, it being understood that the application of Commercially Reasonable Efforts may
result in Sanofi deciding not to market, promote or Commercialize Product in any particular country or countries. 
 5.2
Manufacture and Supply of Product. 
 (a) Generally. MannKind shall Manufacture and supply or have Manufactured and supplied to
Sanofi and its Affiliates or sublicensees their requirements of Product pursuant to the Supply Agreement or any other written agreement between the Parties for such purpose. 

(b) [...***...]. Promptly after the Effective Date, MannKind shall commence and diligently pursue [...***...].

 (c) Investments. Subject to the Supply Agreement, MannKind shall be responsible for making, during the Term, the capital
investments required in order to expand the capacity of the MannKind Facility (as defined in the Supply Agreement) so as to ensure the uninterrupted supply of Sanofi’s potential requirements of up to [...***...] cartridges of Product
annually. 

  
 ***Confidential Treatment
Requested 
 27. 

 CONFIDENTIAL 
  

(d) Capacity Expansion. The Manufacturing working group of the JAC will discuss planning for Manufacturing capacity expansion, which may
include the establishment and qualification of Sanofi or any of its Affiliates as a secondary source of supply of Product in accordance with the Supply Agreement.  

(e) Launch Conditions. Recognizing that Sanofi’s obligations to launch Product are ultimately determined by application of a
standard of Commercially Reasonable Efforts, the Licensors acknowledge that Sanofi does not intend to launch the Product before and until achievement or completion of the [...***...] Milestone. 

ARTICLE 6 

CONSIDERATION 

6.1 Initial Payment. In partial consideration for the licenses and rights granted to Sanofi hereunder, Sanofi shall pay to MannKind a
non-refundable, non-creditable payment in the amount of one hundred fifty million U.S. dollars ($150,000,000) within ten (10) days from the Effective Date. 

6.2 Milestone Payments. In partial consideration for the licenses and rights granted to Sanofi hereunder, Sanofi shall pay to the
Licensors, as specified below, the non-refundable, non-creditable milestone payments set out below following the first (1st) achievement of the corresponding milestone. Such payment shall be made within forty-five (45) days of
(a) Sanofi’s receipt of written notice from MannKind of the achievement of the applicable milestone by MannKind or (b) Sanofi notifying MannKind in writing of the achievement of the applicable milestone event by Sanofi, or any of its
Affiliates, as applicable, which notice must be delivered to MannKind within ten (10) days following the achievement of the applicable milestone event. 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 1. Manufacturing Milestones
	  			
	 (a) [...***...] Milestone
	  	$	[...***...]	  
	 (b) [...***...] Milestone†
	  	$	[...***...]	  
	 (b) [...***...] Milestone†
	  	up to $	[...***...]	* 
	 2. Regulatory Milestones
	  			
	 (a) [...***...]
	  	$	[...***...]	  
	 (b) [...***...]
	  	$	[...***...]	  

  
 ***Confidential Treatment
Requested 
 28. 

 CONFIDENTIAL 
  

 

					
	 3. Sales Milestones
	  			
	 (a) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 (b) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 (c) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 (d) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 (e) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 (f) Annual Net Sales of Product in the Territory first exceed
$[...***...]
	  	$	[...***...]	  
	 4. [...***...]
	  			
	 [...***...]
	  	$	[...***...]	  

  

	*	If the [...***...] Milestone is achieved and MannKind has [...***...] of up to [...***...] Sanofi shall pay an amount equal to the product of: (i) [...***...] U.S. Dollars
($[...***...]) multiplied by (ii) the quotient of the (A) [...***...] divided by (B) 
[...***...]. 

  

	†	 If for any reason (e.g., [...***...], etc.) the JAC determines that MannKind should not [...***...], as contemplated by
Sections 1.62 and 1.63, [...***...] despite the fact that MannKind has demonstrated the ability to [...***...], (i) MannKind shall have no obligation to [...***...], (ii) MannKind will be deemed to have achieved both
the [...***...] Milestone (if not previously achieved) and the [...***...] Milestone and (iii) Sanofi shall pay in full to Licensors the corresponding milestone payments (to the extent not previously paid) in accordance with this
Section 6.2. 

  
 ***Confidential Treatment
Requested 
 29. 

 
Any milestone payment payable by Sanofi pursuant to Section 6.2 shall be made no more than once with respect to the achievement of each such milestone event, upon the first achievement of
such milestone event. “Annual Net Sales” as described above shall be measured on a Calendar Year basis. For clarity, if annual Net Sales in a Calendar Year satisfies more than one milestone event set forth above, then payment shall be made
for each such milestone event that is satisfied. Sales of Product by sublicensees of Sanofi that would be considered Net Sales if made by Sanofi shall be included in the computation of “Annual Net Sales” for purposes of this
Section 6.2. 
 All payments in respect of the Manufacturing Milestones and the [...***...] milestone above shall be made to MannKind. All payments in
respect of the Regulatory Milestones above shall be made to TICV (or one or more permitted assignees designated by TICV). All payments in respect of the Sales Milestones above shall be made to MannKind and TICV (or one or more permitted assignees
designated by the foregoing) in proportion to Net Sales of Product in the United States, and outside the United States, respectively, for the applicable Calendar Year. Notwithstanding the foregoing, MannKind may, upon five (5) Business Days
written notice to Sanofi, change the payee of the foregoing payments as between MannKind, TICV and BV such that the allocation of payments reflects the utilization of assets owned by or exclusively licensed to each such entity in the relevant
territory or territories to which the payments relate. 
 6.3 Payment of Expenses; Sharing of Profit and Loss.
EXHIBIT B sets forth the terms regarding responsibility for payment of Allowable Expenses and calculation and sharing of Profit and Loss. For any countries outside the United States, the Parties may include as an Allowable
Expense in the calculation of Profit the expenses of recordkeeping and compliance with EXHIBIT B; as such, and for other reasons, the Parties may agree that in such other countries it may be preferable to have the
Licensors’ remuneration computed as a royalty on Net Sales (any such country, a “Royalty Country”). All payments of worldwide Profit shall be paid to MannKind and TICV (or one or more permitted assignees
designated by the foregoing) on the basis that (a) MannKind shall be paid the Profit determined for the United States only in U.S. Dollars, and (b) TICV shall be paid the remaining amount of the worldwide Profit after deducting the amount
paid to MannKind pursuant to (a) above; provided that if there is Profit in only one of the United States and the Territory outside the United States and a loss in the other territory, the entirety of the worldwide Profit shall be paid to
either MannKind (in the case of Profit only in the United States) or TICV (in the case of Profit only in the Territory outside the United States) and no balancing payment shall be due for other jurisdiction. All payments of royalties on Net Sales in
Royalty Countries shall be paid to TICV (or one or more permitted assignees designated by TICV). 
 ARTICLE 7 

PAYMENTS, BOOKS AND RECORDS 

7.1 Payment Method. All payments under this Agreement shall be made by bank wire transfer in immediately available funds to an account
in the name of MannKind or TICV (or one or more permitted assignees designated by the foregoing), as applicable, designated in 

  
 ***Confidential Treatment
Requested 
 30. 

 CONFIDENTIAL 
  

writing by the Licensors. Payments hereunder will be considered to be made as of the day on which they are received by the receiving Party’s designated bank. 

7.2 Payment Currency. Unless otherwise expressly stated in this Agreement, all amounts specified to be payable under this Agreement are
in Euros. Net Sales, Allowable Expenses and other elements of Profit invoiced in currency other than Euros, as appropriate, shall be translated to Euros shall be performed in a manner consistent with Sanofi’s normal practices used to prepare
its audited financial statements for external reporting purposes, which uses a widely accepted source of published exchange rates, as disclosed to MannKind. 

7.3 Taxes. 
 (a)
Cooperation and Coordination. The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the extent feasible, taxes payable with respect to their collaborative efforts under this Agreement and that they shall
use their reasonable efforts to cooperate and coordinate with each other to achieve such objective. 
 (b) Payment of Tax. 

(i) Subject to the provisions of this Section 7.3(b), each Party shall pay or economically bear (in the case of withholding taxes)
all taxes imposed upon such Party. If Applicable Laws require that taxes be deducted and withheld from a payment, the remitting Party shall (i) deduct those taxes from the payment; (ii) pay the taxes to the proper taxing authority;
(iii) send evidence of the obligation together with proof of payment to such taxing authority to the other Party within 30 days following that payment; and (iv) cooperate with the other Party in any way reasonably required to obtain
available reductions, credits or refunds of such taxes. The cooperation referred to in clause (iv) of the foregoing sentence shall include that MannKind, TICV and BV shall provide Sanofi with a written confirmation from the competent tax
authority that MannKind has its residence in the United States, and TICV and BV have their respective residences in the Netherlands, together with a copy of the necessary German exemption certificate(s) to benefit from the zero percent withholding
tax rate set forth in Article 12 of the Double Taxation Convention existing between Germany and the United States and the double tax treaty between Netherlands and Germany. 

(ii) All remuneration amounts payable by Sanofi to the Licensors are net amounts. It is the common understanding of the Parties that
the transactions under this Agreement are subject to the reverse-charge-mechanism under the German VAT Code. Sanofi shall be responsible for all Value Added Taxes (“VAT” – Umsatzsteuer) attributable to transactions contemplated
by this Agreement without any offset or reimbursement from the Licensors. The Licensors will refer to the reverse-charge-mechanism in its invoices and will not add VAT to the net amounts in the invoices. Sanofi will pay this VAT according to the
German VAT Code. The Licensors shall cooperate with Sanofi in any way reasonably requested by Sanofi to obtain available reductions, credits or refunds of any VAT amounts attributable to transactions contemplated by this Agreement. In the event that
the reverse-charge-mechanism should not be applicable, VAT shall be added to the net amounts and be paid by Sanofi to the 

  
 31. 

 CONFIDENTIAL 
  

Licensors. In this case, Sanofi is entitled to receive a proper tax invoice where any VAT amount is shown separately. 

(iii) Notwithstanding the foregoing, if Sanofi takes any action, including any assignment or transfer of some or all of its rights and
obligations to any Person and if, as a result of such action, the withholding or deduction of tax is required by (or is increased under) Applicable Law with respect to payments under this Agreement then any amount payable under this Agreement shall
be increased to take into account such withheld taxes as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts) the recipient payee receives an amount equal to the sum they would have
received had no such withholding been made. 
 7.4 Records. Each Party shall keep, and require its Affiliates to keep, complete, true
and accurate books of accounts and records for the purpose of determining the amounts payable pursuant to this Agreement. Such books and records shall be kept for such period of time required by law, but no less than three years following the end of
the Calendar Quarter to which they pertain. Such records shall be subject to inspection in accordance with Section 7.5. 
 7.5
Audits. Upon not less than 60 days’ prior written notice, the Licensors, in the case of Allowable Expenses incurred by the Licensors or Sanofi, in the case of Allowable Expenses incurred by Sanofi and determination of Profit or Loss
according to EXHIBIT B (as applicable, the “Audited Party”) shall permit an independent, certified public accountant selected by the other Party (the “Auditing Party”) and
reasonably acceptable to the Audited Party, which acceptance will not be unreasonably withheld or delayed (for the purposes of this Section 7.5, the “Auditor”), to audit or inspect those books or records of the Audited
Party and its Affiliates that relate to Allowable Expenses and Profit or Loss (including the items included in the calculation of Profit or Loss) for the sole purpose of verifying the amounts payable hereunder. The Auditor will disclose to the
Auditing Party only the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement. The Auditor will send a copy of the report to the Audited Party at the same time it is sent to the Auditing Party. Such
inspections may be made no more than once each Calendar Year and during normal business hours, and shall not be permitted at any time after the three (3) year period immediately following the applicable Calendar Year. No such inspection shall
be made more than once for each applicable period. Such records for any particular Calendar Quarter shall be subject to no more than one inspection. Inspections conducted under this Section 7.5 shall be at the expense of the Auditing Party,
unless a variation or error producing an underpayment in amounts payable exceeding 5% of the amount paid for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period and any
unpaid amounts that are discovered shall be paid by the Audited Party. The Parties will endeavor in such inspection to minimize disruption of the Audited Party’s normal business activities to the extent reasonably practicable. 

7.6 Late Payments. In the event that any payment due under this Agreement is not made when due, the payment shall accrue interest from
the date due at a rate per annum equal to 1% above the U.S. Prime Rate (as set forth in the Wall Street Journal, Eastern Edition) for the date on which payment was due, calculated daily on the basis of a 365-day year, or similar reputable data
source; provided that, in no event shall such rate exceed the maximum legal 

  
 32. 

 CONFIDENTIAL 
  

annual interest rate. The payment of such interest shall not limit the Party entitled to receive such payment from exercising any other rights it may have as a consequence of the lateness of any
payment. 
 ARTICLE 8 

CONFIDENTIALITY 

8.1 Confidential Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by MannKind
and Sanofi, the Parties agree that the receiving Party (the “Receiving Party”), shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement or any
other written agreement between the Parties or between the Licensors and Sanofi any confidential or proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which
is disclosed or made available to it by or on behalf of the other Party (the “Disclosing Party”) including all information concerning Product and any other technical or business information of whatever nature (collectively,
“Confidential Information”). For clarification, all MannKind Technology shall be Confidential Information of MannKind and, as applicable, TICV and BV, and all Sanofi Technology shall be Confidential Information of Sanofi. The
Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its employees, agents, consultants and other
representatives do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information. 

8.2 Exceptions. Notwithstanding Section 8.1, the obligations of confidentiality and non-use
shall not apply to Confidential Information that, in each case as demonstrated by competent evidence: 
 (a) was already known to the
Receiving Party or any of its Affiliates, other than under an obligation of confidentiality, at the time of disclosure; 
 (b) was
generally available to the public or was otherwise part of the public domain at the time of its disclosure to the Receiving Party; 
 (c)
became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party and other than through any act or omission of the Receiving Party or any of its Affiliates in breach of this Agreement;

 (d) was subsequently lawfully disclosed to the Receiving Party or any of its Affiliates by a Person other than the Disclosing
Party, and who, to the best knowledge of the Receiving Party, did not directly or indirectly receive such information directly or indirectly from the Disclosing Party under an obligation of confidence; or 

  
 33. 

 CONFIDENTIAL 
  

(e) was developed by the Receiving Party or its Affiliate without use of or reference to any information or materials disclosed by the
Disclosing Party. 
 8.3 Permitted Disclosures. Notwithstanding Section 8.1, the Receiving Party may disclose Confidential
Information of the Disclosing Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances: 

(a) filing or prosecuting Patents as permitted by this Agreement; 

(b) prosecuting or defending litigation as permitted by this Agreement; 

(c) complying with applicable court orders or governmental regulations; 

(d) disclosure to Affiliates, sublicenseees, contractors, employees and consultants who need to know such information in connection with
Development, Manufacturing, regulatory and Commercialization activities with respect to Product as contemplated by this Agreement, on the condition that any such Persons are subject to confidentiality and non-use obligations consistent in scope with
those set forth in this Article 8; and 
 (e) disclosure to Third Parties in connection with due diligence or similar investigations
by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by similar terms of confidentiality and non-use consistent in scope
with those set forth in this Article 8. 
 In the event the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential
Information pursuant to Section 8.3(b) or (c), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use efforts to secure confidential treatment of such information at least as
diligent as the Receiving Party would use to protect its own confidential information, but in no event less than reasonable efforts; provided, that any Confidential Information so disclosed shall remain subject to the restrictions on use set
forth in this Article 8. In any event, the Receiving Party agrees to take all reasonable action to avoid disclosure of Confidential Information hereunder. 

8.4 Confidentiality of this Agreement and its Terms. Except as otherwise provided in this Article 8, each Party agrees not to disclose
to any Third Party the terms of this Agreement without the prior written consent of the other Party hereto, except that each Party may disclose the terms of this Agreement, which are not otherwise made public as contemplated by Section 8.5, as
permitted under Section 8.3. 
 8.5 Public Announcements. 

(a) Press Releases. As soon as practicable following the execution of this Agreement, the Parties will issue a joint press release
announcing the existence of this Agreement. Except as required by Applicable Laws, including disclosure requirements of the 

  
 34. 

 CONFIDENTIAL 
  

SEC, the NASDAQ stock exchange or any other stock exchange on which securities issued by a Party or its Affiliates are traded, neither Party shall make any
other public announcement concerning this Agreement or the subject matter hereof without the prior written consent of the other, which shall not be unreasonably withheld or delayed; provided, that it shall not be unreasonable for a Party to withhold
consent with respect to any public announcement containing any of such Party’s Confidential Information. In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall
provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text. 

(b) Filing of Agreement. The Parties will coordinate in advance with each other in connection with the filing of this Agreement
(including redaction of certain provisions of this Agreement) with the SEC, the NASDAQ stock exchange or any other stock exchange or governmental agency on which securities issued by a Party or its Affiliate are traded, and each Party will use
reasonable efforts to seek confidential treatment for the terms proposed to be redacted; provided, that each Party will ultimately retain control over what information to disclose to the SEC, the NASDAQ stock exchange or any other stock exchange or
governmental agency, as the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other
governing bodies. Other than such obligation, neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC, the NASDAQ stock exchange or any other stock exchange
or governmental agency. 
 8.6 Publication of the Product Information. During the Term, Sanofi shall be entitled to issue scientific
publications with respect to Product or its testing, in accordance with Sanofi’s internal guidelines; provided, however, that Sanofi shall adhere to academic attribution standards in any such publications;
provided further, that at least thirty (30) days prior to publishing, publicly presenting and/or submitting for written or oral publication a manuscript, abstract or the like that includes Information relating to any
Product that has not been previously published, Sanofi shall provide to MannKind a draft copy thereof for its review (unless Sanofi is required by Applicable Laws to publish such Information sooner, in which case Sanofi shall provide such draft copy
to MannKind as much in advance of such publication as possible). Sanofi shall consider in good faith any comments provided by MannKind during such thirty (30)-day period. In addition, Sanofi shall, at MannKind’s reasonable request, remove
therefrom any Confidential Information of MannKind. MannKind shall not publish or present regarding Product or its testing without Sanofi’s prior consent (except as MannKind may determine is appropriate in connection with the filing,
prosecution and maintenance of the MannKind Patents or Joint Patents and/or is required to comply with Applicable Law). 
 8.7
Prior Non-Disclosure Agreements. As of the Effective Date, the terms of this Article 8 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) dealing with the subject of this
Agreement, including the Confidentiality Agreement. Any information disclosed under such prior agreements shall be deemed disclosed under this Agreement. 

  
 35. 

 CONFIDENTIAL 
  

8.8 Equitable Relief. Given the nature of the Confidential Information and the competitive damage that a party would suffer upon
unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the parties agree that monetary damages would not be a sufficient remedy for any breach of this Article 8. In addition to all other remedies, a party shall
be entitled to specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 8. 

ARTICLE 9 

INTELLECTUAL PROPERTY 

9.1 Ownership of Intellectual Property. 

(a) MannKind Know-How, MannKind Patents. MannKind has, and shall retain all right, title and interest in and to, the MannKind Know-How
and the MannKind Patents. 
 (b) Inventions. For purposes of determining questions of inventorship for Inventions, the Parties shall
apply the laws of the United States. A Party shall have and retain all right, title and interest in all Inventions which are invented solely by one or more employees or contractors of such Party or its Affiliates, and (ii) the Parties shall
jointly own all right, title and interest in all Joint Inventions and Joint Patents. Subject to the rights and licenses granted under this Agreement, each Party shall have the right to use, and grant licenses to use, any Joint Invention and Joint
Patent without the other Party’s consent and shall have no duty to account to the other Party for such use or license, and each Party hereby waives any right it may have under the laws of any country to require any such consent or accounting.

 9.2 Patent Prosecution and Maintenance. 

(a) MannKind Patents. 

(i) Initial Responsibility. MannKind shall be responsible, in its discretion, for the preparation, filing, prosecution and maintenance
of all MannKind Patents (including the right to conduct any interferences or oppositions (subject to Section 9.2(d)) thereon and to request any reissues or patent term extensions thereof), at MannKind’s sole expense. With respect to
MannKind Patents, MannKind shall provide in-house patent counsel designated by Sanofi: 
 (A) with a copy of the final draft of any
proposed application at least 30 days prior to filing the same in any patent office in the Territory, unless otherwise agreed by patent counsel for both parties. Sanofi shall have the right to provide suggestions and recommendations regarding the
content of the proposed application by no later than 15 days prior to its filing. MannKind shall give reasonable consideration to and will not unreasonably refuse to accept any suggestions or recommendations Sanofi provides; 

(B) with a copy of all Patent applications as filed, together with a notice of its filing date and serial number; 

  
 36. 

 CONFIDENTIAL 
  

(C) with a copy of any action, communication, letter, or other correspondence issued by the relevant patent office within at least 10
days of receipt thereof; 
 (D) with a copy of any response, amendment, paper, or other correspondence to be filed with the
relevant patent office no more than 30 days prior to filing the same in any patent office in the Territory, unless otherwise agreed by patent counsel for both Parties. Sanofi shall have the right to provide suggestions and recommendations regarding
the content of the response, amendment, paper, or other correspondence by no later than 15 days prior to its filing. MannKind shall give reasonable consideration to and will not unreasonably refuse to accept any suggestions or recommendations Sanofi
provides; 
 (E) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant patent
office no more than 10 days after MannKind receives confirmation from the relevant patent office that the response, amendment, paper, or other correspondence has indeed been filed; and 

(F) with notification of the allowance, grant, or issuance of any MannKind Patent. 

(ii) Option of Sanofi to Maintain. In the event that MannKind desires to abandon or cease maintenance of any issued MannKind Patent in
the Territory under which Sanofi then has a license under this Agreement, MannKind shall provide reasonable prior written notice to in-house patent counsel designated by Sanofi of such intention to abandon (which notice shall, to the extent
possible, be given no later than 90 days prior to the next deadline for any action that must be taken with respect to any such issued MannKind Patent in the relevant patent office). Sanofi shall then have the right, but not obligation, to assume
responsibility for the maintenance of such issued MannKind Patent in Sanofi’s name and at Sanofi’s own expense, upon providing written notice to MannKind of its assumption of this responsibility. In such case, MannKind shall assign all of
its right, title and interest in such issued MannKind Patent to Sanofi, and shall perform all acts that Sanofi reasonably requests to permit and assist Sanofi, at Sanofi’s expense, in obtaining, perfecting and enforcing the full benefits,
enjoyment, rights and title in such issued MannKind Patent in the Territory. Any issued MannKind Patent so assigned to Sanofi shall no longer be a considered a MannKind Patent and shall be considered a Sanofi Patent. 

(b) Sanofi Patents. Sanofi shall be responsible, in its discretion, for the preparation, filing, prosecution and maintenance of Sanofi
Patents (including the right to conduct any interferences, oppositions, or reexaminations (subject to Section 9.2(d)) thereon and to request any reissues or patent term extensions thereof), at Sanofi’s sole expense. Sanofi shall keep
MannKind informed in a timely manner, but not less frequently than quarterly, with regard to the preparation, filing, prosecution and maintenance of Sanofi Patents. Sanofi will consider in good faith the requests and suggestions of MannKind with
respect to strategies for filing and prosecuting Sanofi Patents. 

  
 37. 

 CONFIDENTIAL 
  

(c) Joint Patents. 

(i) Initial Responsibility. MannKind shall be responsible, in its discretion, for the preparation, filing, prosecution and maintenance
of Joint Patents in the Territory(including the right to conduct any interferences or oppositions (subject to Section 9.2(d)) thereon and to request any reissues or patent term extensions thereof), subject to this Section 9.2(c) and at
MannKind’s sole expense. 
 (ii) Cooperation. For any Joint Patents, MannKind shall keep Sanofi fully informed of progress with
regard to the preparation, filing, prosecution and maintenance of the Joint Patents in the Territory. With respect to Joint Patents, MannKind shall provide in-house patent counsel designated by Sanofi: 

(A) with a copy of the final draft of any proposed application at least 30 days prior to filing the same in any patent office in the
Territory, unless otherwise agreed by patent counsel for both parties. Sanofi shall have the right to provide suggestions and recommendations regarding the content of the proposed application by no later than 15 days prior to its filing. MannKind
shall accept any suggestions or recommendations Sanofi provides; 
 (B) with a copy of all Patent applications as filed,
together with a notice of its filing date and serial number; 
 (C) with a copy of any action, communication, letter, or other
correspondence issued by the relevant patent office within at least 10 days of receipt thereof; 
 (D) with a copy of any
response, amendment, paper, or other correspondence to be filed with the relevant patent office no more than 30 days prior to filing the same in any patent office in the Territory, unless otherwise agreed by patent counsel for both parties. Sanofi
shall have the right to provide suggestions and recommendations regarding the content of the response, amendment, paper, or other correspondence by no later than 15 days prior to its filing. MannKind shall accept any suggestions or recommendations
Sanofi provides; 
 (E) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant
patent office no more than 10 days after MannKind receives confirmation from relevant patent office that the response, amendment, paper, or other correspondence has indeed been filed; and 

(F) with notification of the allowance, grant, or issuance of such Joint Patent. 

(iii) Option of Sanofi to Prosecute and Maintain. In the event that MannKind desires to abandon or cease prosecution or maintenance of
any Joint Patent, MannKind shall provide reasonable prior written notice to Sanofi of such intention to abandon (which notice shall, to the extent possible, be given no later than 90 days prior to the next deadline for any action that must be taken
with respect to such Joint Patent in the relevant patent office). In such case, at Sanofi’s sole discretion, upon written notice from Sanofi, Sanofi may elect to continue prosecution and maintenance of any such Joint Patent at its own expense,
and 

  
 38. 

 CONFIDENTIAL 
  

MannKind shall execute such documents and perform such acts, at MannKind’s expense, as may be reasonably necessary to effect an assignment of MannKind’s entire right, title, and
interest in and to such Joint Patent to Sanofi. Any such assignment shall be completed in a timely manner to allow Sanofi to continue prosecution and maintenance of any such Joint Patent. Any Patents so assigned shall no longer be considered Joint
Patents and shall be considered Sanofi Patents. 
 (d) Post Grant Proceedings. 

(i) By Third Party for Product-Specific MannKind Patents or Joint Patents. In the event that MannKind becomes aware that a Third Party
has filed a post grant proceeding with respect to any Product-Specific MannKind Patent or Joint Patent, MannKind will notify Sanofi in writing to that effect within 10 days of becoming aware of such filing. Once such a post grant proceeding has
commenced, MannKind shall provide in-house patent counsel designated by Sanofi: 
 (A) with a copy of any action, communication,
letter, or other correspondence issued by the relevant patent office or the third party within at least 10 days of receipt thereof; 

(B) with a copy of any response, amendment, paper, or other correspondence to be filed with the relevant patent office no more than 30
days prior to filing the same in any patent office worldwide, unless otherwise agreed by patent counsel for both parties. Sanofi shall have the right to provide suggestions and recommendations regarding the content of the response, amendment, paper,
or other correspondence by no later than 15 days prior to its filing. MannKind shall accept any suggestions or recommendations Sanofi provides;  

(C) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant patent office no more than 10
days after MannKind receives confirmation from the relevant patent office that the response, amendment, paper, or other correspondence has indeed been filed; and  

(D) MannKind shall not settle any post grant proceeding a Third Party files without the prior written approval of Sanofi, not to be
unreasonably withheld or delayed. 
 (ii) By Third Party for Platform MannKind Patents. In the event that MannKind becomes
aware that a third Party has filed a post grant proceeding with respect to any Platform MannKind Patent, MannKind shall provide in-house patent counsel designated by Sanofi: 

(A) with any copy of any action, communication, letter, or other correspondence issued by the relevant patent office or the third party
within at least 10 days of receipt thereof; 
 (B) with a copy of any response, amendment, paper or other correspondence to be
filed with the relevant patent office no more than 30 days prior to filing the same in any patent office worldwide, unless otherwise agreed by patent counsel for both parties. 

  
 39. 

 CONFIDENTIAL 
  

Sanofi shall have the right to provide suggestions and recommendations regarding the content of the response, amendment, paper or other correspondence by no later than 15 days prior to its
filing. MannKind shall give reasonable consideration to and will not unreasonably refuse to accept any suggestions or recommendations Sanofi provides; 

(C) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant patent office no more than 10
days after MannKind receives confirmation from the relevant patent office that the response, amendment, paper or other correspondence has indeed been filed; and 

(D) MannKind shall not settle any post grant proceeding a Third Party files without the prior written approval of Sanofi, not to be
unreasonably withheld or delayed. 
 (iii) By Party for Product-Specific MannKind Patents or Joint Patents. Should a Party
desire to file a post grant proceeding with respect to a Product-Specific MannKind Patent or a Joint Patent, including but not limited to an ex parte reexamination or a supplemental examination, such Party shall so notify the other Party. The
Parties shall then consult with each other and consider each other’s input with respect to whether such a post grant proceeding should be filed; provided, however, Sanofi shall have final decision authority with respect to
the filing of such a proceeding. Should such a proceeding be filed, MannKind shall provide in-house patent counsel designated by Sanofi: 

(A) with a copy of any action, communication, letter, or other correspondence issued by the relevant patent office within at least 10
days of receipt thereof; 
 (B) with a copy of any response, amendment, paper, or other correspondence to be filed with the
relevant patent office no more than 30 days prior to filing the same in any patent office worldwide, unless otherwise agreed by patent counsel for both parties. Sanofi shall have the right to provide suggestions and recommendations regarding the
content of the response, amendment, paper, or other correspondence by no later than 15 days prior to its filing. MannKind shall accept any suggestions or recommendations Sanofi provides; 

(C) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant patent office no more than 10
days after MannKind receives confirmation from the relevant patent office that the response, amendment, paper, or other correspondence has indeed been filed; and 

(D) MannKind shall not settle such a post grant proceeding without the prior written approval of Sanofi, not to be unreasonably
withheld or delayed.  
 (iv) By Party for Platform MannKind Patent. Should a Party desire to file a post grant proceeding
with respect to a Platform MannKind Patent, including but not limited to an ex parte reexamination or a supplemental examination, such Party shall so notify the other Party. The Parties shall then consult with each other and consider each
other’s input with respect to whether such a post grant proceeding should be filed; provided, however, 

  
 40. 

 CONFIDENTIAL 
  

MannKind shall have final decision authority with respect to the filing of such a proceeding. Should such a proceeding be filed, MannKind shall provide in-house patent counsel designated by
Sanofi: 
 (A) with a copy of any action, communication, letter, or other correspondence issued by the relevant patent office
within at least 10 days of receipt thereof; 
 (B) with a copy of any response, amendment, paper, or other correspondence to
be filed with the relevant patent office no more than 30 days prior to filing the same in any patent office worldwide, unless otherwise agreed by patent counsel for both parties. Sanofi shall have the right to provide suggestions and recommendations
regarding the content of the response, amendment, paper, or other correspondence by no later than 15 days prior to its filing. MannKind shall give reasonable consideration to and not unreasonably refuse to accept any suggestions or recommendations
Sanofi provides; 
 (C) with a copy of any response, amendment, paper, or other correspondence as filed with the relevant
patent office no more than 10 days after MannKind receives confirmation from the relevant patent office that the response, amendment, paper, or other correspondence has indeed been filed; and 

(D) MannKind shall not settle such a post grant proceeding without the prior written approval of Sanofi, not to be unreasonably
withheld or delayed.  
 9.3 Infringement by Third Parties. 

(a) Notice. In the event that either MannKind or Sanofi becomes aware of any infringement or threatened infringement by a Third Party of
any Patents that are subject to the prosecution, maintenance or enforcement rights of the other Party under this Agreement, it will notify the other Party in writing to that effect within 10 days of receipt of such notice. Any such notice shall
include evidence to support an allegation of infringement or threatened infringement by such Third Party. 
 (b) MannKind Patents.

 (i) Product-Specific MannKind Patents. Subject to this Section 9.3(b), Sanofi shall have the first right (but not the
obligation), as between MannKind and Sanofi, to bring and control any action or proceeding with respect to infringement of any Product-Specific MannKind Patent, at its own expense and by counsel of its own choice. MannKind shall have the right, at
its own expense, to be represented in any such action by counsel of its own choice, and Sanofi and its counsel will reasonably cooperate with MannKind and its counsel in strategizing, preparing and presenting any such action or proceeding. Sanofi
though shall have the final word regarding litigation strategy. If Sanofi fails to bring an action or proceeding with respect to infringement of any Product-Specific MannKind Patent described in the preceding sentence within (i) 90 days
following the notice of alleged infringement or (ii) 10 days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, MannKind shall have the right (but not
the obligation) to 

  
 41. 

 CONFIDENTIAL 
  

bring and control any such action at its own expense and by counsel of its own choice, and Sanofi shall have the right, at its own expense, to be represented in any such action by counsel of
its own choice. MannKind and its counsel will reasonably cooperate with Sanofi and its counsel in strategizing, preparing and presenting any such action or proceeding. Except as otherwise agreed to by the Parties as part of a cost-sharing
arrangement, any recovery or damages realized as a result of such action or proceeding shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and (A) any remaining
compensatory damages relating to Product (including lost sales or lost profits with respect to the Product) shall be deemed Net Sales for purposes of calculation of Profit or Loss, and (B) any punitive damages shall be shared by the Parties
according to the ratio set forth in Section 3 of EXHIBIT B. 
 (ii) Platform MannKind Patents.
Subject to this Section 9.3(b), the Controlling Party shall have the first right (but not the obligation), as between MannKind and Sanofi, to bring and control any action or proceeding with respect to Competitive Infringement of any Platform
MannKind Patent, at its own expense and by counsel of its own choice, and the other Party shall have the right, at its own expense, to be represented in any such action by counsel of its own choice, and the Controlling Party and its counsel will
reasonably cooperate with the other Party and its counsel in strategizing, preparing and presenting any such action or proceeding. If the Controlling Party fails to bring an action or proceeding with respect to an alleged Competitive Infringement of
any such Platform MannKind Patent within (i) 90 days following the notice of alleged Competitive Infringement or (ii) 10 days before the time limit, if any, set forth in the appropriate laws and regulations for filing such actions,
whichever comes first, the other Party shall have the right (but not the obligation) to bring and control any such Competitive Infringement action or proceeding by counsel of its own choice, thereby becoming the Controlling Party and subject to the
obligation to reasonably cooperate with the other Party and its counsel in strategizing, preparing and presenting any such action or proceeding. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any recovery or
damages realized as a result of such Competitive Infringement action or proceeding shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the infringement action or proceeding, and (A) any
remaining compensatory damages relating to Product (including lost sales or lost profits with respect to the Product) shall be deemed Net Sales for purposes of calculation of Profit or Loss, and (B) any punitive damages shall be shared by the
Parties according to the ratio set forth in Section 3 of EXHIBIT B. For purposes of this Section 9.3(b)(ii), “Controlling Party” shall mean Sanofi for actions commenced during such time
that Sanofi is the sole licensee of such Platform MannKind Patent, and shall mean MannKind for all other actions, and “Competitive Infringement” shall mean (i) any allegedly infringing activity in the Field in the
Territory for the Product, which activity is reasonably expected to reduce Net Sales of Product then being sold by Sanofi and its Affiliates and sublicensees in the Territory, or (ii) the making, using, selling, offering for sale or importing
Product in the Territory. 
 (c) Sanofi Patents. Subject to this Section 9.3(c), Sanofi shall have the sole right (but not the
obligation), as between MannKind and Sanofi, to bring and control any action or proceeding with respect to infringement of any Sanofi Patent worldwide, at its own expense and by counsel of its own choice and any recovery or damages realized as a
result of such action 

  
 42. 

 CONFIDENTIAL 
  

or proceeding shall be used first to reimburse Sanofi’s documented out-of-pocket legal expenses relating to the action or proceeding, and (A) any remaining compensatory damages
relating to Product (including lost sales or lost profits with respect to Product) shall be deemed Net Sales for purposes of calculation of Profit or Loss and (B) any punitive damages relating to Product shall be shared by the Parties according
to the ratio set forth in Section 3 of EXHIBIT B. 
 (d) Joint Patents. Subject to this
Section 9.3(d), Sanofi shall have the first right (but not the obligation) to bring and control any action or proceeding with respect to infringement of any Joint Patent worldwide, at its own expense and by counsel of its own choice. MannKind
shall cooperate in such action in the manner described in Section 9.3(e) and shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Sanofi though shall have the final word regarding
litigation strategy. If Sanofi fails to bring an action or proceeding within (i) 90 days following the notice of alleged infringement or (ii) 10 days before the time limit, if any, set forth in the appropriate laws and regulations for the
filing of such actions, whichever comes first, MannKind shall have the right (but not the obligation) to bring and control any such action at its own expense and by counsel of its own choice, and Sanofi shall cooperate in such an action as defined
in Section 9.3(e) and shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. Except as otherwise agreed to by the Parties as part of a cost-sharing arrangement, any recovery or damages from
an action or proceeding relating to Joint Patents shall be used first to reimburse the Parties’ documented out-of-pocket legal expenses relating to the action or proceeding, and (A) any remaining compensatory damages relating to Product
(including lost sales or lost profits with respect to Product) shall be deemed Net Sales for purposes of calculation of Profit or Loss, and (B) any punitive damages shall be shared by the Parties according to the ratio set forth in
Section 3 of EXHIBIT B. 
 (e) Cooperation. In the event a Party brings an infringement action in
accordance with this Section 9.3, the other Party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being joined as a party to such action. 

9.4 TICV. MannKind warrants that TICV does not have legal title to any of the MannKind Patents or rights to maintain, prosecute or
enforce such patents. If, notwithstanding the foregoing, TICV’s action is required to give effect to the provisions of this Article 9, MannKind shall cause TICV to take such action. 

9.5 Infringement of Third Party Rights. 

(a) Each Party shall promptly notify the other in writing of any allegation by a Third Party that the activity of either of the Parties
pursuant to this Agreement or the Supply Agreement infringes or may infringe the intellectual property rights of such Third Party.  

(b) MannKind shall have the sole right (but not the obligation), as between MannKind, TICV and BV, on the one hand, and
Sanofi, on the other hand, to bring and control any defense of any such claim involving alleged infringement of Third Party rights by MannKind’s, TICV’s or BV’s activities pursuant to this Agreement or the Supply Agreement at its own
expense and by counsel of its own choice; provided, however, that such expenses shall be 

  
 43. 

 CONFIDENTIAL 
  

considered Allowable Expenses for the purposes of EXHIBIT B. Sanofi shall have the right, at its own expense, to be represented in any such defense by
counsel of its own choice. MannKind shall solely bear all of its costs related to the defense of such an infringement action as well as any and all damages awarded to the Third Party. Should MannKind conclude it is necessary to obtain a license in
the intellectual property rights of the Third Party for MannKind, TICV or BV to conduct activities for which it is reasonable as contemplated by this Agreement or the Supply Agreement, MannKind shall pay all costs and royalties necessary to obtain
such license and maintain such license, at its own expense, during the Term. 
 (c) Sanofi shall have the sole right (but not
the obligation), as between Sanofi, on the one hand, and MannKind, TICV and BV, on the other hand, to bring and control any defense of any such claim involving alleged infringement of Third Party rights by Sanofi’s and its Affiliates’ and
sublicensees’ activities pursuant to this Agreement or the Supply Agreement at its own expense and by counsel of its own choice. MannKind shall have the right to be represented in any such defense by counsel of its own choice at its own
expense; provided, however, that such expenses shall be considered Allowable Expenses for purposes of EXHIBIT B. Sanofi shall bear all of its costs related to the defense of such an infringement action
as well as any and all damages awarded to the Third Party; provided, however, that such costs and damages (but excluding any such damages for willful infringement or willful misconduct by Sanofi or its Affiliates or sublicensees
and any litigation sanctions awarded against Sanofi or its Affiliates (collectively, “Special Damages”)) shall be considered Allowable Expenses for purposes of EXHIBIT B. Should Sanofi
conclude it is necessary to obtain a license in the intellectual property rights of the Third Party for Sanofi or its Affiliates or sublicensees to conduct activities for which it is responsible as contemplated by this Agreement or the Supply
Agreement, Sanofi shall pay all costs and royalties necessary to obtain such license and maintain such license, as an Allowable Expense, during the Term. 

9.6 Consent for Settlement. Neither Party shall enter into any settlement or compromise of any action or proceeding under this
Article 9 which would in any manner alter, diminish, or be in derogation of the other Party’s rights under this Agreement without the prior written consent of such other Party. 

9.7 Paragraph IV Notice. If either Party receives a notice under 21 U.S.C. §355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) (or any
foreign equivalent) concerning any MannKind Patent, Joint Patent or Sanofi Patent, then it shall provide a copy of such notice to the other Party within two Business Days after its receipt thereof. Patent infringement litigation based on such a
notice concerning a MannKind Patent, Joint Patent or Sanofi Patent shall be brought and controlled as provided in Section 9.3(b), 9.3(c) or 9.3(d), as applicable.  

9.8 Biosimilar Applications. 

(a) If either Party receives a copy of an application submitted to the FDA under subsection (k) of
Section 351 of the Public Health Service Act (“PHSA”) or comparable provisions of Applicable Laws in any other jurisdiction (a “Biosimilar Application”) naming a Product as a reference product or
otherwise becomes aware that such a Biosimilar Application has been filed (such as in an instance described in Section 351(1)(9)(C) of the PHSA) or any 

  
 44. 

 CONFIDENTIAL 
  

equivalent or similar certification or notice in any other jurisdiction, such Party shall, within 10 Business Days, notify the other Party. Sanofi will then seek permission to view the
application and related confidential information from the filer of the Biosimilar Application under Section 351(l)(1)(B)(iii) of the PHSA. Regardless of the Party that is the “reference product sponsor” for purposes of such Biosimilar
Application, Sanofi shall have the sole right: 
 (i) to designate pursuant to Section 351(l)(1)(B)(ii) of the
PHSA or comparable provisions of Applicable Laws in any other jurisdiction the outside counsel and in-house counsel who shall receive confidential access to the Biosimilar Application;  

(ii) to list any Patents, including MannKind Patents, Sanofi Patents and Joint Patents, insofar as they claim or cover the applicable
Product as required pursuant to Section 351(l)(3)(A), Section 351(l)(5)(b)(i)(II), or Section 351(l)(7) of the PHSA or comparable provisions of Applicable Laws in any other jurisdiction; 

(iii) to respond to any communications with respect to such lists from the filer of the Biosimilar Application;  

(iv) to negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange
other than that specified in Section 351(l) of the PHSA or comparable provisions of Applicable Laws in any other jurisdiction; and 

(v) to identify Patents or respond to communications under any equivalent or similar listing in any other jurisdiction with respect to
the applicable Product.  
 (b) If required pursuant to Applicable Law, MannKind shall prepare such list and make such response
at Sanofi’s direction. MannKind will provide to Sanofi, within 15 days of Sanofi’s request, all information, including a correct and complete list of MannKind and Joint Patents that is necessary or reasonably useful to enable Sanofi to
make such lists of Patents that cover the Product, and cooperate with Sanofi’s reasonable requests in connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted by Applicable Law. Sanofi
shall reasonably consult with MannKind prior to identifying any MannKind Patents to a Third Party as contemplated by this Section 9.8. Sanofi shall consider in good faith advice and suggestions with respect thereto received from MannKind, and
notify MannKind of any such lists or communications promptly after they are made. If Sanofi does not proceed under this Section 9.8, then thereafter MannKind shall have the right to proceed in place of Sanofi under this Section 9.8 with
the roles of the Parties reversed. For clarity, the subsequent enforcement of Patents against a filer of a Biosimilar Application shall be in accordance with Section 9.3. 

9.9 Orange Book Listings. The Parties shall consult with each other and consider input from each other as applicable with respect to the
listing of MannKind Patents, Joint Patents and Sanofi Patents with the applicable Regulatory Authorities; provided, however, that Sanofi shall have the final decision authority with respect to which Patents are to be listed. Sanofi shall have
the sole authority and discretion to maintain with the applicable Regulatory Authorities 

  
 45. 

 CONFIDENTIAL 
  

during the Term listings of applicable Sanofi Patents for Product then being Commercialized by Sanofi in the Territory, including all Orange Book listings required under the Hatch-Waxman Act (and
all foreign equivalents). With respect to MannKind Patents and Joint Patents, Sanofi shall instruct MannKind which Patents are to be listed, and MannKind shall promptly perform all acts necessary to maintain with all the applicable Regulatory
Authorities during the Term listings of the MannKind and Joint Patents Sanofi instructs MannKind to list, including the completion and filing of Form FDA 3542 as required for all Orange Book Listings under the Hatch-Waxman Act. 

ARTICLE 10 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

10.1 Mutual Representations, Warranties and Covenants. Each Party hereby represents and warrants to the other Party, as of the Effective
Date, as follows: 
 (a) Duly Organized. Such Party is a corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction of its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and
failure to have such would prevent such Party from performing its obligations under this Agreement. 
 (b) Due Authorization; Binding
Agreement. The execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary corporate action. This Agreement is a legal and valid obligation binding on such Party and enforceable in accordance
with its terms and does not: (i) to such Party’s knowledge and belief, violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having
jurisdiction over such Party; nor (ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound. 

(c) Consents. Such Party has obtained, or is not required to obtain, the consent, approval, order or authorization of any Third Party,
or has completed, or is not required to complete any registration, qualification, designation, declaration, or filing with, any Regulatory Authority or Governmental Authority, in connection with the execution and delivery of this Agreement and the
performance by such Party of its obligations under this Agreement, except as contemplated by Section 15.16. 
 (d) No Conflicting
Grant of Rights. Such Party has the right to grant the licenses and rights as contemplated under this Agreement and has not, and will not during the Term, grant any right to any Third Party which would conflict with the licenses and rights
granted to the other Party hereunder. 
 (e) Employee/Contractor Agreements. All of such Party’s and its Affiliates’
employees or contractors acting on its behalf pursuant to this Agreement are and will be obligated under a binding written agreement to assign to such Party or its designee all 

  
 46. 

 CONFIDENTIAL 
  

Inventions and to comply with obligations of confidentiality and non-use consistent in scope with those set forth in Article 8. 

(f) Debarment. Such Party is not debarred under the United States Federal Food, Drug and Cosmetic Act, excluded from a federal health
care program, or debarred from federal contracting, and such Party does not, and will not during the Term, employ or use the services of any Person who is so debarred or excluded, or who has been convicted of or pled nolo contendere to any felony,
or to any federal or state legal violation (including misdemeanors) relating to prescription drug or device products or fraud, or convicted of any other crime for which an entity or person could be so debarred or excluded (including by the FDA under
21 U.S.C. § 335a (or subject to a similar sanction of any other Governmental Authority)), in connection with the Development, Manufacture or Commercialization of the Products. In the event that either Party becomes aware of the debarment.
Exclusion, or threatened debarment or exclusion of any Person providing services to such Party, including the Party itself and its Affiliates, which directly or indirectly relate to activities under this Agreement, the other Party shall be
immediately notified in writing, and at the other Party’s option this Agreement shall terminate automatically as of the first date of such noncompliance. 

10.2 Representations and Warranties of the Licensors. The Licensors represent and warrant to Sanofi that, as of the Effective Date: 

(a) Patents. MannKind has delivered to Sanofi a list of MannKind Patents as of the Effective Date under separate cover, which
(i) is a true and complete list of all Patents Controlled by Licensors or their Affiliates as of the Effective Date that that claim or disclose Product or its components, or are necessary for the Development, Manufacture, use or
Commercialization of Product in the Field in the Territory, including all such Patents claiming or covering the design or utility of a Device or a Formulation, and (ii) indicates the current status, date and country of filing and issuance. All
official fees, maintenance fees and annuities for the MannKind Patents have been paid through the Effective Date. 
 (b) Patent and
Technology Status. As of the Effective Date, (i) all issued MannKind Patents are in full force and effect and subsisting, and inventorship of each Patent is properly identified on such Patents; (ii) none of the MannKind Patents is
currently involved in any interference, reissue, reexamination, or opposition proceeding; (iii) neither MannKind nor any of its Affiliates has received any written notice from any Person, or has knowledge, of such actual or threatened
proceeding; (iv) to the knowledge of the Licensors, all issued MannKind Patents and registered MannKind Trademarks are valid; (v) the Licensors have taken reasonable security measures consistent with industry standard practices, including
measures against unauthorized disclosure, to protect the secrecy and confidentiality of trade secrets within MannKind Technology; (vi) the Licensors are in compliance with and have complied with all duties of candor required by applicable
governing bodies or jurisdictions in the course of the Licensors’ prosecution of any rights in any of the MannKind Technology licensed to Sanofi under this Agreement; (vii) the Licensors have obtained valid and enforceable assignments of
interests to any rights in any of the MannKind Technology licensed to Sanofi under this Agreement from any inventors who contributed to the discovery, creation, development or reduction to practice of any such MannKind Technology; (viii) to the
knowledge of the 

  
 47. 

 CONFIDENTIAL 
  

Licensors, the MannKind Technology licensed to Sanofi under this Agreement comprises all of the intellectual property rights necessary and sufficient to develop and distribute Product and no
intellectual property rights owned by any Third Party are necessary to develop and distribute Product; and (ix) the Licensors are not subject to any inventor remuneration obligations related to the MannKind Technology. 

(c) Transfers of Undertakings Directive. Licensors do not employ any personnel in the European Union. 

(d) Non-Infringement by Third Parties. As of the Effective Date, to the Licensors’ knowledge, there are no activities by Third
Parties that would constitute infringement of the MannKind Patents or misappropriation of the MannKind Know-How.  
 (e)
Non-Infringement of Third Party Rights. Neither the Licensors nor any of their Affiliates have received any written notice from any Person, or have knowledge of, any actual or threatened claim or assertion that the use or practice of the
MannKind Patents, or MannKind Know-How infringes or misappropriates the intellectual property rights of a Third Party.  
 (f) No
Action or Claim. As of the Effective Date, there are no actual, pending, or alleged or threatened in writing, adverse actions, suits, claims, interferences or formal governmental investigations by or against the Licensors or any of their
Affiliates in or before any court, Governmental Authority involving any MannKind Know-How, MannKind Patents or Product, including in connection with the conduct of any clinical trials or Manufacturing activities. As of the Effective Date, there are
no material unsatisfied judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court, an administrative agency or by an arbitrator) against the Licensors with respect to any MannKind Know-How, MannKind
Patents or Product. The issued MannKind Patents have not been used or enforced in a manner that would result in the abandonment, cancellation or unenforceability of any such issued MannKind Patent. 

(g) No Governmental Funding. As of the Effective Date, none of the MannKind Patents has been developed with the use of any funding from
any Governmental Authority.  
 (h) Compliance. As of the Effective Date, the Licensors and their Affiliates and, to the
Licensors’ knowledge, any contract research organization to which the Licensors or their Affiliates have subcontracted activities in connection with Product have complied in all material respects with all Applicable Laws, including all good
clinical practices, good laboratory practices and good manufacturing practices, permits, governmental licenses, registrations, approvals, authorizations, orders, injunctions and decrees, in the research, Development, Manufacture and use of
Product, and neither the Licensors nor any of their Affiliates nor, to the Licensors’ knowledge, any contract research organization to which the Licensors or their Affiliates have subcontracted activities in connection with Product, has
received any written notice from any Governmental Authority claiming that any such activities as conducted by them are not in such compliance. 

  
 48. 

 CONFIDENTIAL 
  

(i) No Injunction. No Governmental Authority (including the FDA) has commenced or, to the Licensors’ knowledge, threatened to
initiate any action to enjoin production of Product at any facility, nor have the Licensors or any of their Affiliates or, to the Licensors’ knowledge, any of their subcontractors involved in production of Product, received any notice to such
effect since January 1, 2000.  
 (j) Clinical, Safety and Regulatory Information. The Licensors have made available to
Sanofi a true and correct copy, which is complete in all material respects, of (i) all MAA submissions associated with Product, (ii) all Data from clinical studies conducted under any IND for Product, (iii) all material correspondence
with the FDA regarding Product, and (iv) all minutes of meetings and telephone conferences with the FDA with respect to the MAA for Product. The Licensors have disclosed or otherwise provided Sanofi with all material information in the
Licensors’ possession as of the Effective Date relating to (A) the MannKind Know-How or MannKind Patents, (B) the safety or efficacy of Product, or (C) the Manufacture of Product.  

(k) MannKind Trademarks. MannKind hereby represents and warrants to Sanofi as of the Effective Date that: 

(i) Licensors have all right, title, and interest in and to the MannKind Trademarks;  

(ii) to the best knowledge of MannKind, there is no Third Party using or infringing any of the MannKind Trademarks in the Territory in
derogation of the rights granted to Sanofi in this Agreement;  
 (iii) MannKind has not received notice of any opposition,
cancellation action or pending litigation or any communication which expressly threatens an opposition or cancellation action, or other litigation, before any trademark office, court or any other governmental entity in the Territory with respect to
any of the MannKind Trademarks; 
 (iv) the MannKind Trademarks are the only trademarks owned, held, Controlled, licensed or
otherwise used (or intended to be used) by MannKind or its Affiliates with respect to the Product in the Territory (other than MannKind’s corporate name and/or logo);  

(v) MannKind has all rights to use the MannKind Trademarks with respect to the Product in the Territory and to license the MannKind
Trademarks to Sanofi hereunder; and 
 (vi) to the best knowledge of MannKind, MannKind has not infringed, misappropriated,
diluted or otherwise violated any trademark of any Third Party by registering or using the MannKind Trademarks in the Territory; and 

(vii) to the knowledge of MannKind, no claims or proceedings, asserting that the MannKind Trademarks infringe the right of any Third
Party, are pending or threatened. 

  
 49. 

 CONFIDENTIAL 
  

10.3 Representations and Warranties of Sanofi. Sanofi represents and warrants to the Licensors that there is no action, suit, proceeding
or investigation pending or, to its knowledge, threatened before any court or administrative agency against Sanofi or its Affiliates which could, directly or indirectly, reasonably be expected to materially affect its ability to perform its
obligations hereunder or the Commercialization by Sanofi of the Product. 
 10.4 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT, OR ANY OTHER AGREEMENT CONTEMPLATED HEREUNDER, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND OF
FITNESS FOR A PARTICULAR PURPOSE OR USE, NON-INFRINGEMENT, VALIDITY AND ENFORCEABILITY OF PATENTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF PRODUCT. 

ARTICLE 11 

INDEMNIFICATION AND INSURANCE 

11.1 Indemnification of MannKind. Sanofi shall indemnify and hold harmless each of Licensors and their Affiliates and the directors,
officers, shareholders and employees of such entities and the successors and assigns of any of the foregoing (the “MannKind Indemnitees”), from and against any and all losses, liabilities, damages, penalties, fines, costs and
expenses (including, reasonable attorneys’ fees and other expenses of litigation) (“Losses”) from any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claims”)
incurred by any MannKind Indemnitee, arising from, or occurring as a result of any material breach of any representations, warranties or covenants by Sanofi under this Agreement; except to the extent such Third Party Claims fall within the scope of
the indemnification obligations of MannKind set forth in Section 11.2 of this Agreement or in Section 11.2 of the Supply Agreement. In addition, Sanofi shall indemnify and hold harmless the MannKind Indemnitees from and against any and all
Special Damages (as such term is defined in Section 9.5(c)). 
 11.2 Indemnification of Sanofi. The Licensors shall indemnify and
hold harmless each of Sanofi and its Affiliates and the directors, officers and employees of such entities, and the successors and assigns of any of the foregoing (the “Sanofi Indemnitees”), from and against any and all
Losses from any Third Party Claims incurred by any Sanofi Indemnitee, arising from, or occurring as a result of: (a) the Manufacturing, Development and regulatory activities relating to Product conducted by or on behalf of the Licensors or
their Affiliates before the Effective Date; and (b) any material breach of any representations, warranties or covenants by the Licensors under this Agreement, except to the extent such Third Party Claims falls within the scope of the
indemnification obligations of Sanofi set forth in Section 11.1 of this Agreement or in Section 11.1 of the Supply Agreement. 

11.3 Procedure. A party that intends to claim indemnification under this Article 11 (the “Indemnitee”)
shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such 

  
 50. 

 
indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof. The indemnity arrangement in this Article 11 shall not apply to amounts paid in
settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor
within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 11 if and to the extent the Indemnitor is actually
prejudiced thereby. The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification. 

11.4 Insurance. Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an
amount consistent with industry standards during the Term and shall name the other Party as an additional insured with respect to such insurance. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such
coverage to the other Party upon request. 
 ARTICLE 12 

CONDITIONS PRECEDENT, TERM AND TERMINATION 

12.1 Term. This Agreement shall commence on the Effective Date, and unless terminated earlier as provided in this Article 12, shall
continue in full force and effect until terminated pursuant to Section 12.2, 12.3 or 12.4 (the “Term”). 

12.2 Termination by the Parties. 

(a) Termination for Material Breach. In the event that either Party shall be in material breach in the performance of any of its
obligations under this Agreement (the “Breaching Party”), in addition to any other right and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this
Agreement by giving notice in writing specifying the breach and its claim of right to terminate; provided, however, that if the breach is remediable, the Breaching Party shall have ninety (90) days (or forty-five (45) days for any
payment breach) (the “Notice Period”) to rectify the breach and termination shall become effective at the end of the Notice Period only if the Breaching Party fails to cure the breach complained about during (i) the
Notice Period or, (ii) if such breach (other than any payment breach) has not been cured within such 90-day period, if the Breaching Party has commenced actions to cure such breach within the Notice Period and thereafter uses reasonable efforts
to cure such breach, such longer period as is reasonably required to cure such breach, but in any event, not to exceed ninety (90) days following expiration of the Notice Period; provided further, that, if Sanofi is the Breaching Party
and the breach is with respect to Sanofi’s failure to comply with its obligation to use Commercially Reasonable Efforts with respect to (x) the United States, MannKind may terminate this Agreement in its entirety, and (y) any Major
Market (other than the United States) or [...***...] Country, MannKind may terminate this Agreement only with respect to such Major Market or [...***...] Country (as applicable) and not in its entirety. If the Breaching Party disputes in
good faith that it has materially breached one of 

  
 ***Confidential Treatment
Requested 
 51. 

 CONFIDENTIAL 
  

its obligations under this Agreement, termination shall not take effect pending resolution of such dispute pursuant to Article 14. If, as a result of the application of such dispute resolution
procedures, the Breaching Party is determined to be in material breach of one or more of its obligations under this Agreement (an “Adverse Ruling”), then if the Breaching Party fails to complete the actions specified by the
Adverse Ruling to cure such breach within ninety (90) days (or forty five (45) days for any payment breach) after such Adverse Ruling, then the Complaining Party may terminate this Agreement upon written notice to the Breaching Party. 

(b) Termination Upon Insolvency. Either Party will be entitled to terminate this Agreement with immediate effect by notice in writing if
the other Party files for protection under bankruptcy or insolvency laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver, administrator, manager, trustee or like official over its property that is not
discharged within 90 days, proposes a written agreement of composition or extension of its debts, is a party to any dissolution, winding-up or liquidation or has any such petition filed against it which involuntary petition is not discharged within
60 days of the filing thereof. 
 12.3 Additional Sanofi Termination Rights. 

(a) If, at any time on or after January 1, 2016, Sanofi determines in good faith that Commercialization of Product is no longer
economically viable in the United States, then Sanofi may terminate this Agreement in its entirety upon delivery of at least ninety (90) days’ prior written notice to MannKind. In addition, at any time on or after January 1, 2016,
upon delivery of at least six (6) months’ prior written notice to MannKind, Sanofi shall have the right to terminate this Agreement for any reason (a) in its entirety, or (b) on a country-by-country basis other than with respect
to the United States; provided, however, that if Sanofi terminates this Agreement under this Section 12.3(a) in each of [...***...], then Sanofi shall terminate this Agreement with respect to all countries of the European Union.
For purposes of clarity, Sanofi shall have no right to terminate this Agreement with respect to only the United States under this Section 12.3(a). 

(b) Termination for Safety or Regulatory Reasons. On a country-by-country basis, Sanofi shall have the right in its sole discretion to
terminate this Agreement in such country immediately upon thirty (30) days’ written notice to MannKind in the event: 
 (i)
of withdrawal or indefinite suspension of any MAA for a Product in such country; or 
 (ii) that Sanofi determines in good faith
that pursuing the Development or Commercialization of a Product in the Territory or any part thereof poses an unacceptable medical risk to patients. 

12.4 Additional MannKind Termination Right. MannKind shall have the right to terminate this Agreement immediately upon written notice to
Sanofi if Sanofi or any of its Affiliates or sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, 

  
 ***Confidential Treatment
Requested 
 52. 

 CONFIDENTIAL 
  

or opposes any extension of or the grant of a supplementary protection certificate with respect to, any MannKind Patent; provided that MannKind shall not have such right to terminate this
Agreement for a proceeding, challenge or opposition of the type described above (in each case, a “Challenge”) by a sublicensee if (a) the sublicense agreement with such sublicensee includes a right of the applicable
sublicensor (Sanofi, its Affiliate or another sublicensee, as applicable) to terminate the sublicense following written notice to such sublicensee and, if applicable, a cure period not to exceed sixty (60) days if such sublicensee directly, or
indirectly through any Third Party, institutes a Challenge of any MannKind Patent and (b) either (i) the applicable sublicensor diligently enforces its rights to cause the sublicensee to withdraw or dismiss such Challenge including, if
applicable, exercise of such termination right promptly following the expiration of any applicable cure period or (ii) such Challenge is withdrawn or dismissed within thirty (30) days after a request by the applicable sublicensor or by
MannKind to do. 
 12.5 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not
termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. Notwithstanding the foregoing, termination of this Agreement in the
applicable [...***...] Country in accordance with Section 12.2(a) shall be MannKind’s sole remedy for Sanofi’s failure to comply with its obligations under Section 4.2(c) to use Commercially Reasonable Efforts to file for,
obtain or maintain Marketing Approvals for Product in the Field in any [...***...] Country. 
 ARTICLE 13 

EFFECT OF TERMINATION 

13.1 Partial Termination. In case of termination of this Agreement, not in its entirety, but with respect to only a particular country
(other than the United States) by MannKind pursuant to clause (y) of Section 12.2(a) or with respect to only a particular country or region by Sanofi pursuant to Section 12.3(a) (a “Partial Termination” and
each country or region in which such Partial Termination occurs, a “Terminated Country”), then the effects of termination described under this Article 13 shall only apply to the Terminated Country, and this Agreement shall
remain in full force and effect in accordance with its terms in all countries of the Territory other than the Terminated Country. 
 13.2
Accrued Obligations. The expiration or termination of this Agreement, in whole or part, for any reason shall not release either Party from any liability or deprive either Party of any right which, at the time of such expiration or termination,
has already accrued to such Party or which is attributable to a period prior to such expiration or termination, nor will any expiration or termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under
this Agreement, at law or in equity, with respect to breach of this Agreement. 
 13.3 Rights on Termination Other than Termination By
Sanofi for Cause. This Section 13.3 shall apply and shall only apply upon the termination of this Agreement by MannKind pursuant to Section 12.2 or Section 12.4, or by Sanofi pursuant to Section 12.3(a): 

  
 ***Confidential Treatment
Requested 
 53. 

 (a) Wind-down Period. 

(i) Development. In the event there are any on-going clinical trials of Product in the Field in the Territory, Sanofi shall, to
the extent so requested by MannKind, promptly transition, at MannKind’s expense, to MannKind or its designee such clinical trials then being conducted by Sanofi, or portions thereof, for MannKind or its designee to complete at their expense.

 (ii) Commercialization. Sanofi and its Affiliates and sublicensees shall continue, to the extent that Sanofi and its Affiliates
and sublicensees continue to have stocks of usable Product, to fulfill orders received from customers for Product in the Field in the Territory until up to 180 days after the later of (A) the date on which MannKind notifies Sanofi in writing
that MannKind intends to Commercialize such Product or has secured an alternative distributor or licensee for the Product and (B) Sanofi has initiated transition of the MAAs and Marketing Approvals for Product in the Field in the Territory to
MannKind or such distributor or licensee, but in no event for more for than 12 months after the date of notice of termination. For Product sold by Sanofi after the effective date of a termination (i.e., after the expiration of the applicable
termination notice period), the profit-or-loss provisions in Section 6.3 shall continue to apply. Notwithstanding the foregoing, Sanofi and its Affiliates and sublicensees shall cease such activities in the Territory upon 60 days written notice
given by MannKind at any time after the effective date of a termination requesting that such activities (or portion thereof) cease. In the case of a termination of this Agreement in its entirety, within 30 days after MannKind has given notice to
Sanofi requesting the cessation of activities pursuant to the provision of this Section, Sanofi shall notify MannKind of an estimate of the quantity of Product and its shelf life remaining in Sanofi’s inventory and MannKind shall have the right
to purchase any such quantities of Product from Sanofi at a price mutually agreed by the Parties. To the extent MannKind does not purchase such quantities, Sanofi may sell such quantities during the 180 days after the effective date of such
termination within the shelf life remaining for Product. 
 (b) Assignment of Filings and Marketing Approvals. At MannKind’s
option, which shall be exercised by written notice to Sanofi, to the extent permitted under Applicable Laws, Sanofi shall assign or cause to be assigned to MannKind or its designee (or to the extent not so assignable, Sanofi shall take all
reasonable actions to make available to MannKind or its designee the benefits of) all regulatory filings and registrations (including INDs, MAAs and Marketing Approvals) for Product in the Territory, including any such regulatory filings and
registrations made or owned by its Affiliates. MannKind shall notify Sanofi before the effective date of termination, whether the regulatory filings and registrations should be assigned to MannKind or its designee, and if the latter, identify the
designee, and provide Sanofi with all necessary details to enable Sanofi to effect the assignment (or availability). If MannKind fails to provide such notification prior to the effective date of termination, Sanofi shall assign the regulatory
filings and registrations to MannKind. 
 (c) Transition. The Parties shall negotiate in good faith a written transition agreement
pursuant to which the Parties would effectuate this Section 13.3 to coordinate the transition of relevant obligations and rights to MannKind as necessary to Develop and Commercialize Product in the Field in the Territory to ensure no
interruption of therapy or 

  
 54. 

 CONFIDENTIAL 
  

coverage for patients, including promptly submitting all necessary filings with Governmental Authorities. Sanofi shall use diligent efforts to cooperate with MannKind or its designee to effect a
smooth and orderly transition in the Development and Commercialization of Product in the Territory during the notice and the Wind-down Period. Without limiting the foregoing, Sanofi shall use diligent efforts to conduct, in an expeditious manner,
any activities to be conducted under this Section 13.3. MannKind shall use diligent efforts to identify and finalize an agreement or other arrangement with a Third Party in relation to Product or, to the extent MannKind is able to take over
such activities under Applicable Laws, take over, directly or through an Affiliate, all activities related to Product in the Territory, and in particular Development activities on-going at the time of the effective date of the termination and the
transfer of the regulatory filings and registrations (including INDs, MAAs and Marketing Approvals) into the name of MannKind or MannKind’s designee so that the Wind-down Period will be as limited as
possible. On terms to be further clarified in the written transition agreement, Sanofi shall use commercially reasonable efforts to maintain its Government Health Care Program Contracts for the Product bearing the Sanofi National Drug Codes
(“NDCs”) during the Wind-down Period. Reasonably in advance of the date upon which MannKind or its designee begins Commercialization of the Product, the Parties shall coordinate to permit MannKind to establish such
agreements, and Sanofi shall provide to MannKind (or its designee) all information reasonably necessary to allow MannKind to report government pricing and comply with Applicable Laws. During the Wind-down Period, Sanofi shall work with MannKind and
the applicable Government Health Care Programs to transition the Product from Sanofi’s Government Health Care Program Contracts for the Product bearing the Sanofi NDC to MannKind’s Government Health Care Program Contracts for the Product
bearing the MannKind NDC (or the NDC of MannKind’s designee) as necessary. The transition agreement shall further clarify the Parties’ respective financial obligations as to allocation of any rebates or chargebacks accrued with respect to
Product sold or dispensed during the Wind-down Period (provided, however, that Sanofi shall remain solely liable for such payments as may be accrued, but not yet paid, as of the effective date of termination of this Agreement). 

(d) Rights Become Non-Exclusive. Notwithstanding any other provision of this Agreement, following the effective date of termination and
during the Wind-down Period, Sanofi’s and its Affiliates’ rights with respect to Product in the Field in the Territory shall be non-exclusive, and, without limiting the foregoing, MannKind shall have the right to engage one or more other
distributors and/or licensees of Product in the Field in the Territory. 
 (e) Continuing Payment Obligations. Any Product sold or
disposed of by Sanofi and its Affiliates and sublicensees, in accordance with this Section 13.3 and any Allowable Expenses associated therewith shall be subject to the applicable payment obligations under Article 6. 

(f) Licenses. Sanofi hereby grants to MannKind, effective upon termination of this Agreement, a non-exclusive, worldwide (or in the
event of a Partial Termination, in the applicable Terminated Region), royalty-free, fully-paid license (with rights to sublicense) to use all Sanofi Technology and any Information and Regulatory Filings generated by Sanofi or its Affiliates with
respect to Product, then Controlled by Sanofi or any of its Affiliates as of the effective date of termination, to Develop, Manufacture, have Manufactured, use, Commercialize 

  
 55. 

 
and have Commercialized Product in its form as of the effective date of termination (but excluding any improvements thereafter). 

(g) Insulin Supply. In the case of termination of this Agreement in its entirety or in a particular country, Sanofi shall, for up to
[...***...] months following the effective date of such termination, supply to MannKind and MannKind shall have the right to use, Insulin supplied by Sanofi to MannKind for Product Developed, used, Manufactured and Commercialized in countries
in the Territory where Product has been launched and where such Insulin has been approved for use in Product by the applicable Regulatory Authorities, at a price equal to Sanofi’s cost for such Insulin plus [...***...] percent
([...***...]%). Upon such termination, Sanofi and MannKind shall agree on the maximum quantity of Insulin to be supplied, with the understanding that such maximum quantity shall not exceed [...***...] months’ requirements, as
determined by the good faith estimate of the Parties, taking into account previously approved Budgets for Insulin and current sales trends. 

(h) Competing Product. In the event that, prior to such termination, Sanofi Develops (mutatis mutandis) or Commercializes
(mutatis mutandis) an internally developed Competing Product in accordance with Section 2.8(b)(i), the payment of Allowable Expenses and calculation and sharing of Profit and Loss with respect to each such Competing Product shall survive
such termination for a period of [...***...] years from the date of the First Commercial Sale of such Competing Product. 
 13.4
Rights on Termination By Sanofi for Breach or Insolvency of MannKind. Upon the termination of this Agreement by Sanofi pursuant to Section 12.2(a) for MannKind’s uncured material breach of this Agreement (other than a breach of
Section 5.2 or a material uncured breach of MannKind’s obligations under the Supply Agreement) or pursuant to Section 12.2(b), Sanofi shall have the option to either (a) return the rights granted hereunder with respect to Product
to MannKind, in which case Section 13.4(b) below will apply, or (b) retain its rights to Product hereunder and discontinue MannKind’s participation in the Development, Manufacturing and Commercialization of Product hereunder, in which
case Section 13.4(b) below will apply. In the event of a termination of this Agreement pursuant to Section 12.2(a) for MannKind’s uncured material breach of Section 5.2 or a material uncured breach of MannKind’s obligations
under the Supply Agreement, Sanofi shall not be able to elect to retain its rights granted hereunder and Section 13.4(a) below will apply. For clarity, in the event of a termination of the Supply Agreement for a material uncured breach of
MannKind’s obligations under the Supply Agreement, Sanofi shall have no obligation to terminate this Agreement. 
 (a) Return of
Rights. If Sanofi elects, pursuant to this Section 13.4, to return the rights to the Product to MannKind: 
 (i)
Winding-Down of Development Activities. In the event there are any on-going clinical trials of Product in the Field in the Territory: 

(A) The Parties shall work together in good faith to adopt, and Sanofi shall have the final decision-making authority with respect to,
a plan to wind-down the Development activities in an orderly fashion, with due regard for patient safety and the rights of 

  
 ***Confidential Treatment
Requested 
 56. 

 CONFIDENTIAL 
  

any subjects that are participants in any clinical trials of Product and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in
compliance with all Applicable Laws. Sanofi shall provide to MannKind (or its designee) all information reasonably necessary to allow MannKind to report government pricing and comply with Applicable Law. During the wind-down period, Sanofi shall
work with MannKind and the applicable Government Health Care Programs to transition the Product from Sanofi’s Government Health Care Program Contracts for the Product bearing the Sanofi NDC to MannKind’s Government Health Care Program
Contracts for the Product bearing the MannKind NDC (or the NDC of MannKind’s designee) as necessary. The wind-down plan shall further clarify the Parties’ respective financial obligations as to allocation of any rebates or chargebacks
accrued with respect to Product sold or dispensed during the Wind-down Period (provided, however, that Sanofi shall remain solely liable for such payments as may be accrued, but not yet paid, as of the effective date of termination of this
Agreement); and 
 (B) All costs and expenses incurred from the effective date of the termination in winding-down the Development
activities with respect to the applicable Product and otherwise carrying out the plan described in Section 13.4(a)(i)(A) shall be borne solely by MannKind unless the Parties agree otherwise in writing. 

(ii) Termination of Licenses. Any and all licenses granted by the Licensors to Sanofi under this Agreement shall terminate, except as
otherwise expressly provided herein. 
 (iii) Sanofi Regulatory Filings (including Marketing Approval). Upon Sanofi’s request
and to the extent permitted by Applicable Laws, MannKind may purchase all Regulatory Filings (including Marketing Approval) that are owned by Sanofi or any of its Affiliates for Product, and Sanofi shall assign or cause to be assigned to MannKind or
its designees (or to the extent not so assignable, Sanofi shall take all reasonable actions to make available to MannKind or its designee the benefits of) such Regulatory Filings (including INDs, MAAs and Marketing Approval) for Product in the
Territory that are so purchased, including any such Regulatory Filings made or owned by its Affiliates, at an amount equal to 100% of the costs incurred by Sanofi and its Affiliates and sublicensees in obtaining such Regulatory Filings. 

(iv) Termination Assistance. Sanofi and its Affiliates and sublicensees may continue to sell its inventory of Product in the Territory
for up to [...***...] months after the effective date of the termination or offer MannKind to purchase the inventories of Product at a price mutually agreed by the Parties. MannKind may to the extent permitted by the applicable Third Party,
assume such supply or distribution agreement. MannKind shall provide such other assistance, at no cost to Sanofi, as may be reasonably necessary or useful for Sanofi to terminate the Development or Commercialization of the applicable Product in the
applicable countries of the Territory. 
 (v) Continuing Payment Obligations. Any Product sold or disposed of by Sanofi or its
Affiliates, in accordance with this Section 13.4 shall be subject to the applicable payment obligations under Article 6. 

  
 ***Confidential Treatment
Requested 
 57. 

 (b) Retention of Rights. If Sanofi elects, pursuant to Section 13.4, to retain the
rights to Product: 
 (i) the JAC shall be disbanded, all approval rights of the JAC shall become approval rights of Sanofi, and
MannKind shall no longer have the right to receive any Development or Commercialization reports or other information from Sanofi; 

(ii) a Trigger Event (as defined in the Supply Agreement) under the Supply Agreement shall be deemed to have occurred; 

(iii) Sanofi shall have the option to cause all Development activities being conducted by MannKind to be taken over by Sanofi; 

(iv) Sanofi’s and Licensors’ payment obligations under the Agreement shall remain in full force and effect; and 

(v) Section 4.2(d) shall no longer apply. 

13.5 Rights on Termination By Sanofi for Safety or Regulatory Reasons. Upon termination of this Agreement under Section 12.3(b),
any and all licenses granted by the Licensors to Sanofi under this Agreement shall terminate, except as otherwise expressly provided herein. Following such termination, Sanofi shall have no further obligations with respect to Product. 

13.6 Rights Upon Bankruptcy. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to
be, for purposes of Section 365(n) of Title 11 of the United States Code and other similar laws in any jurisdiction in the Territory or where a Party is situated (collectively, the “Bankruptcy Laws”), licenses of rights
to “intellectual property” as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided in such Bankruptcy Laws, such
Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall perform all of the obligations provided in this Agreement to be performed by such Party. If a case is commenced during the Term by or
against a Party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws, then the Party subject to such case under the
Bankruptcy Laws (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall provide to the other Party copies of all Information necessary for such other Party to prosecute, maintain and
enjoy its rights under the terms of this Agreement promptly upon such other Party’s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition
to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.

  
 58. 

 CONFIDENTIAL 
  

13.7 Return of Confidential Information. Upon termination or expiration of this Agreement, except to the extent that a Party retains a
license from the other Party as contemplated by this Article 13, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party’s possession or control containing Confidential
Information of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to a continuing confidentiality obligations. 

13.8 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any rights or obligation accruing prior to
such expiration or termination. In addition, upon expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement shall terminate, except those described in the following Articles and Sections:
Sections 2.6(b), 7.4, 7.5, 7.6, 8.1, 8.2, 8.3, 8.4, 8.8, 9.1, 10.4, 11.1, 11.2, 11.3 and 12.5, and Articles 1, 13, 14 and 15 (excluding Sections 15.10 and 15.17), which Articles and Sections will survive in accordance with their
terms. 
 ARTICLE 14 

DISPUTE RESOLUTION AND GOVERNING LAW 

14.1 Disputes. In the event of any dispute arising out of or relating to this Agreement or either Party’s rights or obligations
hereunder, except as otherwise provided in this Agreement, the Party wishing to invoke dispute resolution proceedings shall send to the other Party, in accordance with the notice provisions set forth in Section 15.8, a written notice of dispute
indicating that such notifying Party wishes to invoke such negotiations pursuant to this Section 14.1 and that sets out in reasonable detail the claims asserted, the nature of the dispute, any facts that are or are not in dispute, and the
intended treatment and effect of such pending dispute (“Notice of Dispute”). The Parties shall, through their respective executive officers, first meet and attempt to resolve the dispute in face-to-face negotiations. Unless
otherwise agreed in writing by the Parties, this meeting shall occur within fifteen (15) days after either Party provides such notice of dispute to the other Party. If the Parties are unable to resolve such dispute through such negotiations
within the earlier of (x) sixty (60) days after the meeting referenced in this Section 14.1 or (y) sixty (60) days after receipt of the Notice of Dispute (or such longer period agreed in writing by the Parties)
(“Arbitration Deadline”), then, except in the case of a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright, or (b) any antitrust, anti-monopoly or
competition law or regulation, whether or not statutory, the dispute shall be resolved by binding arbitration in accordance with Section 14.2. 

14.2 Arbitration. Any disputes to be resolved by binding arbitration pursuant to Section 14.1 shall be resolved in accordance with
the rules of conciliation and arbitration of the International Chamber of Commerce of Paris by a panel of three (3) independent and neutral experienced arbitrators, one (1) chosen by MannKind, one (1) chosen by Sanofi, and the third
(3rd) chosen by the foregoing two (2) arbitrators (with such third acting as the chairperson of the panel). The place of arbitration shall be New York, New York. Any arbitration shall be conducted in the English language and the
arbitrators shall use the governing law provided for in Section 14.4. The arbitration panel shall issue its decision and award by reasoned, written decision within one (1) year after appointment of the chairperson of the
arbitration panel. The 

  
 59. 

 CONFIDENTIAL 
  

arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Except to the extent necessary to confirm or enforce an
award or as may be required by law, neither a Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both MannKind and Sanofi. In no event shall an arbitration be initiated
after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. Each Party shall bear its own attorneys’ fees, costs and
disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators; provided, however, that the arbitrators shall be authorized to determine whether a Party is the prevailing
Party, and if so, to award to that prevailing Party reimbursement for the fees and costs of the arbitrators. Each Party agrees to fully perform and satisfy any arbitration award made against it within fifteen (15) days of the service of the
award. The taking of evidence in the arbitration shall be guided by the International Bar Association’s 2010 Rules on the Taking of Evidence in International Commercial Arbitration (“IBA Guidelines on Evidence”);
provided, however, that the arbitrators shall permit such pre-hearing discovery and such presentation of evidence at any Evidentiary Hearing (as defined in the IBA Guidelines on Evidence) as, in each case, is reasonably
necessary for a full and fair understanding and resolution of any legitimate issue raised in the arbitration. The arbitration panel shall ensure that document disclosures are conducted on a timely basis. By agreeing to this binding arbitration
provision, the Parties understand that they are waiving certain rights and protections which may otherwise be available if a dispute between the Parties were determined by litigation in court, including the right to seek or obtain certain types of
damages precluded by this provision, the right to a jury trial, certain rights of appeal and a right to invoke formal rules of procedure and evidence. For the sake of clarity, any disputes that arise under both this Agreement and the Supply
Agreement may be consolidated in a single arbitration. Any settlement discussions or arbitration proceedings occurring under this Agreement shall be conducted in strict confidence. Except as necessary to enforce an award or as required by law, no
information or documents produced, generated or exchanged in connection with settlement discussions or arbitration proceedings (including any award(s) that might be rendered by the arbitration panel) shall be disclosed to any person other than
counsel without the prior written consent of all Parties to the settlement or arbitration proceedings. This restriction shall not apply to public records or other documents obtained by the Parties in the normal course of business independent of any
settlement discussions or arbitration proceedings. 
 14.3 Court Actions. Nothing contained in this Agreement shall deny either
Party the right to seek, upon good cause, injunctive or other equitable relief from a court of competent jurisdiction in the context of an emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any
ongoing dispute resolution discussions or arbitration proceedings. 
 14.4 Governing Law. This Agreement, and all questions
regarding the existence, validity, interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of
law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. 

  
 60. 

 CONFIDENTIAL 
  

ARTICLE 15 
 GENERAL
PROVISIONS 
 15.1 Intervening Events. If the performance of any part of this Agreement by either Party (other than making
payment when due) is prevented, restricted, interfered with or delayed by any reason or cause beyond the reasonable control of such Party (including: fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism,
strike, lockout or other labor disturbance (save where such strike, lockout, or other labor disturbance is initiated by the employees of the Party which seeks to rely on this clause), acts of God or any acts, omissions or delays in acting of the
other Party) (an “Intervening Event”), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such Intervening Event, provided that the affected Party
shall use its substantial efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. If either Party becomes aware that such an Intervening Event has occurred,
is imminent or likely, it will immediately notify the other Party. The Party which is subject to such Intervening Event shall exert all reasonable efforts to overcome it. Such Party will keep the other informed as to the progress of overcoming such
Intervening Event. 
 15.2 Waiver of Breach. The failure of either Party at any time or times to require performance of any provision
of this Agreement shall in no manner affect its rights at a later time to enforce such rights. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or
term or of another condition or term. 
 15.3 Performance by Affiliates. To the extent that this Agreement imposes obligations on
Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligation. Either Party may use one or more of its Affiliates to perform its obligation hereunder, provided that the Parties will remain liable hereunder for the
prompt payment and performance of all their respective obligations hereunder. 
 15.4 Modification. No amendment or modification of
any provision of this Agreement shall be effective unless in a prior writing signed by all of MannKind and Sanofi. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or
any other matter not set forth in an agreement in writing and signed by the Parties hereto. 
 15.5 Severability. In the event any
provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate, in good faith and enter into a valid, legal and enforceable substitute provision that most nearly reflects the original
intent of the Parties. All other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in
any other jurisdiction. 

  
 61. 

 CONFIDENTIAL 
  

15.6 Entire Agreement. This Agreement (including the Exhibits attached hereto and any letter delivering information referenced herein)
and the Supply Agreement, including the Exhibits attached thereto, constitute the entire agreement between the Parties relating to the subject matter hereof and thereof and supersede and cancel all previous express or implied agreements and
understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof and thereof. Each of the Parties acknowledges and agrees that in entering into this Agreement, and the documents referred to in
it, it does not rely on, and shall have no remedy in respect of, any statement, representation, warranty or understanding (whether negligently or innocently made) of any Person (whether party to this Agreement or not) other than as expressly set out
in this Agreement or the Supply Agreement. Nothing in this clause shall, however, operate to limit or exclude any liability for fraud.

15.7 Language. The language of this Agreement and all activities to be pursued under this Agreement is English. Any and all documents
proffered by one Party to the other in fulfillment of any provision of this Agreement shall only be in compliance if in English. Any translation of this Agreement in another language shall be deemed for convenience only and shall never prevail over
the original English version. This Agreement is established in the English language. 
 15.8 Notices. Any notice or communication
required or permitted under this Agreement shall be in writing in the English language, delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by
internationally-recognized courier or sent by registered or certified mail, postage prepaid to the following addresses of the Parties (or such other address for a Party as may be at any time thereafter specified by like notice): 

 

			
	 To the Licensors:
  

MannKind Corporation

28903 North Avenue Paine

Valencia, California 91355

Telephone: (661) 775-5300

Facsimile: (661) 775-2086

Attention: General Counsel
	  	 To Sanofi:
  

Sanofi
 c/o Genzyme

500 Kendall Street
 Cambridge, MA 02142

Telephone: +1 617 768 6527
 Facsimile: +1 617 252 7600.

Attention: Vice President, Corporate
 Business
Development

  
 62. 

 CONFIDENTIAL 
  

 

			
	 with a copy to:
  

Cooley LLP
 4401 Eastgate
Mall
 San Diego, CA 92121

Telephone: (858) 550-6000

Facsimile: (858) 550-6420

Attention: L. Kay Chandler, Esq.
	  	 with a copy to:
  

Sanofi
 54 Rue La Boétie, 75008

Paris, France
 Telephone: +33 1 53 77 90 24

Facsimile: +33 1 53 77 43 03
 Attention: General
Counsel

 Any such notice shall be deemed to have been given: (a) when delivered if personally delivered;
(b) on the next Business Day after dispatch if sent by confirmed facsimile or by internationally-recognized overnight courier; and/or (c) on the third Business Day following the date of mailing if sent by mail or nationally recognized
courier. Notices hereunder will not be deemed sufficient if provided only between or among each Party’s representatives on the JAC. 

15.9 Assignment. This Agreement shall not be assignable, pledged or otherwise transferred, nor may any right or obligations hereunder be
assigned, pledged or transferred, by either Party to any Third Party without the prior written consent of the other Party, which consent, in the event of a financing transaction by the Party asking for consent, shall not be unreasonably withheld,
conditioned or delayed by the other Party; except either Party may assign or otherwise transfer this Agreement without the consent of the other Party to an entity that acquires all or substantially all of the business or assets of the assigning
Party relating to the subject matter of this Agreement, whether by merger, acquisition or otherwise; provided that intellectual property rights that are owned or held by the acquiring Person to such transaction (if other than one of the Parties to
this Agreement) shall not be included in the technology licensed hereunder. In addition, either Party shall have the right to assign or otherwise transfer this Agreement to an Affiliate upon written notice to the non-assigning Party; provided,
however, the assigning or transferring Party shall continue to remain liable for the performance of this Agreement by such Affiliate and, prior to the Effective Date, Sanofi may assign this Agreement to any Affiliate. Nothing herein shall be
deemed to prohibit MannKind or any of its Affiliates from granting a security interest in this Agreement and any rights hereunder to any Third Party in connection with any financing transaction to the extent provided under (and subject to the
restrictions on the rights of secured parties contained in) Sections 9-406 and 9-408 of the New York Uniform Commercial Code. In addition, MannKind or any Affiliate of MannKind shall have the right to sell, assign, pledge or otherwise transfer any
accounts and payment intangibles (each as defined under the New York Uniform Commercial Code but including, for the avoidance of doubt, rights to payment of MannKind pursuant to Sections 6.2 and 6.3) in connection with any financing transaction.
Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and permitted assigns. Any assignment of this Agreement in contravention of this Section 15.9 shall be null and void. 

  
 63. 

 15.10 Change of Control of MannKind. 

(a) If MannKind’s Board of Directors determines to pursue a Change of Control of MannKind (whether such determination is made in
response to an offer or term sheet submitted by a Third Party or such determination is made by the Board of Directors independently of any such Third Party offer or term sheet), MannKind shall provide written notice to Sanofi of such determination
no later than the date MannKind or its representatives first notifies any potential Third Party acquirer of such determination, so that Sanofi may, at its discretion, participate in the sale process and negotiate with MannKind for the potential
acquisition of MannKind by Sanofi. MannKind shall not enter into a Change of Control transaction with a Third Party within the thirty (30) day period following delivery of such notice to Sanofi. MannKind shall ensure that during the Term of
this Agreement that neither TICV nor BV undergoes a Change of Control other than a transaction in which MannKind undergoes the same Change of Control. 

(b) In the case MannKind, BV or TICV undergoes a Change of Control involving [...***...], Sanofi may by written notice delivered
to MannKind within thirty (30) days after the first public announcement of such Change in Control, elect to retain its rights to Product hereunder and discontinue MannKind’s participation in the Development, Manufacture, and
Commercialization of Product hereunder, in which case Section 13.4(b) shall apply. 
 15.11 No Partnership or Joint Venture.
Nothing in this Agreement or any action which may be taken pursuant to its terms is intended, or shall be deemed, to establish a joint venture or partnership between Sanofi and the Licensors. Neither Party to this Agreement shall have any express or
implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party. 

15.12 Standstill Agreement. Until the date that is five years after the Effective Date (the “Standstill
Period”), none of Sanofi, Sanofi’s Affiliates, nor any of their respective directors, officers, employees, agents or representatives (provided such person is acting on behalf of Sanofi) will, in any manner, directly or indirectly,
without the prior express written consent of MannKind: 
 (a) make, effect, initiate, directly participate in or cause (i) any
acquisition of beneficial ownership of any securities of MannKind or any securities of any subsidiary or other Affiliate of MannKind, if, after such acquisition, Sanofi would beneficially own more than 5% of the outstanding common stock of MannKind,
(ii) any acquisition of any assets of MannKind or any assets of any subsidiary or other Affiliate of MannKind, (iii) any tender offer, exchange offer, merger, business combination, recapitalization, restructuring, liquidation, dissolution
or extraordinary transaction involving MannKind or any subsidiary or other Affiliate of MannKind, or involving any securities or assets of MannKind or any securities or assets of any subsidiary or other affiliate of MannKind or (iv) any
“solicitation” of “proxies” (as those terms are used in the proxy rules of the SEC) or consents with respect to any securities of MannKind; provided that nothing in this Section 15.12 shall preclude any activities of Sanofi
or its Representatives with 

  
 ***Confidential Treatment
Requested 
 64. 

 CONFIDENTIAL 
  

respect to the grant by MannKind or any Affiliate of MannKind of any license in each case to Sanofi or any of its Affiliates as contemplated by this Agreement; 

(b) form, join or participate in a group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as
amended) with respect to the beneficial ownership of any securities of MannKind; 
 (c) act, alone or in concert with others, to seek
to control the management, board of directors or policies of MannKind; 
 (d) take any action that would reasonably be expected to
require MannKind to make a public announcement regarding any of the types of matters set forth in Section 15.12(a); 
 (e) agree
or offer to take, or encourage or propose (publicly or otherwise) the taking of, any action referred to in Section 15.12(a), (b), (c) or (d); 

(f) assist, induce or encourage any Third Party to take any action of the type referred to in Section 15.12(a), (b), (c),
(d) or (e); or 
 (g) enter into any discussions, negotiations, arrangement or agreement with any Third Party relating to any of
the foregoing. 
 For purposes of this Agreement, a Party’s “Representatives” will be deemed to include each person or entity that is or
becomes (i) an Affiliate of such Party, or (ii) an officer, director, employee, partner, attorney, advisor, accountant, agent or representative of such Party or of any of such Party’s Affiliates, providing such person is acting on
behalf of such Party. 
 Notwithstanding the foregoing, Section 15.12 shall no longer apply (i) during a period commencing with MannKind’s
announcement in a filing with the SEC or a press release that (a) it is seeking a purchaser for itself or (b) is otherwise exploring strategic options in this regard, and ending with MannKind’s announcement in a filing with the SEC or
a press release that is terminating such search or exploration; (ii) during the period beginning with the commencement by a Third Party of a publicly-announced tender or exchange offer for more than 50% of voting power of the outstanding voting
securities of MannKind, and ending with the termination by such Third Party of such tender or exchange offer; or (iii) if MannKind announces in a filing with the SEC or a press release a transaction, or an intention to effect any transaction,
which would result in (a) the sale by MannKind or one or more Affiliate(s) of assets representing 50% or more of the consolidated assets of MannKind; or (b) the common shareholders of MannKind immediately prior to such transaction owning
less than 50% of the outstanding common stock of the acquiring entity or, in case of a merger transaction, the surviving corporation (or, if the surviving corporation is an Affiliate of a parent company, the parent company); provided that, in the
case of clause (ii) Sanofi has not directly or indirectly taken any action prohibited under this Section 15.12. 
 The expiration of the
Standstill Period will not terminate or otherwise affect any of the other provisions of this Agreement. 

  
 65. 

 CONFIDENTIAL 
  

15.13 Interpretation. The captions to the several Articles and Sections of this Agreement are not a part of this Agreement but are
included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression;
(b) the word “or” means “and/or” unless the context dictates otherwise because the subject of the conjunction are mutually exclusive; (c) the words “herein,” “hereof” and “hereunder” and
other words of similar import refer to this Agreement as a whole and not to any particular Article or Section or other subdivision; (d) references in this Agreement to “days” shall mean calendar days; (e) the singular shall
include the plural and vice versa; and (f) masculine, feminine and neuter pronouns and expressions shall be interchangeable. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under IFRS,
or if not defined by IFRS, the meaning applied to it by Sanofi in preparing its publicly reported financial statements, in each case, consistently applied, but only to the extent consistent with its usage and the other definitions in this Agreement.

 15.14 Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which
shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the
same effect as if the original signature had been delivered to the other Party. 
 15.15 Limitation of Liability. EXCEPT FOR LIABILITY
FOR BREACH OF ARTICLE 8, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE OR RIGHT GRANTED HEREUNDER; provided,
however, that this Section 15.15 shall not be construed to limit either Party’s indemnification obligations with respect to Third Party Claims under Article 11. 

15.16 Antitrust Filings/Agreement Effectiveness. Each of MannKind and Sanofi shall use its reasonable best efforts to file, as soon as
practicable after the date of this Agreement, all notices, reports and other documents required to be filed by such Party, pursuant to the Antitrust Laws, with any Governmental Authority (the “Filings”) with
respect to this Agreement and the transactions contemplated hereby, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, each of MannKind and Sanofi agrees
to prepare and make appropriate filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the “HSR Act”) relating to this Agreement
and the transactions contemplated hereby as soon as reasonably practicable, but in any event within ten (10) Business Days after the Execution Date (the “HSR Filing Date”). The Parties agree to cooperate
and consult with each other in connection with the making of all Filings. Sanofi will pay all fees, payable to any Governmental Authority, associated with Filings. Other than the provisions of this Section 15.16, the rights and obligations of
the Parties under this Agreement shall not become effective until the earliest date on which all of the following have occurred: (i) the waiting period provided by the HSR Act, and those associated with any other of the Filings which the
Parties reasonably conclude must be obtained prior to making the rights and 

  
 66. 

 CONFIDENTIAL 
  

obligations of this Agreement effective, shall have terminated or expired; and (ii) either (A) MannKind and Hoechst GmbH (or its permitted assignee) have entered into the “Loan
Documents” as defined and described in the Commitment Letter between MannKind and Hoechst GmbH dated of even date herewith (the “Commitment Letter”) or (B) MannKind, in its sole discretion, has terminated the Commitment Letter
and waived in writing the condition set forth in the preceding subclause (A) of this clause (ii) (such date, the “Effective Date” of this Agreement), provided that, pursuant to Section 15.9 hereof, Sanofi shall
be permitted to assign this Agreement to any Affiliate at any time between the Execution Date and the Effective Date. Upon the occurrence of the Effective Date, all provisions of this Agreement shall become effective automatically without the need
for further action by the Parties. In the event that (I) any such clearance associated with the Filings is not obtained, or (II) the Loan Documents are not executed within 120 days after the Execution Date (or such later date as
agreed in writing by the Parties), this Agreement may be terminated by either Party; provided that a Party shall not have the right to terminate under clause (II) of this sentence if the Loan Documents have not been executed as a result of a
breach by such Party (or, in the case of Sanofi, by Hoechst GmbH or its permitted assignee) of the Commitment Letter (for so long as such Party is in breach) or if MannKind has terminated the Commitment Letter. 

15.17 Restrictions on Sale of Profit Share. None of the Licensors shall enter into any transaction or arrangement pursuant to which
(i) it receives a fixed (single or recurring) sum in exchange for any portion of its share of Profits (other than in connection with a permitted assignment of this Agreement pursuant to Section 15.9); or (ii) borrows any sums against
its share of Profits on a non-recourse basis; in each case without the prior written consent of Sanofi, not to be unreasonably withheld, conditioned or delayed. 

ARTICLE 16 

COMPLIANCE WITH LAW 

16.1 Export Laws. Notwithstanding anything to the contrary contained herein, all obligations of MannKind and Sanofi are subject to
prior compliance with export and import regulations and such other laws and regulations in effect in such jurisdictions or any other relevant country as may be applicable, and to obtaining all necessary approvals required by the applicable agencies
of the governments of any relevant countries. The Licensors and Sanofi shall cooperate with each other and shall provide assistance to the other as reasonably necessary to obtain any required approvals. 

16.2 Securities Laws. Each of the Parties acknowledges that it is aware that the securities laws of the United States and the securities
laws of other countries prohibit any person who has material non-public information about a publicly listed company from purchasing or selling securities of such company or from communicating such information to any person under circumstances in
which it is reasonably foreseeable that such person is likely to purchase or sell such securities. Each Party agrees to comply with such securities laws make its Affiliates, employees and agents aware of the existence of such securities laws and
their need to comply with such laws. 

  
 67. 

 CONFIDENTIAL 
  

16.3 Conduct of Activities. As to all matters contained in this Agreement, each Party shall conduct the activities allocated to it in
compliance in all material respects with all Applicable Laws and in accordance with good scientific, clinical and manufacturing practices and applicable industry ethical codes, applicable under the laws and regulations of the country in which such
activities are conducted. Each Party represents, warrants and covenants to the other Party as of the Effective Date that: 
 (a) it is
familiar with the provisions and restrictions contained in the OECD Convention and FCPA and it has adopted and maintains an FCPA policy; 

(b) In the performance of its obligations under this Agreement, it shall comply and shall cause its and its Affiliates’ employees
and contractors to comply with all Applicable Laws, and shall obtain and maintain all licenses, permits, approvals and other authorizations applicable to it in order to enable it to perform its respective obligations hereunder.  

(c) its and its Affiliates’ employees and contractors shall not, in connection with the performance of their respective obligations
under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or
Entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including either Party (it being understood that such Party, and to its knowledge, its and its Affiliates’ employees and
contractors, has not directly or indirectly promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person
in connection with the performance of such Party’s obligations under this Agreement, and shall not, directly or indirectly, engage in any of the foregoing).  

[SIGNATURE PAGE FOLLOWS] 

  
 68. 

 IN WITNESS WHEREOF, the Parties have executed
this License and Collaboration Agreement as of the Execution Date. 
  

			
	SANOFI-AVENTIS DEUTSCHLAND GMBH
		
	By:	 	/s/ Emmanuel Siregar
	Name:	 	Emmanuel Siregar
	Title:	 	VP HR Sanofi Germany
		
	By:	 	/s/ ppa. Bergmann
	Name:	 	Bergmann
	Title:	 	Head of Finance

 [SIGNATURE PAGE TO LICENSE AND
COLLABORATION AGREEMENT] 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties have executed this License and Collaboration Agreement as
of the Execution Date. 
  

			
	MANNKIND CORPORATION
		
	By:	 	/s/ Alfred E. Mann
	Name:	 	Alfred E. Mann
	Title:	 	Chairman & CEO

  

[SIGNATURE PAGE TO LICENSE AND COLLABORATION
AGREEMENT] 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties have executed this License and Collaboration Agreement as
of the Execution Date. 
  

			
	 TECHNOSPHERE INTERNATIONAL C.V.
  

By: MannKind Corporation, its General Partner

		
	By:	 	/s/ Matthew J. Pfeffer
	Name:	 	Matthew J. Pfeffer
	Title:	 	Corporate Vice President and Chief Financial Officer

  

[SIGNATURE PAGE TO LICENSE AND COLLABORATION
AGREEMENT] 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties have executed this License and Collaboration Agreement as
of the Execution Date. 
  

			
	MANNKIND NETHERLANDS B.V.
		
	By:	 	/s/ Matthew J. Pfeffer
	Name:	 	Matthew J. Pfeffer
	Title:	 	Managing Director

  

[SIGNATURE PAGE TO LICENSE AND COLLABORATION
AGREEMENT] 

 CONFIDENTIAL 
  

EXHIBIT A 

MANNKIND TRADEMARK LICENSE 

This Exhibit sets forth the terms of the license granted with respect to the trademark(s) and/or trade name(s) owned by the Licensors that are
set forth on EXHIBIT A-1 (the “MannKind Trademarks”). All capitalized terms used and not otherwise defined in this Exhibit will have the meaning given such terms in this Agreement.
References in this EXHIBIT A to MannKind shall refer to TICV or BV as applicable outside the United States. 
 1. License to
MannKind Trademarks. Subject to the terms and conditions of this Agreement, including this EXHIBIT A, the Licensors hereby grant to Sanofi during the Term a non-exclusive license, with the right to grant limited
sublicenses pursuant to Section 2.4 of this Agreement, to use the MannKind Trademarks, solely in connection with Developing, obtaining Marketing Approval of, Manufacturing, having Manufactured, using and Commercializing Product in the Field in
the Territory. 
 2. Quality Control. All uses by Sanofi and its Affiliates and sublicensees of the MannKind Trademarks shall be in compliance with
all Applicable Laws and shall be in accordance with such commercially reasonable quality standards as have been used by Sanofi in the past for comparable products. In all packaging, labeling, advertising, promotional and other material of Sanofi and
its Affiliates and sublicensees referencing the MannKind Trademarks, Sanofi and its Affiliates and sublicensees shall not: (a) vary the spelling, add or delete hyphens, abbreviate, make one word two, or use a possessive or plural form of the
MannKind Trademarks; (b) modify the design, add or delete any elements or words, change any colors or proportion of the MannKind Trademarks; (c) use the MannKind Trademarks in a manner which disparages MannKind or any of its products or
services; or (d) use the MannKind Trademarks in a manner that interferes with or adversely affects MannKind’s use of the MannKind Trademarks; in each case except to the extent required by Applicable Laws, provided that Sanofi will review
and discuss with MannKind any such exceptions required by Applicable Laws before using the MannKind Trademarks pursuant to such exception. At the request of MannKind, Sanofi will provide from time to time copies of packaging, labeling, advertising,
promotional and other material of Sanofi or its Affiliates referencing the MannKind Trademarks to allow MannKind to confirm compliance with the foregoing. 

3. Ownership Rights, as Between Parties. MannKind shall own and shall retain the ownership of the entire right, title and interest in and to the
MannKind Trademarks. Sanofi acknowledges, as between the Parties, the exclusive right, title and interest of MannKind in and to the MannKind Trademarks and will not do or cause to be done any act or thing contesting or, in any way, impairing any
part of said right, title and interest for the Term and after its expiration. Sanofi will not, and will require that its Affiliates not, make any representations or take any actions, which may be taken to indicate that it has any right title or
interest in or to the ownership or use of the MannKind Trademarks except under the terms of this Agreement, including this EXHIBIT A, and acknowledges that nothing contained in this Agreement, including this
EXHIBIT A, shall give Sanofi or any of its Affiliates any right, title or interest in or to the MannKind Trademarks except the license rights granted under Section 1 of this EXHIBIT A. 

  
 A-1. 

 CONFIDENTIAL 
  

4. Registration of the MannKind Trademarks. MannKind shall, at its own cost and expense, and in its sole discretion, file within the Territory and
endeavor in good faith to obtain the registration of the MannKind Trademarks in the Territory, and when registered, thereafter maintain the applicable MannKind Trademark in the Territory at its own expense. 

5. Enforcement. Sanofi shall, as soon as practicable after receiving notice of any potential infringement of a MannKind Trademark in the Territory,
inform MannKind of any such potential infringement. MannKind shall have the first right and discretion to bring infringement or unfair competition proceedings involving the MannKind Trademark in the Territory and MannKind shall bear all costs in
connection with any such proceedings. Sanofi shall cooperate with MannKind in any such proceedings at its own expense including by giving testimony and producing documents and materials supporting the MannKind Trademark, and shall endeavour to cause
the employees of Sanofi, as appropriate, to cooperate with MannKind, all at MannKind’ expense. Any recoveries obtained as a result of any infringement litigation undertaken by MannKind alone or in settlement of such infringement shall be
retained by MannKind. Sanofi shall have the right, but shall not be obliged, to participate with MannKind as a party plaintiff in any infringement or unfair competition action undertaken by MannKind hereunder in the Territory, at Sanofi’s costs
and expense, and any recovery obtained shall be shared between MannKind and Sanofi in proportion to incurred expenses, except that any recovery with respect to unfair competition claims in the Territory shall be retained solely by Sanofi. Should
MannKind fail to institute infringement proceedings in the Territory, Sanofi, if it deems necessary, shall have the right but shall not be obligated, to bring suit for such infringement under its name and at its own costs and expenses. MannKind
shall cooperate with Sanofi in any such proceedings at its own expense including giving testimony and producing document and material supporting the MannKind Trademark and shall endeavour to cause the employees of MannKind, as appropriate, to
cooperate with Sanofi, all at Sanofi’s expense. Any recoveries obtained in suit for trademark infringement litigation or in settlement of such infringement undertaken without MannKind’ involvement shall be retained by Sanofi. 

6. Infringement of Third Party rights by the MannKind Trademarks. MannKind shall: (i) defend, through counsel of its choosing, at its own cost and
expense, any claim from a Third Party that claims that the MannKind Trademarks infringe such Third Party’s intellectual Property in the Territory; (ii) consult with Sanofi, take into consideration Sanofi’s comments, incorporate and
act on such comments to the extent reasonable in defending against any such claim; and (iii) release and hold Sanofi, its Affiliates and sublicensees harmless from any liabilities arising from or connected with any such claim. 

7. Goodwill. Any accretion of goodwill derived by Sanofi or any of its Affiliates to the extent attributed to the MannKind Trademarks shall accrue to
MannKind and MannKind may call for, and Sanofi will provide, and require its Affiliates to provide, a confirmatory assignment thereof. 
 8. Registered
User. Where reasonably required to carry out the purpose of the Agreement, MannKind shall make applications to the applicable Governmental Authority for the registration of Sanofi or any of its Affiliates as a registered user of the MannKind
Trademarks, and Sanofi 

  
 A-2. 

 CONFIDENTIAL 
  

and its Affiliates and sublicensees shall cooperate with MannKind in making such applications. Sanofi and its Affiliates and sublicensees shall take reasonable actions requested by MannKind at
MannKind’s expense which may be necessary or desirable for registering and maintaining registration of Sanofi and its Affiliates and sublicensees as registered users of the MannKind Trademarks. 

9. Reasonable Assistance. Sanofi shall, and shall require its Affiliates to, reasonably cooperate, upon request, with MannKind or its authorized
representative to provide information as to its use of the MannKind Trademarks which MannKind may require and will render any assistance reasonably required by MannKind in securing and maintaining the registration(s) of the MannKind Trademark in the
Territory. 
 10. Further Acts. MannKind shall execute, acknowledge and deliver such instruments and do all such other acts as may be necessary or
appropriate in order to have this Agreement recorded by any authority operating as a trademark office in the Territory or in order to ascertain or confirm Sanofi’s right to use the MannKind Trademarks. 

  
 A-3. 

 CONFIDENTIAL 
  

EXHIBIT A-1 

MANNKIND TRADEMARKS 

Attached. 

  
 A-4. 

 Confidential 

 
 Trademarks 

 

											
	 Mark
	  	 Country
	  	 Status
	  	 Applic. No./

File Date
	  	 Reg. No./

Reg. Date
	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 1 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 2 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 3 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 4 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 5 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 6 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 7 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 8 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 9 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 10 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 11 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 12 of 13 

 Confidential 

 
  

											
	Mark	  	Country	  	Status	  	Applic. No./
File Date	  	Reg. No./
Reg. Date	 	 Class/Goods/Services

	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested 
 Page 13 of 13 

 CONFIDENTIAL 
  

EXHIBIT B 

PAYMENT OF EXPENSES; SHARING OF PROFIT 

Attached. 

  
 B-1. 

 EXECUTION VERSION 

EXHIBIT B 

PAYMENT OF EXPENSES; SHARING OF PROFIT 

This EXHIBIT B to the License and Collaboration Agreement (the “Agreement”), dated as of
August 11, 2014, between MANNKIND CORPORATION (“MannKind”), TECHNOSPHERE INTERNATIONAL C.V.
(“TICV”), MANNKIND NETHERLANDS BV (“BV” and together with MannKind and TICV, the “Licensors”) and
SANOFI-AVENTIS DEUTSCHLAND GMBH (“Sanofi”), addresses the accounting policies and procedures to be followed with respect to Allowable Expenses and
determination and sharing of Profit (where applicable) separately for the United States on the one hand and all other countries in the Territory, cumulatively, on the other hand. Capitalized terms used and not otherwise defined in this
EXHIBIT B shall have the meanings set forth for such terms in the Agreement. 
 1. General Principles. The Parties acknowledge
and agree that the accounting policies and procedures be followed with respect to computation of Allowable Expenses and computation and sharing of Profit (including the computation of the individual components thereof) is intended to be consistent
with the accounting policies and procedures used by Sanofi in generating its publicly-reported financial statements in accordance with International Financial Reporting Standards (“IFRS”). Each Party shall
prepare and provide all reports and calculations required hereunder in accordance with such accounting policies and procedures. Notwithstanding the foregoing, (a) if a specific category of Allowable Expense described below is also one accounted
for in Sanofi’s books and records, then the amounts recorded in Sanofi’s books and records shall control provided that they are consistent with IFRS and Sanofi’s publicly-reported financial statements; and (b) if IFRS changes
after the Effective Date in any manner that would affect computations hereunder, the Parties shall implement such change in a manner consistent with Sanofi’s implementation of such change in Sanofi’s publicly-reported financial statements.
 
 2. Reporting of Allowable Expenses. Within 15 days after the end of each Calendar Quarter beginning with the first full Calendar Quarter
after the Execution Date, MannKind will provide Sanofi with a written report (each, a “Quarterly Report”) setting forth the Allowable Expenses incurred by MannKind or its Affiliates for such Calendar Quarter (including, in
the first such report, the Allowable Expenses incurred from the Effective Date until the beginning of the first full Calendar Quarter) in reasonable detail sufficient to enable Sanofi’s calculations of Profit as set forth in Section 3.
Neither Party shall be entitled to include Allowable Expenses in such Profit calculations that exceed the Budget for such Allowable Expenses by more than ten percent (10%) unless otherwise approved by the JAC; provided that the JAC shall
in good faith consider adjustments to the Budgets for any Allowable Expenses to accommodate unexpected circumstances that arise following the determination of the applicable Budget. 

3. Sharing of Profit and Loss. “Profit” shall equal the positive amount of (a) Net Sales of Product in the
Territory plus any additional net revenue received from sublicensees of the Product (collectively, “Net Receipts”) less (b) Allowable Expenses. “Loss” shall equal the
positive amount of Allowable Expenses less Net Receipts. Subject to the terms of this EXHIBIT B, the Parties shall share Profit and Loss on the basis of thirty-five percent (35%) to MannKind and sixty-five
(65%) to Sanofi (the “Sharing Percentages”). 

  
 1. 

 3.1 Periodic Calculations. Sanofi shall be responsible for the calculation of Profit and
Loss and the determination of the cash payment to or from the Licensors for each Calendar Quarter of the Term so that following such payment each Party has borne the Sharing Percentage of Profit or Loss.  

3.2 Calculation of Profit. All calculations of Profit and Loss will be made using, and all defined and undefined terms will be
construed in accordance with the principles set forth in Section 1 of this EXHIBIT B. Without limiting the foregoing, no cost item will be included more than once in calculating any Allowable Expenses or Profit. For the
sake of example only, a sample demonstration of the Profit sharing calculations are set forth as SCHEDULE B-2 to this EXHIBIT B.  

4. Profit/Loss Reporting and Payment. 

4.1 Profit/Loss Statement. 

(a) The reporting and determination of Profit and Loss shall be governed by a statement of Profit and Loss
for the applicable Calendar Quarter (the “Profit/Loss Statement”). Sanofi will provide to MannKind, by the submission dates set forth in Section 4.1(b), a Profit/Loss Statement (i) showing the results for the
applicable Calendar Quarter (including the Calendar Year-to-date) in a similar form to that attached hereto as SCHEDULE B-1, (ii) comparing the applicable Calendar Quarter (including the
Calendar Year-to-date) results to the Budgets, (iii) calculating Profit or Loss for the applicable Calendar Quarter and (iv) determining the cash payment to or from the Licensors for the applicable Calendar Quarter. To the extent any
Calendar Year-end adjustments are determined in good faith by Sanofi to be appropriate, an appropriate adjustment to Profit or Loss for the applicable Calendar Year will be made and an appropriate payment will be made by the applicable Party within
thirty (30) days following receipt of the Profit/Loss Statement describing such adjustment; provided, however, that in the event of a dispute between the Parties with respect to whether any such adjustment is
appropriate, such dispute will be referred to the JAC for resolution pursuant to Section 3.1 of the Agreement. Any such adjustment payment will be without interest if such amount is less than ten percent (10%) of Profit or Loss for such
Calendar Year and will bear interest at the rate set forth in Section 7.6 of the Agreement if the absolute value of such amount is greater than or equal to ten percent (10)% of Profit or Loss for such Calendar Year.  

  
 2. 

 (b) Reporting of Profit and Loss will be performed as follows: 

 

					
	 Reporting Event
	  	 Frequency
	  	 Timing of Submission

	Actuals	  	Each Calendar Quarter	  	The earlier of (i) the day that Sanofi reports its earnings or (ii) 30 days following the end of each Calendar Quarter
			
	Adjustment	  	Each Calendar Year	  	The earlier of (i) the day that Sanofi reports its earnings or (ii) 45 days following the end of each Calendar Year

 4.2 Payment of Profit. For each Calendar Quarter, Sanofi or Licensors, as applicable, shall make any
payment of Profit or Loss as determined pursuant to Section 1 no later than fifteen (15) days following Sanofi’s delivery of the Profit/Loss Statement for such Calendar Quarter (the “Payment
Date”). The Licensors shall be jointly and severally liable for payment of any such Loss. Payments of Profit or reimbursements of Loss made by one Party to the other after the Payment Date shall accrue interest from the
applicable Payment Date at a rate per quarter of two point zero six percent (2.06%) (equivalent to eight point five percent (8.5%) annually) until such outstanding amounts are paid to the applicable Party. If MannKind disputes an amount
provided in the Profit/Loss Statement, then such disputed amount shall be reviewed by the JAC and any payment owed with respect to the undisputed amounts in the Profit/Loss Statement shall be paid within fifteen (15) days following
Sanofi’s delivery of such Profit/Loss Statement.  
 4.3 Foreign Exchange. The functional currency for accounting for
Profit will be Euros, except for Profit within the United States, which shall be in U.S. Dollars. The Profit/Loss Statement will be translated into Euros using Sanofi’s standard exchange rate conversion methodology. 

5. Definitions. As used in this EXHIBIT B and as a supplement to the definitions set forth in Article 1 of the Agreement, the
following terms shall have the meanings set forth in this Section 5 unless otherwise specifically provided herein.  

5.1 “Allocable Overhead” means (for any particular cost item) a Party’s
internal allocation (determined in accordance with the last two (2) sentences of this Section 5.1), based on direct project headcount or other generally accepted activity-based accounting methods, of
indirect overhead costs incurred by a Party or any of its operating units to support and carry out the activities of the specific business function, such as Development, obtaining or maintaining Regulatory Filings, Manufacturing (which, for the
avoidance of doubt, shall be included solely as Cost of Goods under the Supply Agreement) and Commercialization, with respect to Product for the Territory, which indirect costs may include but are not limited to: indirect labor costs; 

  
 3. 

 
occupancy costs; repair and maintenance costs; office supplies and service costs; equipment costs; insurance costs; outside professional and other service costs; and excise taxes and other taxes
including those related to the U.S. Affordable Care Act. Such overhead will exclude any indirect costs associated with any excess or unused capacity. Except as provided herein, overhead costs of a Party or operating units that are not engaged in the
Development, obtaining or maintaining Regulatory Filings, Manufacturing or Commercialization of Product in the Territory, including, by way of example only, executive management, investor relations, business development, legal affairs, human
resources and finance, will not be recoverable as Allocable Overhead or otherwise. The Parties acknowledge and agree that each Party’s Allocable Overhead for all applicable cost items shall be determined by mutual agreement of the Parties on an
annual basis prior to each Calendar Year and such agreed-upon annual Allocable Overhead amount shall be the amount used for such Calendar Year for all calculations of Allowable Expenses hereunder. For the sake of clarity, neither Party shall be
entitled to any reimbursement for Allocable Overhead that exceed such mutually agreed-upon annual Allocable Overhead amount. 

5.2 “Allowable Expenses” means those costs and expenses incurred by the
Parties or for their account that are specifically attributable or related to the Development, JAC-approved Product- and process-improvements (but not to the extent included in Cost of Goods), obtaining or maintaining Regulatory Filings,
Manufacturing or Commercializing of Product in the Territory, and consisting of: (i) Paid Price, as trued-up to Cumulative COGS in accordance with Section 4.1(c) of the Supply Agreement, with respect to Product manufactured by or for
MannKind; (ii) Cost of Goods for Product manufactured by or for Sanofi; (iii) Development Expenses; (iv) Commercial Expenses; (v) Replacement Supply Costs; and (vi) costs arising under or relating to sublicense agreements
for Product.  
 5.3 “Commercial Expenses” shall mean, with respect to the applicable Calendar
Quarter, the sum of the following costs and expenses (each of which is specified below) incurred by the Parties and their Affiliates after the Execution Date, in each case to the extent directly attributable to the Commercialization of Product in
the Field in the Territory in such Calendar Quarter in accordance with the Commercialization Plan and the Commercialization Budget, excluding the Cost of Goods for Product used in conducting or performing such activities, calculated on a fully
burdened basis (i.e., Commercial Expenses shall include Allocable Overhead specifically attributable thereto): 
 (a)
Advertising; 
 (b) Distribution; 

(c) Education; 

(d) Legal and Litigation; 

(e) Marketing Management; 

(f) Market Research; 

(g) Promotion; 

  
 4. 

 (h) Selling Expenses; and 

(i) any other expenses included in the Commercialization Budget approved by the JAC. 

The costs of activities that promote a Party’s business as a whole without being product specific (such as corporate image
advertising) are specifically excluded from Commercial Expenses. To the extent multiple products are involved and some of such products are not the Product, then such allowances will be allocated on a pro rata basis consistent with
Sanofi’s standard internal allocation methodology. Commercial Expenses shall not include any costs or expenses that have been included in Cost of Goods, Development Expenses or any time spent traveling to or attending any meeting of the JAC, or
any subcommittee or working group of the foregoing.  
 “Advertising” shall mean all media costs associated
with Product advertising in the Territory including, but not limited to production expense/artwork including set up; design and art work for an advertisement; consumer and professional internet and digital media spending; social media spending; the
cost of securing print space, air time, etc. in newspapers, magazines, trade journals, television, radio, billboards, etc. 

“Distribution” shall mean the sales commissions payable to distributors and the portion of distribution costs relating
to moving Product in the Territory from the manufacturing point to a warehouse to the customer as follows: landing costs and duties (in-house or subcontracted), handling and transportation to fulfill orders including export/import taxes, insurance
and transit running costs, etc. (excluding such costs, if any, treated as a deduction in the definition of Net Sales); customer services, including order entry, billing and adjustments, inquiry and credit, collection, and litigation with customers
concerning orders/deliveries; order administration; and departments coordinating sales forecasts and supply management; physical distribution centers and other direct cost of storage and distribution of the Products, including distribution and
storage subcontracted to third parties; distribution services between physical distribution centers and commercial activities; local supply chain department; transportation packaging modifications as a result of marketing decisions or regulatory
requirements; and the costs of the traffic department where there is a separate department that has responsibility for administration of freight costs. “Distribution” at the local country level shall be deemed to apply at a rate equal to
two percent (2%) of Net Sales in the United States and five percent (5%) of Net Sales in all countries of the Territory other than the United States, as applicable, in such Calendar Quarter. 

“Education” shall mean expenses associated with professional education with respect to Product in the Territory
through any means, including, but not limited to, articles appearing in journals, newspapers, magazines or other media; seminars, and scientific exhibits; symposia, advisory boards and opinion leader development activities; peer-to-peer activities; speakers programs, including training of such speakers; transporting, housing and maintaining sales representatives for training and the costs of all
training materials used for such purpose; medical management and support; the coordination of medical information requests and field based medical scientific liaisons with respect to Product, including activities of medical scientific liaisons and
the provision of medical information services. 

  
 5. 

 “Legal and Litigation” shall mean the expenses associated with general,
worldwide administrative legal and litigation expenses for Product including Losses from any Third Party Claims relating to the Manufacturing or Commercializing of the Product and costs associated with recall or withdrawal of Product other than, in
each case, expenses, Losses and costs subject to indemnification under Section 11.1 or 11.2 of the Supply Agreement or under Section 11.1 or 11.2 of this Agreement, or relating to or arising from a Party’s gross negligence or willful
misconduct; and real losses on receivables (other than Net Sales) that have become irrecoverable; insurance liabilities for Product; and license fees, royalties and other payments under licenses to the extent attributable to, and based on, the
Development, Manufacture or Commercialization of Product. 
 “Marketing Management” shall mean expenses for product
management and sales promotion management, including, but not limited to, costs associated with developing overall sales and marketing strategies at the global and country level (e.g., product line or customer segment); launch meetings;
advertising and public relations agencies, including development and distribution of selling and advertising and promotional materials; developing reimbursement programs; call center set-up, maintenance and
operation for personnel used in connection therewith as well as planning and programs for Product in the Territory. In addition, payments to Third Parties in connection with trademark selection, filing, prosecution and enforcement in the Territory
will be included in this category. 
 “Market Research” shall mean expenses for primary and secondary market and
consumer research personnel and payments to Third Parties related to conducting and monitoring professional and consumer appraisals of Product in the Territory, such as primary and secondary market share services (e.g., IMS data), special research
testing and focus groups. 
 “Promotion” shall mean the expenses associated with programs to promote Product in the
Territory directly to the prescriber or end user, including, but not limited to, expenses associated with promoting products directly to the professional community such as professional literature; costs associated with patient assistance programs;
promotional material costs; patient aids and detailing aids; sales force tools and aids; managed care programs charged directly to the brand (including speaker programs, distribution of promotional material, contract administration, etc.); field
force meetings and training; professional agency fees; direct field funding; public relations; pharmacy programs; coupons and voucher programs; advocacy; sponsorships; scientific and medical promotion, including expenses associated with grants and
medical education, conventions, non-certified medical expense medical activities, scientific publications, commercial and medical advisory boards, field medical events, evidence-based medicine non-research projects; and Product samples (which, for
the avoidance of doubt, will not be double counted with associated costs contained in Paid Price or Cumulative COGS), including associated expenses such as per unit costs, costs of distributing samples from the warehouse to sales representatives or
fulfillment warehouses, and any other costs related to Product samples such as sample fulfillment, sample optimization programs, and management fees for sample voucher programs (i.e., vouchers provided by the physicians to patients in order to
obtain free trade units at the pharmacy). 
 “Selling Expenses” shall mean the following costs directly associated
with the efforts of field sales representatives with respect to Product in the Territory: field sales force; field 

  
 6. 

 
medical liaisons, field sales offices; home offices; staffs directly involved in the management of and the performance of the selling functions; and payments to Third Parties under contract sales
and marketing agreements. The costs of detailing sales calls will be allocated at an accounting charge rate consistently applied within and across Sanofi’s operating units consistent with the internal charge rate used by Sanofi for its own
internal cost accounting purposes for products other than the Product (excluding internal profit margins and markups). Selling Expenses may be allocated differently on a country-by-country basis but in any event shall be determined consistently with
the manner in which Sanofi prepares its internal financial statements. 
 5.4 “Cost of
Goods” shall have the meaning set forth in the Supply Agreement.  
 5.5 “Development
Expenses” shall mean, with respect to the applicable Calendar Quarter, the costs and expenses incurred by a Party or any of its Affiliates after the Execution Date in conducting or performing Development activities in the Field in the
Territory in such Calendar Quarter in accordance with the Development Plan and the Development Budget, excluding the Cost of Goods for Product used in conducting or performing such studies and other activities, calculated on a fully burdened basis
(i.e., Development Expenses shall include Allocable Overhead specifically attributable thereto). Development Expenses shall include all Regulatory Expenses and payments and accruals recorded in such Party’s accounting system according to
its standard accounting practices and IFRS. 
 5.6 “Regulatory Expenses” shall mean, with respect to the
applicable Calendar Quarter, the costs and expenses incurred by a Party or any of its Affiliates after the Execution Date in connection with filing, revising, obtaining or maintaining Regulatory Filings with respect to Product in the Field in the
Territory in such Calendar Quarter in accordance with the Development Budget, excluding the Cost of Goods for Product used in conducting or performing such activities, calculated on a fully burdened basis (i.e., Regulatory Expenses shall
include Allocable Overhead specifically attributable thereto). Regulatory Expenses shall include payments and accruals recorded in such Party’s accounting system according to its standard accounting practices and IFRS. 

5.7 “Replacement Supply Costs” shall mean costs and expenses incurred by Sanofi in
connection with establishing replacement source(s) of supply and associated supply chain following a Trigger Event (as defined in the Supply Agreement) except to the extent reimbursed by MannKind under the Supply Agreement. 

  
 7. 

 SCHEDULE B-1 

PROFIT/LOSS STATEMENT 
  

							
	 	  	Sanofi	  	MannKind	  	Total
	 REVENUES
	  		  		  	
	 Sublicensing Revenue
	  		  		  	
	 Total Net Sales
	  		  		  	
	 Paid Price
	  		  		  	
	 Distribution
	  		  		  	
	 Gross Profit
	  		  		  	
	 OPERATING EXPENSES
	  		  		  	
	 Development Expenses:
	  		  		  	
	 Clinical trials
	  		  		  	
	 CMC development
	  		  		  	
	 Allocable Overhead
	  		  		  	
	 Total Development Expenses
	  		  		  	
	 Commercial Expenses:
	  		  		  	
	 Advertising
	  		  		  	
	 Education
	  		  		  	
	 Legal and Litigation
	  		  		  	
	 Marketing Management
	  		  		  	
	 Market Research
	  		  		  	
	 Promotion
	  		  		  	
	 Selling Expenses
	  		  		  	
	 Allocable Overhead
	  		  		  	
	 Total Commercial Expenses
	  		  		  	
	 Profit (loss)
	  		  		  	
	 Adjustments per Section 4.1:
	  		  		  	
	 Balancing Payment
	  		  		  	
	 Interest on outstanding payments of Profit or Loss
	  		  		  	
	 Total
	  		  		  	

  
 8. 

 SCHEDULE B-2 

EXAMPLE OF PROFIT/LOSS SHARE CALCULATIONS 

[...***...] 

  
 ***Confidential Treatment
Requested 
 1. 

 CONFIDENTIAL 
  

EXHIBIT C 

MANNKIND PATENTS 
 Attached. 

  
 C-1. 

 July 31, 2014 

Confidential 
 1 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]

	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 2 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 3 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 4 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 5 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 6 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 7 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 8 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 9 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 10 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]

	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 11 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 12 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 13 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 14 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 15 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 16 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 17 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 18 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	 [...***...]
	  		  		  		  		  		  		  		  	
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 19 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
		  		  	[...***...]	  		  		  		  		  	
	 [...***...]
	  		  		  		  		  		  		  		  	
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 20 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	[...***...]	  		  		  		  		  		  		  		  	
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 21 

 

																	
	 Reference #
	  	 Country Name
	  	Serial #	  	Filed Date	  	Patent #	  	Issue Date	  	Status	  	*Anticipated
Expiration
Date	  	**PRODUCT-
specific or
Platform
	[...***...]	  		  		  		  		  		  		  		  	
	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

 July 31, 2014 

Confidential 
 22 

 

																	
	 Reference #
	 	 Country Name
	 	Serial #	 	Filed Date	 	Patent #	 	Issue Date	 	Status	 	*Anticipated
Expiration
Date	 	**PRODUCT-
specific or
Platform
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  

	*	Expiration dates are computer generated and may not take into account patent term adjustments, patent term extensions, terminal disclaimers or the like. These dates should be used as general guides only.

	**	The classification of pending applications as Product-specific or Platform must be considered tentative until such time as a patent is allowed. 

  
 ***Confidential
Treatment RequestedEX-10.2

 Exhibit 10.2 

***Text Omitted and Filed Separately with 

the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. 

EXECUTION VERSION 

SUPPLY AGREEMENT 
 This
SUPPLY AGREEMENT (together with all schedules attached hereto, the “Agreement”) is entered into as of August 11, 2014 (the “Execution Date”) and is
effective as of the Effective Date (as defined in the License Agreement (as defined below)) between MANNKIND CORPORATION, a Delaware corporation (“MannKind”),
having a principal place of business at 28903 North Avenue Paine, Valencia, California 91355, USA, and SANOFI-AVENTIS DEUTSCHLAND GMBH, a company organized and existing under the
laws of Germany (“Sanofi”), with a place of business at 65926 Frankfurt am Main, Germany. 
 RECITALS 

WHEREAS, MannKind has developed and has obtained approval in the United States of Product for improvement of glycemic
control in adult patients with diabetes and owns or controls certain patents, know-how and other intellectual property related to Product; 

WHEREAS, Sanofi is engaged in the development and commercialization of pharmaceutical products; 

WHEREAS, MannKind, Technosphere International C.V., a Dutch limited partnership, MannKind Netherlands B.V., a Dutch
limited liability company, and Sanofi are entering into a License and Collaboration Agreement of even date herewith (as may be amended, the “License Agreement”) under which Sanofi is receiving licenses to develop and
commercialize Product in the Territory; and 
 WHEREAS, MannKind desires to supply Product to Sanofi and its
Affiliates in connection with the License Agreement on the terms and conditions set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, MannKind and Sanofi hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth for such terms in the License
Agreement. The following terms used herein shall have the following meanings: 
 1.1 “Amphastar” shall mean
Amphastar France Pharmaceuticals S.A.S. 
 1.2 “[...***...]
Insulin” shall have the meaning set forth in Article 13. 
 1.3 “Arbitration Deadline” shall have
the meaning set forth in Section 12.2. 
 ***Confidential Treatment Requested 

 1.4 “Audit Disagreement” shall have the meaning set forth in
Section 4.4(d). 
 1.5 “Binding Forecast” shall have the meaning set forth in Section 3.2. 

1.6 “Certificate of Conformance” shall have the meaning set forth in Section 5.2(b). 

1.7 “cGMP” shall mean the current good manufacturing practices for the manufacture and testing of pharmaceutical
materials and devices required by the FDA or other Regulatory Authority(ies). 
 1.8 “Clinical Supply
Agreement” shall have the meaning set forth in Section 2.1(a)(ii). 
 1.9 “Clinical Supply Quality
Agreement” shall have the meaning set forth in Section 2.1(a)(ii). 
 1.10 “COGS Cap” shall
have the meaning set forth in Section 4.1. 
 1.11 “Commercially Reasonable Manufacturing
Efforts” shall mean, with respect to the efforts and resources required to fulfill any Manufacturing obligation hereunder, the use of reasonable efforts and resources, in good faith, consistent with the customary legal, medical,
scientific judgment and business practices of large or medium size Manufacturing companies in the pharmaceutical industry or the biotech industry. 

1.12 “Cost of Goods” shall mean, with respect to any Product supplied within the
scope of this agreement the unit cost of manufacture consisting of (a) Direct Material Costs, (b) Direct Operating Labor Costs and (c) Indirect Expenses, each as defined below, all as fairly and reasonably attributable to the Product
within the scope of this Agreement. 
 (a) “Direct Material Costs”
means the cost of purchased materials used in the manufacture or packaging of the Product, including costs of Raw Materials, excipients, intermediates and laboratory reagents and consumables, and costs of packaging materials, labels and other
printed materials used in the production of Product; 
 (b) “Direct Operating
Labor Costs” means the personnel cost of employees directly employed in the manufacturing, packaging, quality testing or release of the Product, including basic wages, labor and related payroll taxes and benefits; and 

(c) “Indirect Expenses” means: 

(i) Depreciation costs or lease/rental for manufacturing buildings and equipment and costs for maintenance and repair of such buildings
and equipment. The depreciation costs shall be allocated using an appropriate methodology. Costs of equipment shall be based on a planned utilization of equipment. Facility and equipment depreciation and/or lease/rental shall be allocated to
production proportionate to the usage of the Manufacturing facility and equipment for the actual Manufacturing of Product; 

  
 2. 

 (ii) Allocable Overhead, as such term is defined in Exhibit B to the License
Agreement; 
 (iii) Quality assurance activities; 

(iv) Interim transportation, or any related transportation cost including tertiary packaging and storage of Product, as incurred or
spent in connection with this Agreement; 
 (v) Costs of approved Third Party manufacturers (such costs will include the actual
amount paid including the benefit of any price reductions, payment or terms discounts or other reimbursements, such as volume discounts, that may be applicable to such purchases); and 

(vi) Subject to Section 6.4, costs associated with changes of the Product Specifications or the Manufacturing Process. 

For the avoidance of doubt, the following expenses will not be included in Cost of Goods: 

(A) Expenses associated with excess or idle capacity (including insurance and maintenance thereof), subject to Section 2.1(b)(ii);

 (B) The value of any stock provisions or write-offs, either due to quality non-compliance, or obsolescence and any associated
costs for physical destruction; 
 (C) Project related costs (e.g., process development, plant commissioning, process
improvement projects); 
 (D) Support functions not allocated to the Product within the scope of this Agreement; 

(E) Costs of asset write off; 

(F) Indemnities incurred by the supplier; and 

(G) Business interruption insurance and product liability insurance. 

1.13 “CPI” shall have the meaning set forth in Section 4.1(b). 

1.14 “Cumulative COGS” shall have the meaning set forth in Section 4.1(c)(i). 

1.15 “Due Date” shall have the meaning set forth in Section 4.3(b). 

1.16 “Estimated Annual Volume” shall have the meaning set forth in Section 3.2. 

1.17 “Estimated COGS” shall have the meaning set forth in Section 4.1. 

1.18 “Forecast” shall have the meaning set forth in Section 3.2. 

  
 3. 

 1.19 “Grace Period” shall have the meaning set forth in
Section 6.7(c). 
 1.20 “Hardship” shall have the meaning set forth in Section 4.1(b)(ii). 

1.21 “IBA Guidelines on Evidence” shall have the meaning set forth in Section 12.2. 

1.22 “ICH” shall mean the International Conference on Harmonization (of Technical Requirements for Registration
of Pharmaceuticals for Human Use). 
 1.23 “Indemnitee” shall have the meaning set forth in Section 11.3.

 1.24 “Indemnitor” shall have the meaning set forth in Section 11.3. 

1.25 “Insulin Exercise Notice” shall have the meaning set forth in Article 13. 

1.26 “Insulin Price” shall have the meaning set forth in Article 13. 

1.27 “Insulin Put Option” shall have the meaning set forth in Article 13. 

1.28 “Intervening Event” shall have the meaning set forth in Section 14.1. 

1.29 “Launch Quantities” shall have the meaning set forth in Section 3.1. 

1.30 “License Agreement” shall have the meaning set forth in the Recitals to this Agreement. 

1.31 “Losses” shall have the meaning set forth in Section 11.1. 

1.32 “MannKind Facility” shall mean MannKind’s facility located in Danbury, Connecticut, USA, where Product
shall be Manufactured for Sanofi under this Agreement. 
 1.33 “MannKind Indemnitees” shall have the meaning
set forth in Section 11.1. 
 1.34 “Manufacturing Process” shall have the meaning set forth in
Section 6.4. 
 1.35 “Manufacturing Right” shall have the meaning set forth in Section 6.7(b). 

1.36 “Manufacturing Technology” shall mean all MannKind Technology that is necessary or useful for the
Manufacture of Product, including such Information contained in the CMC section of any applicable Regulatory Filing and trade secrets, and including materials receiving and inspection procedures, Product work instructions and standard operating
procedures, records of yield for each Manufacturing step, Product engineering reports and improvement plans, list of instrumentation and description of the analytical methods used for the testing of the Product and the materials, device master file,
device design history file and mold process documentation. 
 1.37 “Objection Notice” shall have the meaning
set forth in Section 5.3(b). 
 1.38 “Paid Price” shall have the meaning set forth in Section 4.1.

  
 4. 

 1.39 “Party” shall mean MannKind or Sanofi individually, and
“Parties” shall mean MannKind and Sanofi collectively. 
 1.40 “Product
Specifications” shall mean the specifications for Product contained in the NDA for Product or in the applicable Marketing Approval of any country or jurisdiction in the Territory other than the United States, as applicable, and any
other specifications mutually agreed to in writing by the Parties and changes to such specifications made at the request of a Regulatory Authority in a given country or jurisdiction in the Territory or by written agreement of the Parties from time
to time, including the specifications set forth in the Quality Agreement. 
 1.41 “Put Closing Date” shall
have the meaning set forth in Article 13. 
 1.42 “Quality Agreement” shall have the meaning set forth in
Section 5.1. 
 1.43 “Raw Materials” shall have the meaning set forth in Section 6.1(a). 

1.44 “S&OP Process” shall have the meaning set forth in Section 2.3(b). 

1.45 “Sanofi Indemnitees” shall have the meaning set forth in Section 11.2. 

1.46 “Sanofi Site” shall have the meaning set forth in Section 2.1(b)(ii). 

1.47 “Semi-Finished Product” shall have the meaning set forth in Section 6.5(b). 

1.48 “SKU” shall mean stock keeping unit. 

1.49 “Term” shall have the meanings provided in Section 10.1. 

1.50 “Testing Technology/Processes” shall mean all technology and processes in the possession, custody or
control of MannKind that are necessary or useful for the testing of Product or any component thereof to determine whether it meets Product Specifications. 

1.51 “Third Party Claims” shall have the meaning set forth in Section 11.1. 

1.52 “Trigger Event” shall have the meaning set forth in Section 6.7(b). 

ARTICLE 2 
 PURCHASE AND
SUPPLY 
 2.1 Supply by MannKind. 

(a) Supply Obligation. 

(i) Commercial Supply. Subject to the terms and conditions of this Agreement (including Sections 2.1(b)(ii) and 6.7), MannKind will
Manufacture or have Manufactured and supply or have supplied to Sanofi or its Affiliates or its sublicensees such quantities and SKUs of Product as requested by Sanofi to cover total commercial requirements of

  
 5. 

 
Sanofi (for Sanofi and its Affiliates and its sublicensees) for Product in the Field in the Territory, including Product requested by Sanofi for promotional activities. 

(ii) Clinical Supply. As soon as reasonably practicable after the Effective Date, the Parties shall enter into a written agreement (the
“Clinical Supply Agreement”) setting forth terms and conditions pursuant to which MannKind will Manufacture or have Manufactured and supply or have supplied to Sanofi such quantities and SKUs of Product as requested by Sanofi
for any Development activities in the Field in the Territory as well as a quality agreement that details the quality assurance obligations of each Party relating thereto (the “Clinical Supply Quality Agreement”). Prior to
effectiveness of the Clinical Supply Agreement and the Clinical Supply Quality Agreement, MannKind will Manufacture or have Manufactured and supply or have supplied to Sanofi in accordance with the terms of this Agreement and the Quality Agreement,
as applicable, such quantities and SKUs of Product as requested by Sanofi for any Development activities in the Field in the Territory. 

(b) Exclusivity. 
 (i)
Exclusive Supply. Subject to the terms and conditions of this Agreement (including Sections 2.1(b)(ii) and 6.7), (a) MannKind will be the exclusive supplier to Sanofi and its Affiliates and its sublicensees of Product during the Term, and
(b) Sanofi agrees that in no event shall Sanofi or its Affiliates or its sublicensees Manufacture or have Manufactured Product, or purchase Product from any party other than MannKind. Notwithstanding the foregoing, the Parties shall upon
Sanofi’s request discuss in good faith the possibility that Sanofi perform final packing of Product (insertion of Device and sealed foil packages containing blister cards of cartridges). 

(ii) Sanofi Option. Notwithstanding the foregoing, the Parties acknowledge and agree that Sanofi shall have the option (the
“Sanofi Option”), exercisable at Sanofi’s sole discretion upon written notice to MannKind, to establish another facility of Sanofi or its Affiliate in which Product will be Manufactured (such facility, the
“Sanofi Site”), it being understood that such Sanofi Option shall not be exercised before MannKind has committed the capital investment required to bring the MannKind Facility to a level of capacity representing approximately
[...***...] percent ([...***...]%) of its maximum capacity (corresponding under MannKind’s current investment plan to the Manufacture of approximately [...***...] cartridges
of Product annually). For the avoidance of doubt, development of capacity at the MannKind Facility and/or the Sanofi Site shall be submitted to the approval of the JAC. 

(iii) Effect of Exercise of the Sanofi Option and Qualification of the Sanofi Site. Upon the exercise of the Sanofi Option,
(x) the Parties will coordinate the planning for the Sanofi Site with any further expansion of the MannKind Facility to minimize underutilization of both the MannKind Facility and the Sanofi Site after the Sanofi Site is subsequently qualified,
and (y) MannKind will perform those technology transfer obligations triggered by exercise of the Sanofi Option set forth in Section 6.6. Upon qualification of the Sanofi Site, Section 2.1(b)(i) shall be deemed amended so that all
references to “MannKind” therein shall be deemed to be references to “MannKind and the Sanofi Site”. From and after qualification of the Sanofi Site, the MannKind Facility and the Sanofi Site shall each be entitled 

  
 ***Confidential Treatment
Requested 
 6. 

 
to Manufacture and supply one-third (1/3) of total Product volumes (at their respective Cost of Goods and without reference to any COGS Cap), with the last one-third (1/3) of Product
volumes being allocated to the MannKind Facility and/or the Sanofi Site in a manner that minimizes the overall Cost of Goods; provided, however, that if such allocation of Product volumes results in underutilization of either the MannKind
Facility or the Sanofi Site, then notwithstanding Section 1.12, (1) during such period(s) that MannKind delivers all of its volume allocation within the tolerances set forth in Section 3.4, then the costs of such underutilization
shall be included in the Cost of Goods for Product Manufactured and supplied from the MannKind Facility at all times that the MannKind Facility is under-utilized as a result of such allocation of Product volumes between the MannKind Facility and the
Sanofi Site; and (2) the costs of such underutilization shall be included in the Cost of Goods for Product Manufactured and supplied from the Sanofi Site at all times that the Sanofi Site is under-utilized as a result of such allocation of
Product volumes between the MannKind Facility and the Sanofi Site. 
 2.2 Form of Supply. MannKind shall supply Product to Sanofi in
the form of finished Product (i.e., individual doses, final packaging, etc.) ready and suitable for distribution and sale to the market in the relevant jurisdiction in the Territory (or as otherwise reasonably requested by Sanofi with respect to
Product for any Development activities permitted under the License Agreement). Without limiting the foregoing, MannKind shall be responsible for packaging Product in blister cards contained in a foil overwrap and supplying Product to Sanofi in
finished packaging, including (a) all labeling and other written, printed or graphic content (i) affixed to Product or any container or wrapper utilized with Product or (ii) accompanying Product, including package inserts, and
(b) all containers for Product, including cartons, shipping cases or any other like matter used in packaging or accompanying Product. All such packaging shall be in a form approved in advance by Sanofi and MannKind shall include Sanofi’s
name on such packaging in the manner and format specified by Sanofi. MannKind shall be responsible for ensuring that all labels and packaging for Product supplied hereunder shall, at the time of supply, conform to the labels for the Product approved
by Sanofi. 
 2.3 Cooperation. 

(a) Monthly Review. Each Party shall forthwith upon execution of this Agreement, appoint one (1) of its employees to be a
relationship manager responsible for acting as liaison between the Parties with regard to matters described in this Agreement. The relationship managers shall meet (either in person or by phone) not less than monthly to review the current status of
the business relationship and manage any issues that have arisen. 
 (b) Sales and Operational Planning. The Parties, through their
relationship managers, shall establish a process for aligning Sanofi’s sales plans with MannKind’s operations plans in order to (i) optimize Product supply taking into account the utilization of production resources and any equipment
and material constraints, (ii) manage inventory levels and order backlogs, and (iii) establish metrics for the measurement of effective performance (the “S&OP Process”). The Parties agree that the S&OP
Process will form the basis for MannKind’s master production schedule and for decisions about material and labor resources. Accordingly, Sanofi acknowledges the need for accurate and timely adjustments to Forecasts so that supply capacity can
be managed appropriately. 

  
 7. 

 (c) Person-in-Plant. Upon MannKind’s receipt of at least seven (7) days’
prior notice from Sanofi during the Term and at no additional cost to Sanofi, Sanofi may place up to two (2) employees or authorized representatives (with such authorized representatives being subject to MannKind’s prior approval, such
approval not to be unreasonably withheld, conditioned or delayed) on-site at the MannKind Facility during the Term. Sanofi’s representatives shall have access to MannKind’s production and quality control areas related to the Product
(including when in operation) and to Product documentation, it being understood that Sanofi’s representatives at the MannKind Facility shall accept MannKind’s procedures regulating external customer relationships (including cGMP training,
hygiene, confidentiality and controlled access to facilities and documents) and will obtain MannKind’s written agreement (such agreement not to be unreasonably withheld, conditions or delayed) prior to any active participation in the
Manufacture or testing of Product. MannKind will make available office space to any such Sanofi representatives on-site at the MannKind Facility, and any reasonable and customary related office resources and support services (such as telephone and
data communications wiring in such facilities and patch cables located in network wiring closets in such facilities, parking privileges, access cards or badges, and furniture), at a level of support that MannKind provides such items to its own
comparable employees. 
 (d) Continuous Improvement. MannKind shall continuously seek to improve the actual Cost of Goods throughout
the Term, and, at the request of Sanofi, provide Sanofi with written evidence demonstrating the efforts and activities undertaken by MannKind in furtherance thereof through the Manufacturing working group of the JAC. At the request of MannKind,
Sanofi shall provide reasonable support to MannKind therefor, such as offering (i) certain Manufacturing services related to the Product at their fully burdened manufacturing cost without any markup, as well as (ii) the supply of certain
Raw Materials under the conditions set forth in Section 6.1(a). Notwithstanding the foregoing, MannKind acknowledges and agrees that (x) MannKind is and shall remain solely responsible for the negotiation and execution of supply agreements
with all suppliers of Insulin and other Raw Materials; and (y) Sanofi shall not have any obligation with respect to the negotiation or execution of such supply agreements. The Manufacturing working group of the JAC shall discuss and oversee the
efforts to reduce Cost of Goods and approve in advance any costs to be incurred by MannKind for such efforts. 
 (e) Manufacturing
Prioritization. MannKind will dedicate to the Manufacture of Products for Sanofi hereunder the first priority with respect to facilities, equipment, and Raw Materials used therefor. If there is a conflict between Manufacture of Product for
Sanofi hereunder and the Development or Manufacture of any other product, the conflict will be resolved in favor of Manufacture of Product for Sanofi hereunder. 

(f) CAPA Obligations. The Parties acknowledge that (i) prior to the execution of this Agreement, Sanofi performed a formal quality
audit and inspection of the MannKind Facility, and (ii) as a result of such audit and inspection, Sanofi identified those corrective actions and preventive actions (each, a “CAPA”) set forth on SCHEDULE
D hereto. As soon as reasonably practicable after the Execution Date, but in any event prior to the receipt of Sanofi’s written purchase order for Product, MannKind shall perform each CAPA to the reasonable satisfaction of Sanofi. 

  
 8. 

 ARTICLE 3 

FORECASTS AND PURCHASE ORDERS 

3.1 Commercial Launch. Sanofi shall notify MannKind approximately
[...***...] months in advance of the anticipated First Commercial Sale of Product in the Field in the Territory. Such notification shall include a preliminary estimate of the quantity of
Product needed for the commercial launch. Sanofi may change the estimated date of the First Commercial Sale and the estimated quantity of Product needed for such commercial launch at any time by notifying MannKind; provided, however, that
Sanofi will provide MannKind with its binding forecast for the amount of Product that will be necessary for commercial launch upon achievement of the [...***...] Milestone, and in any event, at least [...***...] months prior to such launch
(the “Launch Quantities”). 
 3.2 Forecasts. In the first week of each month, Sanofi shall provide MannKind
with a written eighteen (18) month rolling forecast of its anticipated requirements for Product in the Territory (each a “Forecast”). Sanofi’s initial Forecast is attached hereto as SCHEDULE E.
Each Forecast is a non-binding estimate and shall not obligate Sanofi to purchase the volume of Product set forth in such Forecast; provided, however, that, from and after achievement of the [...***...] Milestone, the volume forecasted for
the first (1st) three (3) months of each Forecast shall be binding upon Sanofi (such first (1st) three (3) months, the “Binding Forecast”). MannKind shall not be obligated to Manufacture or supply Sanofi
with quantities of Product in excess of one hundred ten percent (110%) of the most recent Binding Forecast provided to MannKind but agrees to use Commercially Reasonable Manufacturing Efforts to satisfy Sanofi’s requirement of Product in
excess of one hundred ten percent (110%) of the Binding Forecast quantities in accordance with the terms of this Agreement. In addition to the Forecast, the Parties shall by October 1 of each Calendar Year agree upon an annual Product
volume forecast, expressed in number of cartridges, for the following Calendar Year (the “Estimated Annual Volume”) for the purpose of determining, in accordance with Section 4.1, the Estimated COGS and the COGS Cap for
purchase orders of Product submitted during such Calendar Year. 
 3.3 Purchase Orders. Sanofi shall order Product by submitting
written purchase orders, in such form as the Parties shall agree from time to time, to MannKind specifying the quantities of Product ordered, the desired delivery date for such Product and any special shipping instructions. Sanofi shall order
Product in lots of a defined number of units/lot pursuant to each purchase order as reasonably specified by MannKind. Sanofi shall submit each purchase order to MannKind at least ninety (90) days in advance of the desired delivery date
specified in such purchase order. MannKind shall confirm acceptance of the purchase order within five (5) days of receipt of the purchase order from Sanofi. If MannKind fails to confirm acceptance of a purchase order within five (5) days
of receipt of the purchase order from Sanofi, then such purchase order shall be deemed to have been accepted by MannKind. MannKind shall accept all purchase orders for quantities of Product that are within the amounts specified in the applicable
Binding Forecast. MannKind shall make (or in the case of orders in excess of one hundred ten percent (110%) of the Binding Forecast, use Commercially Reasonable Manufacturing Efforts to make) each delivery of Product in the quantity and on the
delivery date specified for it on Sanofi’s purchase order, via the mode(s) of transportation and to the party and destination 

  
 ***Confidential Treatment
Requested 
 9. 

 
specified on such purchase order. Any purchase orders for Product submitted by Sanofi to MannKind shall reference this Agreement and shall be governed exclusively by the terms contained herein.
The Parties hereby agree that the terms and conditions of this Agreement shall supersede any term or condition in any purchase order, confirmation or other document furnished by Sanofi or MannKind that is in any way inconsistent with the terms and
conditions contained herein. 
 3.4 Delivery. MannKind will ship Product to Sanofi in such quantities and on such monthly delivery
dates as are specified in purchase orders (with a tolerance of plus/minus five percent (5%) for the quantity, and a tolerance of minus three (3) / plus zero (0) days for the delivery date). Deliveries shall be made FCA (“Free
Carrier,” as such term is defined in INCOTERMS 2010) from the location of final Product completion. All deliveries of Product to Sanofi shall be made via such carrier(s) as Sanofi may direct. 

3.5 Shelf Life.  

(a) For the period prior to FDA or other Regulatory Authority approval of a total shelf life of the Product that is greater than
twenty-four (24) months in a particular jurisdiction: Upon delivery for that jurisdiction, the residual shelf life of Product shall, unless otherwise approved by Sanofi, be at least fifteen (15) months; provided, however, that
MannKind shall use Commercially Reasonable Manufacturing Efforts to deliver Product with residual shelf life of at least eighteen (18) months; and 

(b) For the period from and after FDA approval or other Regulatory Authority of a total shelf life of the Product that is greater than
twenty-four (24) months in a particular jurisdiction: Upon delivery for that jurisdiction, the residual shelf life of Product shall, unless otherwise approved by Sanofi, be at least eighty percent (80%) of the Product’s total approved
shelf life in the relevant jurisdiction. 
 3.6 Changes to Purchase Orders. MannKind shall use Commercially Reasonable Manufacturing
Efforts to comply with unplanned changes in purchase orders requested by Sanofi either in terms of quantities or delivery dates. In no event shall MannKind implement such unplanned changes without the prior written approval of Sanofi if such changes
result in supplementary costs for Sanofi. 
 ARTICLE 4 

PAYMENT TERMS 
 4.1
Price.  
 (a) Paid Price, Estimated COGS and COGS Cap. No later than October 2 of each Calendar Year during the Term,
the JAC shall determine the price to be paid by Sanofi to MannKind for each unit (i.e., each cartridge) of Product supplied by MannKind to Sanofi during the subsequent Calendar Year (the “Paid Price”), which price
shall equal the lower of the Estimated COGS per unit for that year and the COGS Cap per unit, in each case, at the Estimated Annual Volume. The Paid Price shall subsequently be subject to true-up as described in Section 4.1(c). For purposes of
this Agreement: 

  
 10. 

 (i) “Estimated COGS” shall mean the estimated Cost of Goods for
Product to be supplied by MannKind to Sanofi or its Affiliates or sublicensees under this Agreement for a specified annual volume of cartridges and at the estimated weighted average Insulin price for a Calendar Year, as adjusted pursuant to
Section 4.1(b). The Parties agree that the Estimated COGS for the period from the Effective Date to December 31, 2015, shall be as set forth in SCHEDULE A to this Agreement; and 

(ii) “COGS Cap” shall be the maximum price for Product, for a specified annual volume of cartridges and at the
weighted average Insulin price determined in accordance with Section 4.1(b)(i), which (A) for the period from the Effective Date until December 31, 2019, shall be as set forth in SCHEDULE B, subject to adjustment
in accordance with Section 4.1(b); and (B) for the Calendar Year starting January 1, 2020 and all subsequent Calendar Years during the Term, shall be determined by the JAC for each five-year period prior to the commencement of each
such five-year period and shall be subject to adjustment in accordance with Section 4.1(b); in each case, provided that there shall be no COGS Caps from and after qualification of the Sanofi Site. 

(b) Adjustments. On January 1, 2016 and at the beginning of each Calendar Year thereafter, the COGS Cap shall be adjusted in
accordance with any increase or decrease in the U.S. Consumer Price Index for Prescription Drugs (seasonally adjusted) published by the U.S. Bureau of Labor Statistics (“CPI”) during the previous Calendar Year up to a maximum
increase of five percent (5%) per Calendar Year. The Parties acknowledge and agree that unless mutually agreed by the Parties in writing, the COGS Cap shall be calculated in accordance with the values, model and methodology set forth on
SCHEDULE B and as exemplified in SCHEDULE C to this Agreement, except that the values reflecting the prices for Insulin and critical Raw Materials (other than Insulin) may be adjusted in accordance with
Sections 4.1(b)(i) and 4.1(b)(ii), respectively. 
 (i) Insulin. The Parties acknowledge and agree that the COGS Cap set forth in
SCHEDULE B shall assume the following prices paid by MannKind for Insulin supply: (A) for [...***...] an Insulin price of $[...***...]/gram, (B) for
[...***...], subject to Section 4.1(b), an Insulin price of $[...***...]/gram, and (C) for [...***...], subject to Section 4.1(b), [...***...], an Insulin price of $[...***...]/gram. 

(ii) Hardship. If, due to any reason or cause beyond MannKind’s reasonable control (including market shortage, market embargo,
etc.) (a “Hardship”), MannKind is prevented from procuring any critical Raw Material (other than Insulin) at a price reasonably equivalent to that used to calculate the applicable COGS Cap, then MannKind shall promptly inform
Sanofi of such Hardship and Parties shall meet to discuss appropriate means, if any, to adjust the values for such critical Raw Material used in the calculation of the COGS Cap to alleviate or mitigate the effects of such Hardship. If the
Parties cannot agree upon an appropriate adjustment, the matter shall be referred to the JAC, which shall determine whether to adjust the COGS Cap during the period of such Hardship (and if so, the terms and conditions of such 

  
 ***Confidential Treatment
Requested 
 11. 

 
modification). For the avoidance of doubt, “Hardship” shall not include MannKind’s mere failure to negotiate or execute a supply agreement with its Raw Material
suppliers. 
 (c) True-Up. Within forty-five (45) days after the end of the Calendar Year in which First Commercial Sale of
Product occurs and each subsequent Calendar Year of the Term (each, a “Sales Period”), the Parties shall calculate an annual true-up payment as follows: 

(i) The Parties shall compute (A) the cumulative Paid Price for all Product supplied by MannKind in such Sales Period (the
“Cumulative Price Paid”); and (B) the lower of (x) the actual cumulative Cost of Goods for all Product supplied by MannKind in such Sales Period, and (y) the COGS Cap determined on the basis of the total annual
volume for such Sales Period (such lower amount, the “Cumulative COGS”); provided, however, that if in any Calendar Year the actual cumulative Cost of Goods exceeds the applicable COGS Cap (such difference, the
“Overage”), and in the immediately following Calendar Year the actual cumulative Cost of Goods is less than the applicable COGS Cap, then MannKind shall be entitled to add to the Cumulative COGS, for such successive Calendar
Year only, an amount equal to the Overage up to, but not exceeding, the COGS Cap. 
 (ii) (A) If the Cumulative COGS exceeds the
Cumulative Price Paid, Sanofi shall pay the difference to MannKind no later than forty-five (45) days after calculation of the true-up payment is due; and (B) if the Cumulative COGS is lower than the Cumulative Price Paid, the difference
shall be, at Sanofi’s option, either (1) a credit to be applied against any or all subsequent purchases of Product hereunder or (2) reimbursed to Sanofi no later than forty-five (45) days after calculation of the true-up payment
is due. 
 (d) True-Up Estimates. Within thirty (30) days of each Quarter, MannKind shall provide to Sanofi with MannKind’s
then-current estimates of the total true-up amount that MannKind expects to be paid to or by Sanofi at the end of such Calendar Year pursuant to Section 4.1(c). 

4.2 Taxes. All payments payable hereunder shall be paid without any reduction or offset for taxes. MannKind shall pay any and all U.S.
federal, state, and local income taxes levied on payments to MannKind hereunder and Sanofi shall, in addition to amounts payable pursuant to Section 4.1, pay all other taxes levied on amounts payable hereunder. The Parties acknowledge and agree
that it is their mutual objective and intent to minimize, to the extent feasible, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use their reasonable efforts to cooperate and coordinate with each
other to achieve such objective as allowed under Applicable Laws. Each Party shall cooperate with the other to the extent reasonably requested for the purpose of filing any tax returns relating sales, use, transfer, stamp, VAT, withholding, or
similar taxes, if any, levied on amounts payable hereunder. 
 4.3 Invoices; Method of Payments. 

(a) MannKind shall invoice Sanofi for the aggregate Estimated COGS or COGS Cap, as applicable, of each shipment of Product at the time
of such delivery. 
 (b) All payments due hereunder to MannKind shall be paid to MannKind in U.S. Dollars not later than forty-five
(45) days following the date of receipt of the applicable 

  
 12. 

 
invoice but not earlier than the date of delivery (the “Due Date”), unless such shipment of Product is rejected in accordance with the provisions of Section 5.3. All
payments under this Agreement shall be made by bank wire transfer in immediately available funds to a U.S. account designated in writing by MannKind or by other mutually acceptable means. Payments hereunder will be considered to be made as of the
day on which they are received by MannKind’s designated bank. 
 4.4 Records. 

(a) During the Term, and for a period of three (3) years thereafter, MannKind shall, and shall ensure that its Affiliates shall,
keep at either its normal place of business, or at an off-site storage facility, detailed, accurate and up to date: (i) records and books of account sufficient to confirm the calculation of the Paid Price, Estimated COGS, actual Cost of Goods
and COGS Cap; and (ii) information and data contained in any invoices provided to Sanofi in connection with this Agreement. 
 (b)
On no less than sixty (60) days’ prior written notice from Sanofi, MannKind shall make all such records, books of account, information and data concerning the Paid Price, Estimated COGS, actual Cost of Goods and COGS Cap available for
inspection during normal business hours by an independent, certified public accountant selected by Sanofi and reasonably acceptable to MannKind, which acceptance will not be unreasonably withheld or delayed, for the purpose of general review or
audit; provided that Sanofi may not request such inspection more than once in any Calendar Year. As a condition to such inspection, the independent public accountant selected shall execute a written agreement, reasonably satisfactory in form and
substance to MannKind, to maintain in confidence all information obtained during the course of any such examination and all reasonable documents will be disclosed to the accountant under these confidential terms. Additionally no accountant may be
employed on a contingency basis. 
 (c) Sanofi shall be solely responsible for its costs in making any such review and audit, unless
such review and audit discloses that the Cumulative COGS for a Sales Period, after true-up in accordance with Section 4.1(c), were overstated by more than five percent (5%) by MannKind, in which event MannKind shall be solely responsible
for the cost of such review and audit. Any underpayment by Sanofi shall be promptly paid to MannKind, and any overpayment to MannKind by Sanofi shall be promptly refunded to Sanofi or credited toward any unpaid invoice by MannKind to Sanofi. All
information disclosed by MannKind or its Affiliates pursuant to this Section 4.4 shall be deemed Confidential Information of MannKind. 

(d) If there is a dispute between the Parties related to compliance with applicable accounting standards following any audit performed
pursuant to Section 4.4, either Party may refer the issue (an “Audit Disagreement”) to an independent certified public accountant for resolution. In the event an Audit Disagreement is submitted for resolution by either
Party, the Parties shall comply with the following procedures: 
 (i) The Party submitting the Audit Disagreement for resolution
shall provide written notice to the other Party that it is invoking the procedures of this Section. 

  
 13. 

 (ii) Within thirty (30) days of the giving such notice, the Parties shall jointly
select a recognized international accounting firm to act as an independent expert to resolve such Audit Disagreement. 
 (iii) The
Audit Disagreement submitted for resolution shall be described by the Parties to the independent expert, which description may be in written or oral form, within ten (10) days of the selection of such independent expert. 

(iv) The independent expert shall render a decision on the matter as soon as practicable. 

(v) The decision of the independent expert shall be final and binding and shall not be subject to Article 12 hereof, unless such Audit
Disagreement involves alleged fraud, breach of this Agreement or construction or interpretation of any of the terms and conditions hereof. 

(vi) All fees and expenses of the independent expert, including any Third Party support staff or other costs incurred with respect to
carrying out the procedures specified at the direction of the independent expert in connection with such Audit Disagreement, shall be borne by the Party against whom such expert rules. 

ARTICLE 5 
 QUALITY
ASSURANCE; ACCEPTANCE 
 5.1 Quality Agreement. Within ninety (90) days from the Effective Date (or such longer period as
agreed by the Parties but in any event at least three (3) months prior to the first delivery of Product to Sanofi), the Parties will enter into an agreement that details the quality assurance obligations of each Party (the “Quality
Agreement”). In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the provisions of this Agreement shall govern; provided, however, that the Quality Agreement shall govern in
respect of quality issues. 
 5.2 Specifications; Testing. 

(a) Batch Testing. MannKind will have standard analytical testing performed on each Manufactured batch of Product to be shipped to
Sanofi to verify that it meets Product Specifications, according to the procedure described in the corresponding documentation, and that Product was Manufactured in accordance with Applicable Laws. 

(b) Certificate of Conformance. In connection with delivery of any batch of Product, MannKind shall provide Sanofi with a certificate of
conformance signed by an appropriately Qualified Person (“QP”, as such term is defined under the European Union pharmaceutical regulation) or appropriately qualified quality assurance representative when the QP function does
not exist, as applicable (the “Certificate of Conformance”). Such Certificate of Conformance shall certify with respect to each batch (identified by batch number) (i) that Product delivered conforms to Product
Specifications (including that the Product is free of any viruses and/or transmissible spongiform encephalopathies), as well as any further information 

  
 14. 

 
required by the relevant Regulatory Authorities that Sanofi may have previously notified MannKind is necessary and (ii) that the Product batch has been Manufactured in accordance with cGMP.
Sanofi shall be under no obligation to accept any shipment of Product without an accompanying Certificate of Conformance. 
 5.3
Acceptance and Rejection. 
 (a) Product Testing. Sanofi, at its expense, may from time to time, but shall have no obligation to,
perform such samplings and tests that are designed, in accordance with the methods of analysis and Product Specifications, to determine whether each batch of Product shipped to Sanofi meets Product Specifications. Regardless of Sanofi’s
performance or absence of performance of testing, Sanofi may reject any shipment (or portion thereof) of Product if any Product fails to conform to any warranty set forth in Section 8.2 of this Agreement by providing to MannKind written notice
of such rejection and the reasons therefor within 30 days of delivery of such Product; otherwise, Sanofi shall be deemed to have accepted such shipment of Product; provided, however, that in the case of Product having a defect that causes
Product to fail to conform to any warranty set forth in Section 8.2 of this Agreement, which defect is not discoverable upon reasonable physical inspection of the shipping container (or upon any other inspection or testing that Sanofi, in its
sole discretion, may decide to perform) but is discovered at a later time, Sanofi shall, once it discovers the possibility that a Product may have such a defect, notify MannKind within ten (10) days after such discovery of such possible defect.

 (b) Replacement of Product and Dispute Procedure. If MannKind notifies Sanofi in writing, within thirty (30) days of
MannKind’s receipt of notice that Sanofi is rejecting Product, that MannKind disagrees with Sanofi’s claim that the Product is defective (an “Objection Notice”), the following procedures shall apply. Sanofi and
MannKind will review available documentation and perform re-testing of the Product as appropriate to attempt to reach agreement as to whether or not Product fails to conform to any warranty set forth in Section 8.2 of this Agreement. If Sanofi
and MannKind fail within ten (10) days after delivery of the Objection Notice to agree as to whether Product is defective, representative samples of the batch of Product in question shall be submitted to a mutually-acceptable independent
laboratory or consultant for analysis or review. The results of such evaluation shall be binding upon the Parties. The Parties shall share equally the cost of such evaluation except that the Party that is determined to have been incorrect in its
determination of whether Product should be rejected shall assume the responsibility for, and pay, the costs of any such evaluation and reimburse the other for any amounts previously paid to the independent laboratory or consultant in connection with
that determination. 
 (c) Cost of Replacement of Rejected Product. If any shipment of Product is rejected by Sanofi, Sanofi shall
have no obligation or duty to pay any amounts payable to MannKind in respect of the rejected Product unless and until there is a determination by the independent laboratory or consultant in support of MannKind’s Objection Notice in accordance
with Section 5.3(b). If only a portion of a shipment is rejected, Sanofi shall have no obligation or duty to pay the amount allocable to the defective portion only. 

(d) Return of Rejected Product. If a shipment or partial shipment is rejected by Sanofi pursuant to the provisions of this
Section 5.3 and there is not a determination by the 

  
 15. 

 
independent laboratory or consultant in support of MannKind’s Objection Notice in accordance with Section 5.3(c), Sanofi shall return to MannKind at MannKind’s request and expense
(or, at the election of MannKind, destroy at MannKind’s cost and provide evidence of such destruction to MannKind) any such rejected Product. MannKind shall (i) credit the original invoice in respect of the rejected Product, and
(ii) adjust the invoice to Sanofi for any Product that was not rejected, payment of which is due in accordance with the terms of the original invoice. 

(e) Supply of Replacement Product. During the pendency of any rejection discussions MannKind shall use Commercially Reasonable
Manufacturing Efforts to supply Sanofi with additional Product which Sanofi shall purchase on the same terms as Product that is the subject of the rejection discussions. 

ARTICLE 6 
 MANUFACTURE
OF PRODUCT 
 6.1 Raw Materials. 

(a) Procurement. MannKind shall be responsible for obtaining, and shall store any Insulin, raw materials, components, devices, other
ingredients and packaging materials required for the Manufacture of Product (“Raw Materials”), in reasonable quantities consistent with Sanofi’s Forecasts and purchase orders. MannKind shall ensure that all Raw Materials
conform to their respective specifications and are stored and handled in accordance with cGMP and the Quality Agreement. MannKind shall use Commercially Reasonable Manufacturing Efforts to procure all Raw Materials (other than Insulin) based on
tiered pricing (i.e., lower prices for higher volumes). In addition, within two (2) years after the Effective Date, MannKind shall (1) identify alternative suppliers for all critical Raw Materials, and (2) use Commercially Reasonable
Manufacturing Efforts to start to qualify alternative suppliers for all critical Raw Materials, in each case, for the purpose of establishing dual-sourcing and back-up supply thereof. At Sanofi’s request, Sanofi and MannKind will negotiate and
enter into a separate supply agreement pursuant to which Insulin and, if agreed by the Parties, other Raw Materials, would be supplied by Sanofi or its Affiliates, at Sanofi’s cost (calculated in accordance with IFRS as consistently applied)
for such Insulin and other Raw Materials without markup, for use in the Manufacture of Product supplied by MannKind hereunder. 
 (b)
Insulin Restrictions. Notwithstanding any other provision of this Agreement to the contrary, MannKind agrees that it shall not, without the prior written consent of Sanofi (in its sole discretion), use in the Manufacture of any Product hereunder
any Insulin that was formulated more than [...***...] years prior to the desired date of use. Without limiting the foregoing, MannKind acknowledges and agrees that [...***...]. 

6.2 Manufacture of Product. MannKind will Manufacture Product in accordance with Product Specifications, cGMPs and Applicable Laws. The
Parties shall notify each other within three (3) Business Days of any new instructions or specifications required by Regulatory 

  
 ***Confidential Treatment
Requested 
 16. 

 
Authorities with jurisdiction over the Manufacture, import, export, use, marketing or sale of Product in the Field in the Territory. The Parties shall confer with each other with respect to any
response regarding such instruction or specification and the best means to comply with such requirements. To the extent the instruction or specification specifically relates to the Product (as opposed to a general requirement such as cGMPs), the
costs for implementing such changes will be incorporated into the Estimated COGS and actual Cost of Goods. The Manufacturing working group of the JAC shall discuss the Manufacture of Product in accordance with cGMP outside of FDA or ICH
requirements, if applicable. 
 6.3 Packaging. MannKind shall package Product to be supplied in accordance with MannKind’s
standard operating procedures, which shall comply and be in accordance with Product Specifications, cGMPs and Applicable Laws. 
 6.4
Changes to Product Specifications or to the Manufacturing Process. 
 (a) A Party proposing a change to Product Specifications or
the Raw Materials, equipment, process or procedures used to Manufacture Product (the “Manufacturing Process”) shall provide written notice to the other Party. If the proposed change is required by a Regulatory Authority, then
such notice shall include disclosure of the Regulatory Authority request and relevant correspondence. Any changes to Product Specifications or to the Manufacturing Process shall be in compliance with the NDA and other Marketing Approvals for
Product. Each Party shall notify the other Party of any proposed change to Product Specifications or to the Manufacturing Process. 
 (b)
Any proposed change (other than changes required by a Regulatory Authority in the Territory) shall be subjected to a cost/benefit analysis and to the approval by the JAC, it being understood and agreed that: 

(i) neither Party shall be obliged to accept or implement any change where the cost of such change to that Party is greater than the
benefit of such change to that Party, and 
 (ii) neither Party shall withhold or delay acceptance of any change where the cost of
such change to that Party is nil or borne by the other Party. 
 (c) If the change is required by a Regulatory Authority in the
Territory, then: 
 (i) If, at the time of such change and at all times thereafter, no other products are Manufactured at the
MannKind Facility, then any expenses of implementing such change shall be paid by MannKind and subsequently reflected in the Paid Price, Estimated COGS and Cost of Goods. 

(ii) If, at or after the time of such change, other products are Manufactured at the MannKind Facility, then any expenses of
implementing such change shall be paid by MannKind and the relative portion thereof shall be subsequently reflected in the Paid Price, Estimated COGS and Cost of Goods. For the sake of example only, if one (1) other product is Manufactured at
the MannKind Facility and utilizes one-half (1/2) of the available capacity of such facility, then one-half (1/2) of such expenses shall be subsequently reflected in 

  
 17. 

 
the Paid Price, Estimated COGS and Cost of Goods; however, if such other product only utilizes one-third (1/3) of the available capacity, then two-thirds (2/3) of such expenses shall be
subsequently reflected in the Paid Price, Estimated COGS and Cost of Goods. 
 (d) For the sake of clarity, MannKind shall bear all of
the expenses incurred to implement a change that is necessary to bring MannKind back into compliance with the Product Specifications or remedy any non-compliance with a prior approval from a Regulatory Authority (and, for the further sake of
clarity, such expenses shall not be reflected in the Paid Price, Estimated COGS and/or Cost of Goods). 
 6.5 Inventory. 

(a) Sanofi shall carry a reasonable quantity of inventory of Product (i.e., at least
[...***...] of inventory of Product (calculated based on the amounts of Product set forth in the [...***...] of the most current Forecast)). The cost of Sanofi carrying such inventory
of Product and insuring the same shall be borne by Sanofi. 
 (b) Commencing on the Effective Date and subject to achievement of the
[...***...] Milestone, MannKind shall use Commercially Reasonable Manufacturing Efforts to build at least [...***...] months of inventory of Semi-Finished Product (calculated based on the amounts of Product set forth in the first
[...***...] months of the most current Forecast and inclusive of Launch Quantities) prior to the First Commercial Sale of Product in the Field in the Territory. For the period from and after the shipment to Sanofi of the Launch Quantities,
MannKind shall carry at least [...***...] months of inventory of Semi-Finished Product (calculated based on the amounts of Product set forth in the most current Binding Forecast). The cost of MannKind carrying such inventories of Product and
insuring the same shall be borne by MannKind. For purposes of this Agreement, “Semi-Finished Product” shall mean semi-finished Product (i.e., foil-wrapped blister packs) with remaining shelf life sufficient to allow the
supply of finished Product that meets the minimum remaining shelf life requirements set forth in Section 3.5. 
 (c) MannKind
shall use Commercially Reasonable Manufacturing Efforts to maintain at least [...***...] months of inventory (calculated based on the amounts of Product set forth in the first [...***...] months of the most current Forecast) of Insulin
less than [...***...] years old, unless otherwise approved by Sanofi in accordance with Section 6.1(b). 
 6.6 Technology
Transfer. 
 (a) Testing Technology/Processes. Upon Sanofi’s request, MannKind will promptly: (i) transfer to Sanofi or
its Affiliate any Testing Technology/Processes and other information necessary to enable Sanofi or its Affiliate to test Product to determine if such Product complies with Product Specifications; (ii) describe to Sanofi all testing equipment
reasonably necessary to enable Sanofi or its Affiliate to test Product to determine if such Product complies with Product Specifications; (iii) otherwise provide the technology transfer services described in Section 6.6(c) reasonably
necessary to enable Sanofi or its Affiliate to test Product to determine if such Product complies with Product Specifications; and (iv) perform parallel testing of the same Product in order to validate that full testing capabilities have been
effectively 

  
 ***Confidential Treatment
Requested 
 18. 

 
transferred to Sanofi. For the sake of clarity, the obligations of MannKind pursuant to this Section 6.6(a) shall renew on a jurisdiction-by-jurisdiction basis outside of the United States
with respect to any subsequent testing (or re-testing) that may be required by any applicable Regulatory Authority prior to any Commercialization of the Product in each such jurisdiction. 

(b) Manufacturing Technology. Upon a Trigger Event or exercise of the Sanofi Option, MannKind will: (i) transfer to Sanofi or its
Affiliate any and all Manufacturing Technology necessary to enable Sanofi or its Affiliate or sublicensee to Manufacture Product in accordance with the Product Specifications and (ii) otherwise provide Sanofi or its Affiliate the technology
transfer services described in Section 6.6(c) reasonably necessary to enable Sanofi or its Affiliate or sublicensee to Manufacture and supply Product in accordance with Product Specifications. At Sanofi’s request, MannKind shall promptly
provide to Sanofi copies of all agreements between MannKind or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply of any Raw Materials used in or in connection with the Products in the Territory. Upon a
Trigger Event or exercise of the Sanofi Option, MannKind shall promptly and reasonably cooperate to assist Sanofi in obtaining the benefits of any Third Party agreements of MannKind relating to the Products (including assisting Sanofi in identifying
and contacting such Third Party suppliers, agreeing to relieve such Third Party suppliers of any exclusivity obligations to MannKind, etc.). For the sake of clarity, the costs incurred by MannKind in performing such activities (i) in the event
of a Trigger Event, shall be borne by MannKind and shall not be reflected in the Paid Price, Estimated COGS and/or Cost of Goods, and shall not be considered Allowable Expenses for purposes of Exhibit B to the License Agreement and (ii) in the
event of the exercise of the Sanofi Option, shall be reimbursed by Sanofi and shall be considered Allowable Expenses for purposes of Exhibit B to the License Agreement. 

(c) Technology Transfer Obligations. MannKind acknowledges and agrees that the technology transfer obligations pursuant to Sections
6.6(a) and 6.6(b) shall include MannKind’s obligation to provide such support, cooperation, consulting, training and assistance as is reasonably requested by Sanofi, including: (i) permitting Sanofi and its representatives to observe the
testing and Manufacture of the Products at the MannKind Facility, (ii) providing reasonable access to and consultation with MannKind personnel and consultants knowledgeable about, trained and experienced in the testing and Manufacture of
Product, (iii) providing, organizing, explaining and interpreting any and all Product testing and/or manufacturing documentation, including, but not limited to, all Testing Technology/Processes and Manufacturing Technology; (iv) assisting
and training Sanofi and its representatives how to select, design, configure, procure, produce, assemble, test, qualify, validate, calibrate, maintain, and operate the testing and Manufacturing processes, equipment and lines for testing and
manufacturing the Products, or otherwise establish testing and Manufacturing operations at the Sanofi Site; (v) teaching Sanofi and its representatives about the MannKind Technology and its use in connection with the testing and Manufacturing
of Products; and (vi) providing reasonable assistance to Sanofi in identifying, contacting and securing supply sources for Insulin and other Raw Materials. 

  
 19. 

 6.7 Manufacturing Rights. 

(a) MannKind acknowledges that the avoidance of shortfalls in the supply of Product in accordance with the purchase orders provided by
Sanofi in accordance with the terms of this Agreement (i.e., on-time delivery in full) is critical and of the essence. Subject to Section 14.1, in the event MannKind anticipates that it will be unable to timely supply to Sanofi, in whole or in
part for any month of the Forecast, all Product requested for any reason (except to the extent knowingly caused by Sanofi), then MannKind shall promptly notify Sanofi in writing of such shortage, or potential shortage, or inability to timely supply
Product and, if possible, the date when MannKind will again be able to supply Product. MannKind will use Commercially Reasonable Manufacturing Efforts to remedy any shortfall of Product as soon as practicable. 

(b) If, at any time during the Term, (A) MannKind notifies Sanofi under Section 6.6(a) that it is or will be unable to supply
sufficient quantities of Product to meet the Forecasts provided by Sanofi for a period of three (3) consecutive months or longer, (B) MannKind has delivered over the immediately preceding twelve (12) months in aggregate less than
ninety-five percent (95%) of the amount of Product specified in purchase orders provided and accepted in accordance with this Agreement by the specified delivery dates, (C) an arbitration panel determines in accordance with
Section 12.2 that MannKind has committed an uncured material breach of this Agreement; or (D) MannKind files for protection under bankruptcy or insolvency laws, makes an assignment for the benefit of creditors, appoints or suffers
appointment of a receiver, administrator, manager, trustee or like official over its property that is not discharged within ninety (90) days, proposes a written agreement of composition or extension of its debts, is a party to any dissolution,
winding-up or liquidation or has any bankruptcy or insolvency petition filed against it which involuntary petition is not discharged within sixty (60) days of the filing thereof or undergoes or suffers any analogous event or process in any
jurisdiction (each of (A) through (D), a “Trigger Event”), then, in each case, in addition to all other remedies available to Sanofi under this Agreement, MannKind shall promptly, at Sanofi’s option: (i) select
a Third Party contract manufacturer reasonably acceptable to Sanofi, and establish at its own cost the capability of such Third Party contract manufacturer to supply adequate quantities of Product to Sanofi on behalf of MannKind, or (ii) allow
Sanofi or its Affiliates or sublicensees to Manufacture Product in the Territory solely for use and sale in the Field in the Territory under the Manufacturing Technology, in order to satisfy Sanofi’s and its Affiliates’ and
sublicensees’ requirements of Product (the “Manufacturing Rights”). MannKind shall provide Sanofi with written notice of its ability to recommence Manufacturing and supplying Sanofi with its requirements of Product no
less than six (6) months in advance, and the Parties shall discuss in good faith the conditions under which the Third Party contract manufacturer, or Sanofi as the case may be, shall continue to Manufacture certain quantities of the Product in
order to maintain Product Manufacturing expertise. For the sake of clarity, MannKind shall solely bear one-hundred percent (100%) of all costs and expenses incurred by MannKind and/or Sanofi in connection with the establishment of the
replacement source(s) of supply and associated supply chain described in this Section 6.7(b) (and such costs and expenses shall not be reflected in the Paid Price, Estimated COGS and Cost of Goods), but MannKind shall not be responsible for
costs that would otherwise be included in Cost of Goods or for any capital expenditures incurred by Sanofi, its Affiliates, its sublicensees or Third Parties in connection with the establishment of alternate Manufacturing locations under this
Section 6.7(b). 

  
 20. 

 (c) Notwithstanding any other provision of this Agreement to the contrary and without
limiting MannKind’s performance of its obligations pursuant to this Agreement (including Section 6.7(b)), if MannKind fails to deliver at least ninety-five percent (95%) of Sanofi’s deliveries by or within ten (10) days
after the delivery date specified on the applicable purchase order, subject to the tolerances set forth in Section 3.4 (the “Grace Period”), then, in each case, unless otherwise agreed by Sanofi in writing, MannKind
shall pay Sanofi liquidated damages in an amount equal to one-half of one percent (0.5%) of the amounts due per unit of Product that MannKind failed to deliver for each day after the Grace Period that such delivery is delayed (up to a maximum of ten
percent (10%)). 
 ARTICLE 7 

REGULATORY 
 7.1
Regulatory Compliance. MannKind shall comply with all regulatory requirements with respect to Product imposed by Applicable Laws upon MannKind as the Manufacturer of Product. MannKind shall also provide, upon request by Sanofi, information
concerning its production processes and quality control procedures with respect to Product. MannKind acknowledges and agrees that (a) it is MannKind’s sole responsibility and obligation to obtain and maintain all drug or device master
files relating to Product in the United States; (b) it is MannKind’s sole responsibility and obligation to use Commercially Reasonable Manufacturing Efforts to obtain all drug or device master files relating to Product for each relevant
jurisdiction in the Territory other than the United States, and (c) it is MannKind’s sole responsibility and obligation to maintain all obtained drug or device master files relating to Product for each relevant jurisdiction in the
Territory other than the United States. MannKind represents and warrants that at the time of Manufacture of Product, the MannKind Facility shall have all approvals required from the FDA or any other Regulatory Authority or otherwise required by
Applicable Laws. If MannKind receives a notice or request from the FDA or any other Regulatory Authority relating to the Manufacture of Product, then MannKind shall promptly (and in any event within five (5) business days of receipt of such
notice or request) provide a copy of such notice or request to Sanofi. MannKind shall provide Sanofi with a copy of any response or other communication of MannKind to the FDA or any other Regulatory Authority and shall take into account any
reasonable requests of Sanofi with respect to revisions or changes thereto. 
 7.2 FDA and Regulatory Support. MannKind will provide
Sanofi and its Affiliates with necessary information and data regarding the Manufacture of Product to the extent necessary for Sanofi and its Affiliates to prepare and defend any inquiries from the FDA or other Regulatory Authorities to satisfy
regulatory requirements with respect to Product in the Territory. 
 7.3 Regulatory Authorities’ Right of Inspection. MannKind
shall permit authorized officials of any Regulatory Authorities or other competent Governmental Authority to inspect its facilities, including the equipment used in the Manufacturing, testing, and shipping or receiving of Product, as required or
necessary for the granting or maintaining of any Marketing Approval or compliance with Applicable Law. Prior to any such inspection, MannKind shall 

  
 21. 

 
notify Sanofi and Sanofi shall have the right to have its representatives present during such inspections. 

7.4 cGMP Compliance and QA Audits. Upon no less than sixty (60) days’ advance written notice to MannKind, Sanofi shall have
the right to have representatives visit the MannKind Facility and any other locations at which any Manufacturing activities are undertaken, in each case, during normal business hours to discuss any related issues with MannKind’s Manufacturing
and management personnel and to review and inspect (a) MannKind’s Manufacturing and storage facilities, (b) the quality control procedures, and/or (c) any records and reports pertinent to the Manufacture, disposition or transport
of Product as may be necessary to evidence MannKind’s compliance with all applicable Marketing Approvals for the Manufacture of Product, including compliance with cGMP. Such visits shall occur no more than once per year, except in the case of
audits by Sanofi that are required by Applicable Laws, and except that additional visit(s) may occur in the event of shortages, significant deviations, quality problems or recalls requiring resolution by the Parties. Sanofi shall also have the right
to be present at audits and inspections conducted by MannKind of its Third Party manufacturer(s) and Raw Materials suppliers, and MannKind shall give Sanofi thirty (30) days’ notice of such audits and inspections. Sanofi representatives
will be advised of the confidentiality obligations of Sanofi under this Agreement and will follow such security, safety and facility access procedures as are reasonably designated by MannKind and its Third Party manufacturer(s) and suppliers, as
applicable. MannKind shall provide to Sanofi any audit reports generated by or prepared for MannKind in the conduct of any inspections or audits, which reports shall be deemed Confidential Information of MannKind. Each Party’s costs in
conducting inspections or audits under this Section 7.4 shall be borne by the respective Party and shall be considered Allowable Expenses for purposes of Exhibit B to the License Agreement. 

7.5 Recall of Product. For any Product, in the event that: (a) any Regulatory Authority in the Territory issues a request,
directive or order that Product be recalled or retrieved; (b) a court of competent jurisdiction orders that Product be recalled or retrieved; or (c) Sanofi reasonably determines, after reasonable, good faith discussion with MannKind, that
Product should be recalled or retrieved, Sanofi shall promptly notify MannKind of such event (to the extent time allows) and shall conduct such activity and take appropriate corrective actions, and MannKind shall provide such assistance to Sanofi as
is reasonably necessary to carry out such activities. All reasonable costs and expenses of such recall and corrective actions shall be equitably allocated between the Parties taking into account the relative fault of Sanofi and the relative fault of
MannKind. 
 7.6 Compliance with Laws. MannKind shall comply with all Applicable Laws in performing its obligations under this
Agreement. MannKind represents and warrants to Sanofi that it has and will maintain during the Term all government permits, including, health, safety and environmental permits, necessary for the conduct of the actions and procedures that it
undertakes pursuant to the Agreement. 
 7.7 Documentation. MannKind shall keep complete, accurate and authentic accounts, notes, data
and records of the work performed under this Agreement (including batch records) and shall maintain complete and adequate records pertaining to the methods and facilities used for the Manufacture, processing, testing, packing, labeling, holding and

  
 22. 

 
distribution of a Product in accordance with Applicable Laws so that such Product may be used in humans. 

7.8 Samples. MannKind shall retain samples of each batch of Product for a period equal to the Product shelf life plus one (1) year
(or, if longer, the minimum period required by Applicable Law) after Sanofi’s acceptance of such Product. 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party, as of the Effective Date, as follows:

 (a) Duly Organized. Such Party is a corporation duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to
have such would prevent such Party from performing its obligations under this Agreement. 
 (b) Due Authorization; Binding
Agreement. The execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary corporate action. This Agreement is a legal and valid obligation binding on such Party and enforceable in accordance
with its terms and does not: (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over such Party; nor
(ii) conflict with, or constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound. 

(c) Consents. Such Party has obtained, or is not required to obtain, the consent, approval, order or authorization of any Third Party,
or has completed, or is not required to complete any registration, qualification, designation, declaration, or filing with, any Regulatory Authority or governmental authority, in connection with the execution and delivery of this Agreement and the
performance by such Party of its obligations under this Agreement. 
 (d) No Conflicting Grant of Rights. Such Party has the
right to grant the licenses and rights as contemplated under this Agreement and has not, and will not during the Term, grant any right to any Third Party which would conflict with the licenses and rights granted to the other Party hereunder. 

 8.2 Product Warranty. MannKind represents and warrants that Product delivered hereunder will (a) be Manufactured by
MannKind in accordance with all applicable Marketing Approvals, cGMPs and other Applicable Laws, (b) conform to Product Specifications at the time of delivery, (c) not be adulterated or mislabeled under Applicable Laws, (d) at the
time of delivery, be free and clear of any lien or encumbrance, (e) be supplied in accordance and compliance with the Quality Agreement, and (f) meet quality and purity characteristics that it purports or is represented to possess through
its assigned expiry date. Sanofi’s remedies and MannKind’s liability with respect to this warranty are set forth in Section 5.3 and as otherwise 

  
 23. 

 
expressly set forth in this Agreement. In no event shall any failure to comply with any representation or warranty in this Section 8.2 that is caused by or results from any failure of
Insulin supplied by Sanofi or its Affiliate to conform to any representations and warranties in the supply agreement for such Insulin, including the failure of such Insulin to conform to the specifications therefor, be deemed a breach of these
representations and warranties or entitle Sanofi to any remedy or subject MannKind to any liability under this Agreement. 
 8.3 No
Debarred or Disqualified Persons. MannKind represents and warrants that it shall not employ, contract with, or retain any person directly or indirectly to perform any services under this Agreement if such a person (a) is under investigation
by the FDA for debarment or is presently debarred by the FDA pursuant to 21 U.S.C. § 335a or its successor provisions or by the applicable Regulatory Authority in any country or jurisdiction in the Territory outside the United States under
comparable regulations, or (b) has a disqualification hearing pending or has been disqualified by the FDA pursuant to 21 C.F.R. § 312.70 or its successor provisions or by the applicable Regulatory Authority in any country or jurisdiction
in the Territory outside the United States under comparable regulations. In addition, MannKind represents and warrants that it has not engaged in any conduct or activity which could lead to any of the above-mentioned disqualification or debarment
actions. If, during the Term, MannKind or any person employed or retained by it to perform under this Agreement (i) comes under investigation by the FDA or by the applicable Regulatory Authority in any country or jurisdiction in the Territory
outside the United States for a debarment action or disqualification, (ii) is debarred or disqualified, or (iii) engages in any conduct or activity that could lead to any of the above-mentioned disqualification or debarment actions,
MannKind shall immediately notify Sanofi of same. 
 8.4 Insulin Supply. MannKind represents and warrants that it has provided Sanofi
with a true and complete (except with respect to redactions of confidential information) copy of MannKind’s binding and enforceable supply agreement for purchase of Insulin from Amphastar (the “Amphastar API Supply
Agreement”). MannKind shall not, without the prior written approval of Sanofi (in its sole discretion), terminate, amend or otherwise modify the Amphastar API Supply Agreement in any manner that would reasonably be expected to result in
the decrease (annually or in the aggregate) in the amount of Insulin supplied to MannKind thereunder. 
 8.5 Disclaimer. EXCEPT AS
EXPRESSLY SET FORTH IN THIS AGREEMENT OR THE LICENSE AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY
AND OF FITNESS FOR A PARTICULAR PURPOSE OR USE, NON- INFRINGEMENT, VALIDITY AND ENFORCEABILITY OF PATENTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF PRODUCT. 

8.6 Limitation of Liability. EXCEPT FOR LIABILITY FOR PAYMENTS IN ACCORDANCE WITH ARTICLE 4 AND LIABILITY FOR BREACH OF ARTICLE 9,
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN 

  
 24. 

 
CONNECTION WITH THIS AGREEMENT OR ANY LICENSE OR RIGHT GRANTED HEREUNDER; provided, however, that this Section 8.6 shall not be construed to limit either Party’s indemnification
obligations with respect to Third Party Claims under Article 11. 
 ARTICLE 9 

CONFIDENTIALITY 

Confidential Information shall be treated in accordance with Article 8 of the License Agreement. 

ARTICLE 10 
 TERM AND
TERMINATION 
 10.1 Term. This Agreement shall commence on the Effective Date and shall continue until the expiration or
termination of the License Agreement in its entirety unless this Agreement is terminated earlier pursuant to Section 10.2 (the “Term”). 

10.2 Early Termination. The Parties may terminate this Agreement in its entirety before the end of the Term as follows: 

(a) by mutual written agreement of the Parties; or 

(b) upon written notice to the other Party if such other Party is in material breach of this Agreement and has not cured such breach
within ninety (90) days (forty-five (45) days with respect to any payment breach) after notice from the terminating Party requesting cure of the breach. Any such termination shall become effective at the end of such ninety (90) day
(forty-five (45) days with respect to any payment breach) period unless the breaching Party has cured any such breach or default prior to the end of such period. 

10.3 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected
and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. 

10.4 Effect of Expiration or Termination; Surviving Obligations. 

(a) Effect of Termination. Upon termination or expiration of this Agreement all rights and obligations of the Parties under this
Agreement shall terminate. 
 (b) Return of Confidential Information. Within thirty (30) days following the expiration or
termination of this Agreement, each Party shall deliver to the other Party any and all Confidential Information of such Party then in its possession, except for one copy which may be kept in such Party’s counsel’s office for archival
purposes and except to the extent a Party retains the right to use such Confidential Information pursuant to any license granted under the License Agreement which survives termination or expiration of the License Agreement, as applicable. 

  
 25. 

 (c) Survival. Expiration or termination of this Agreement shall not relieve the Parties of
any rights or obligation accruing prior to such expiration or termination. In addition, upon expiration or termination of this Agreement, all rights and obligations of the Parties under this Agreement shall terminate, except those described in the
following Articles and Sections: Articles 1, 9, 12 and 14 and Sections 4.2, 4.4, 7.7, 7.8, 8.5, 8.6, 10.3, 10.4, 11.1, 11.2 and 11.3, which sections and Articles shall survive in accordance with their terms. 

10.5 Exercise of Right to Terminate. The rightful use by either Party hereto of a termination right provided for under this Agreement
shall not, in itself, give rise to the payment of damages or any other form of compensation or relief to the other Party with respect thereto. 

10.6 Damages; Relief. Subject to Section 10.5 above, termination of this Agreement shall not preclude either Party from claiming
any other damages, compensation or relief that it may be entitled to upon such termination. 
 10.7 Rights Upon Bankruptcy. The
Parties acknowledge and agree that for purposes of the Bankruptcy Laws, this Agreement and the License Agreement shall be deemed to be one integrated whole agreement and shall therefore be subject to the provisions of Section 13.4 of the
License Agreement, which is incorporated herein by reference. 
 ARTICLE 11 

INDEMNIFICATION 
 11.1
Indemnification of MannKind. Sanofi shall indemnify and hold harmless each of MannKind and its Affiliates and the directors, officers, shareholders and employees of such entities and the successors and assigns of any of the foregoing (the
“MannKind Indemnitees”), from and against any and all losses, liabilities, damages, penalties, fines, costs and expenses (including reasonable attorneys’ fees and other expenses of litigation)
(“Losses”) from any claims, actions, suits or proceedings brought by a Third Party (“Third Party Claims”) incurred by any MannKind Indemnitee, arising from, or occurring as a result of: (a) gross
negligence or willful misconduct in connection with Sanofi’s performance of its obligations or exercise of its rights under this Agreement; or (b) any material breach of any representations, warranties or covenants by Sanofi under this
Agreement, except to the extent such Third Party Claims fall within the scope of the indemnification obligations of MannKind set forth in Section 11.2. 

11.2 Indemnification of Sanofi. MannKind shall indemnify and hold harmless each of Sanofi and its Affiliates and the directors, officers
and employees of such entities and the successors and assigns of any of the foregoing (the “Sanofi Indemnitees”), from and against any and all Losses from any Third Party Claims incurred by any Sanofi Indemnitee, arising
from, or occurring as a result of: (a) gross negligence or willful misconduct in connection with MannKind’s performance of its obligations or exercise of its rights under this Agreement; or (b) any material breach of any
representations, warranties or covenants (including a failure to timely supply all required quantities ordered in accordance with the terms of this Agreement) by MannKind under this Agreement, except to the extent such Third Party Claims fall within
the scope of the indemnification obligations of Sanofi set forth in Section 11.1. 

  
 26. 

 11.3 Procedure. Any of the MannKind Indemnitees or Sanofi Indemnitees, as applicable, that
intends to claim indemnification under this Article 11 (the “Indemnitee”) shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party Claim, in respect of which the
Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof. The indemnity arrangement in this Article 11 shall not apply to amounts paid in settlement of any action with
respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after
the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 11 if and to the extent the Indemnitor is actually prejudiced thereby. The Indemnitee shall
cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification. 

11.4 Insurance. Each Party, at its own expense, shall maintain appropriate general liability insurance and product liability insurance
with respect to its activities under this Agreement in an amount consistent with industry standards during the Term. MannKind agrees that Sanofi may satisfy its obligations under this Section 11.4 through self-insurance. 

ARTICLE 12 
 DISPUTE
RESOLUTION AND GOVERNING LAW 
 12.1 Disputes. In the event of any dispute arising out of or relating to this Agreement or either
Party’s rights or obligations hereunder, except as otherwise provided in this Agreement, the Party wishing to invoke dispute resolution proceedings shall send to the other Party, in accordance with the notice provisions set forth in
Section 14.8, a written notice of dispute indicating that such notifying Party wishes to invoke such negotiations pursuant to this Section 12.1 and that sets out in reasonable detail the claims asserted, the nature of the dispute, any
facts that are or are not in dispute, and the intended treatment and effect of such pending dispute (“Notice of Dispute”). The Parties shall, through their respective executive officers, first meet and attempt to resolve the
dispute in face-to-face negotiations. Unless otherwise agreed in writing by the Parties, this meeting shall occur within fifteen (15) days after either Party provides such notice of dispute to the other Party. If the Parties are unable to
resolve such dispute through such negotiations within the earlier of (x) sixty (60) days after the meeting referenced in this Section 12.1 or (y) sixty (60) days after receipt of the Notice of Dispute (or such longer period
agreed in writing by the Parties) (“Arbitration Deadline”), then, except in the case of a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright, or (b) any
antitrust, anti-monopoly or competition law or regulation, whether or not statutory, the dispute shall be resolved by binding arbitration in accordance with Section 12.2. 

12.2 Arbitration. Any disputes to be resolved by binding arbitration pursuant to Section 12.1shall be resolved in accordance with
the rules of conciliation and arbitration of the International Chamber of Commerce of Paris by a panel of three (3) independent and neutral experienced arbitrators, one (1) chosen by MannKind, one (1) chosen by Sanofi, and the third
(3rd) chosen by the foregoing two (2) arbitrators (with such third acting as the chairperson of the panel). The place of arbitration shall be New York, New York. Any arbitration shall be 

  
 27. 

 
conducted in the English language and the arbitrators shall use the governing law provided for in Section 12.4. The arbitration panel shall issue its decision and award by reasoned, written
decision within one (1) year after appointment of the chairperson of the arbitration panel. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Except to
the extent necessary to confirm or enforce an award or as may be required by law, neither a Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both MannKind and Sanofi. In
no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. Each Party shall bear its
own attorneys’ fees, costs and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators; provided, however, that the arbitrators shall be authorized to determine whether a Party
is the prevailing Party, and if so, to award to that prevailing Party reimbursement for the fees and costs of the arbitrators. Each Party agrees to fully perform and satisfy any arbitration award made against it within fifteen (15) days of the
service of the award. The taking of evidence in the arbitration shall be guided by the International Bar Association’s 2010 Rules on the Taking of Evidence in International Commercial Arbitration (“IBA Guidelines on
Evidence”); provided, however, that the arbitrators shall permit such pre-hearing discovery and such presentation of evidence at any Evidentiary Hearing (as defined in the IBA Guidelines on Evidence) as, in each case, is
reasonably necessary for a full and fair understanding and resolution of any legitimate issue raised in the arbitration. The arbitration panel shall ensure that document disclosures are conducted on a timely basis. By agreeing to this binding
arbitration provision, the Parties understand that they are waiving certain rights and protections which may otherwise be available if a dispute between the Parties were determined by litigation in court, including the right to seek or obtain
certain types of damages precluded by this provision, the right to a jury trial, certain rights of appeal and a right to invoke formal rules of procedure and evidence. For the sake of clarity, any disputes that arise under both this Agreement and
the License Agreement may be consolidated in a single arbitration. Any settlement discussions or arbitration proceedings occurring under this Agreement shall be conducted in strict confidence. Except as necessary to enforce an award or as required
by law, no information or documents produced, generated or exchanged in connection with settlement discussions or arbitration proceedings (including any award(s) that might be rendered by the arbitration panel) shall be disclosed to any person other
than counsel without the prior written consent of all Parties to the settlement or arbitration proceedings. This restriction shall not apply to public records or other documents obtained by the Parties in the normal course of business independent of
any settlement discussions or arbitration proceedings. 
 12.3 Court Actions. Nothing contained in this Agreement shall deny either
Party the right to seek, upon good cause, injunctive or other equitable relief from a court of competent jurisdiction in the context of an emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any
ongoing dispute resolution discussions or arbitration proceedings. 
 12.4 Governing Law. This Agreement, and all questions regarding
the existence, validity, interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law
principles with the exception of sections 5-1401 and 5-

  
 28. 

 
1402 of New York General Obligations Law. The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. 

ARTICLE 13 
 INSULIN PUT
OPTION 
 For purposes of this Article 13, the following terms shall have the following meanings: 

“[...***...] Insulin” means (i) [...***...], and
(ii) [...***...]. 
 “Put Closing Date(s)” means the date(s) that occur (i) thirty (30) days
following delivery of the Insulin Exercise Notice by MannKind for [...***...] Insulin [...***...], and, if applicable, (ii) thirty (30) days following [...***...]. 

13.1 If this Agreement expires or terminates because the License Agreement is terminated by MannKind pursuant to Section 12.2 or
12.4 thereof, or by Sanofi pursuant to Section 12.3(a) thereof, MannKind shall have the option (the “Insulin Put Option”), exercisable by providing written notice (the “Insulin Exercise Notice”)
to Sanofi within thirty (30) days following the effective date of such expiration or termination, to sell to Sanofi, and if such option is exercised by MannKind, Sanofi shall purchase, the lesser of (i) 65% of each lot of [...***...]
Insulin, at the [...***...] (“Insulin Price”) and (ii) such equal percentage of each lot of [...***...] Insulin representing an Insulin Price of US$50 million in the aggregate, at the Insulin Price. For the
avoidance of doubt, in no event shall the aggregate Insulin Price payable by Sanofi pursuant to MannKind’s exercise of the Insulin Put Option exceed US$50 million. 

13.2 The closing of the transactions contemplated above shall occur on each Put Closing Date. The sale shall be Ex Works (INCOTERMS
2010) and upon each Put Closing Date MannKind shall make the purchased Insulin available to Sanofi at the location at which it is stored. 

ARTICLE 14 
 GENERAL
PROVISIONS 
 14.1 Intervening Events. If the performance of any part of this Agreement by either Party (other than making
payment when due) is prevented, restricted, interfered with or delayed by any reason or cause beyond the reasonable control of such Party (including: fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism,
strike, lockout or 

  
 ***Confidential Treatment
Requested 
 29. 

 
other labor disturbance (save where such strike, lockout, or other labor disturbance is initiated by the employees of the Party which seeks to rely on this clause), acts of God or any acts,
omissions or delays in acting of the other Party) (an “Intervening Event”), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such Intervening Event,
provided that the affected Party shall use its substantial efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. If either Party becomes aware that such an
Intervening Event has occurred, is imminent or likely, it will immediately notify the other Party. The Party which is subject to such Intervening Event shall exert all reasonable efforts to overcome it. Such Party will keep the other informed as to
the progress of overcoming such Intervening Event. 
 14.2 Waiver of Breach. The failure of either Party at any time or times to
require performance of any provision of this Agreement shall in no manner affect its rights at a later time to enforce such rights. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or
continuing waiver of such condition or term or of another condition or term. 
 14.3 Performance by Affiliates. To the extent that
this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligation. Either Party may use one or more of its Affiliates to perform its obligation hereunder, provided that the Parties will
remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder. 
 14.4 Modification. No
amendment or modification of any provision of this Agreement shall be effective unless in a prior writing signed by both Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of
dealing or performance or any other matter not set forth in an agreement in writing and signed by both Parties hereto. 
 14.5
Severability. In the event any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate, in good faith and enter into a valid, legal and enforceable substitute provision that
most nearly reflects the original intent of the Parties. All other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or
enforceability of such provision in any other jurisdiction. 
 14.6 Entire Agreement. This Agreement (including the Schedules attached
hereto and any letter delivering information referenced herein) and the License Agreement (including the Exhibits attached thereto) constitute the entire agreement between the Parties relating to the subject matter hereof and thereof and supersede
and cancel all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof and thereof. Each of the Parties acknowledges and agrees that in
entering into this Agreement, and the documents referred to in it, it does not rely on, and shall have no remedy in respect of, any statement, representation, warranty or understanding (whether negligently or innocently made) of any Person (whether
party to this Agreement or not) 

  
 30. 

 
other than as expressly set out in this Agreement or the License Agreement. Nothing in this clause shall, however, operate to limit or exclude any liability for fraud.

14.7 Language. The language of this Agreement and all activities to be pursued under this Agreement is English. Any and all documents
proffered by one Party to the other in fulfillment of any provision of this Agreement shall only be in compliance if in English. Any translation of this Agreement in another language shall be deemed for convenience only and shall never prevail over
the original English version. This Agreement is established in the English language. 
 14.8 Notices. Any notice or communication
required or permitted under this Agreement shall be in writing in the English language, delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by
internationally-recognized courier or sent by registered or certified mail, postage prepaid to the following addresses of the Parties (or such other address for a Party as may be at any time thereafter specified by like notice): 

 

			
	 To MannKind:
  

MannKind Corporation
 28903 North Avenue Paine

Valencia, California 91355 USA
 Telephone: (661) 775-5300

Facsimile: (661) 775-2086
 Attention: General Counsel
	  	 To Sanofi:
  

Sanofi
 c/o Genzyme

500 Kendall Street
 Cambridge, MA 02142

Telephone: +1 617 768 6527
 Facsimile: +1 617 252 7600.

Attention: Vice President, Corporate
 Business
Development

		
	 with a copy to:
  

Cooley LLP
 4401 Eastgate Mall

San Diego, CA 92121
 Telephone: (858) 550-6000

Facsimile: (858) 550-6420
 Attention: L. Kay Chandler,
Esq.
	  	 with a copy to:
  

Sanofi
 54 Rue La Boétie, 75008

Paris, France
 Telephone: +33 1 53 77 90 24

Facsimile: +33 1 53 77 43 03
 Attention: General
Counsel

 Any such notice shall be deemed to have been given: (a) when delivered if personally delivered;
(b) on the next Business Day after dispatch if sent by confirmed facsimile or by internationally-recognized overnight courier; and/or (c) on the third Business Day following the date of mailing if sent by mail or nationally recognized
courier. Notices hereunder will not be deemed sufficient if provided only between or among each Party’s representatives on the JAC. 

14.9 Assignment. This Agreement shall not be assignable, pledged or otherwise transferred, nor may any right or obligations hereunder be
assigned, pledged or transferred, by 

  
 31. 

 
either Party to any Third Party without the prior written consent of the other Party, which consent, in the event of a financing transaction by the Party asking for consent, shall not be
unreasonably withheld, conditioned or delayed by the other Party; except either Party may assign or otherwise transfer this Agreement without the consent of the other Party to an entity that acquires all or substantially all of the business or
assets of the assigning Party relating to the subject matter of this Agreement, whether by merger, acquisition or otherwise; provided that intellectual property rights that are owned or held by the acquiring Person to such transaction (if other than
one of the Parties to this Agreement) shall not be included in the technology licensed hereunder. In addition, either Party shall have the right to assign or otherwise transfer this Agreement to an Affiliate upon written notice to the non-assigning
Party; provided, however, the assigning or transferring Party shall continue to remain liable for the performance of this Agreement by such Affiliate, and, prior to the Effective Date, Sanofi may assign this Agreement to any Affiliate.
Nothing herein shall be deemed to prohibit MannKind or any of its Affiliates from granting a security interest in this Agreement and any rights hereunder to any Third Party in connection with any financing transaction to the extent provided under
(and subject to the restrictions on the rights of secured parties contained in) Sections 9-406 and 9-408 of the New York Uniform Commercial Code. In addition,
MannKind or any Affiliate of MannKind shall have the right to sell, assign, pledge or otherwise transfer any accounts and payment intangibles (each as defined under the New York Uniform Commercial Code but including, for the avoidance of doubt,
rights to payment of MannKind pursuant to Articles 4 and 13) in connection with any financing transaction. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and permitted assigns. Any assignment of
this Agreement in contravention of this Section 14.9 shall be null and void. 
 14.10 No Partnership or Joint Venture. Nothing in
this Agreement or any action which may be taken pursuant to its terms is intended, or shall be deemed, to establish a joint venture or partnership between Sanofi and MannKind. Neither Party to this Agreement shall have any express or implied right
or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party. 

14.11 Interpretation. The captions to the several Articles and Sections of this Agreement are not a part of this Agreement but are
included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression;
(b) the word “or” means “and/or” unless the context dictates otherwise because the subjects of the conjunction are mutually exclusive; (c) the words “herein,” “hereof” and “hereunder” and
other words of similar import refer to this Agreement as a whole and not to any particular Article or Section or other subdivision; (d) references in this Agreement to “days” shall mean calendar days; (e) the singular shall
include the plural and vice versa; and (f) masculine, feminine and neuter pronouns and expressions shall be interchangeable. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under IFRS,
or if not defined by IFRS, the meaning applied to it by Sanofi in preparing its publicly reported financial statements, in each case, consistently applied, but only to the extent consistent with its usage and the other definitions in this Agreement.

  
 32. 

 14.12 Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in
any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or
facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party. 
 14.13
MannKind Third Party Manufacturer. The Parties acknowledge and agree that MannKind may, with the prior written approval of Sanofi (such approval not to be unreasonably withheld, conditioned or delayed), use Third Party manufacturers to
Manufacture and supply Product under this Agreement and that the terms “MannKind shall” or “MannKind will” or the like, shall be deemed to be followed by the words “or MannKind’s designated Third Party manufacturer
will” or “or “MannKind’s designated Third Party manufacturer shall” or “MannKind shall require that its designated Third Party manufacturer shall” or the like, with respect to MannKind’s Manufacturing and
supply obligations herein. For the avoidance of doubt, no Third Party Manufacturing (other than Third Party Manufacturing as described in the Regulatory Filing on the Execution Date) shall be deemed to have been agreed upon by Sanofi by the sole
virtue of this Article, and any additional Third Party manufacturer shall be subjected to the rules as set forth in the remainder of this Agreement, and the Quality Agreement. In the event that MannKind uses Third Party manufacturers to Manufacture
and supply Product under this Agreement, MannKind shall be responsible for the performance of this Agreement by such Third Party manufacturers. 

[SIGNATURE PAGE FOLLOWS] 

  
 33. 

 IN WITNESS WHEREOF, the Parties have executed
this Supply Agreement as of the Execution Date. 
 SANOFI-AVENTIS DEUTSCHLAND GMBH 

 

			
	By:	 	 /s/ Siregar

	Name:	 	Siregar
	Title:	 	VP HR Sanofi Germany
		
	By:	 	 /s/ ppa. Bergmann

	Name:	 	Bergmann
	Title:	 	Head of Finance

 [SIGNATURE PAGE TO SUPPLY
AGREEMENT] 

 IN WITNESS WHEREOF, the Parties have executed
this Supply Agreement as of the Execution Date. 
 MANNKIND CORPORATION 
  

			
	By:	 	 /s/ Matthew J. Pfeffer

	Name:	 	Matthew J. Pfeffer
	Title:	 	CFO

 [SIGNATURE PAGE TO SUPPLY
AGREEMENT] 

 SCHEDULE A 

ESTIMATED COGS 
 (From
the Effective Date until December 31, 2015) 
  

									
	 Estimated Annual Volume (total cartridges, in millions)
	 	
Cost in US$ per thousand cartridges for all such cartridges

	 	 4U cartridges
	 	 8U cartridges
	 	 12U cartridges
	 	 16U cartridges

	 Less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 Notes: 
 In Calendar Year 2015,
the Estimated COGS assumes [...***...] per gram Insulin. 

  
 ***Confidential
Treatment Requested 

 SCHEDULE B 

COGS CAP 
 For purposes of determining
Paid Price, the COGS Cap for a specified dosage strength shall be the sum of (i) the cost of Insulin, which is determined by multiplying the weighted average price of Insulin in US Dollars per gram (as specified in Section 4.1(b)(i)) for
the applicable Calendar Year by the yield and potency factor set forth in Table B-1; and (ii) the corresponding amount set forth in Table B-2 contained in the volume band corresponding to the Estimated Annual Volume. 

For purposes of determining Cumulative COGS, the COGS Cap shall be the aggregate sum for all dosage strengths of (i) the cost of Insulin, which is
determined by multiplying the weighted average price of Insulin in US Dollars per gram (as specified in Section 4.1(b)(i)) for the applicable Calendar Year by the yield factors set forth in Table B-1; and (ii) the corresponding amounts set
forth in Table B-2 contained in the volume band corresponding to the actual total volume of cartridges for the applicable Calendar Year. 
 Table B-1: 

 

									
	 	  	 Insulin cost per thousand cartridges for all such
cartridges

	  	 4U cartridges
	  	 8U cartridges
	  	 12U cartridges
	  	 16U cartridges

	 At all volumes
	  	Insulin Price x [...***...]	  	Insulin Price x [...***...]	  	Insulin Price x [...***...]	  	Insulin Price x [...***...]

  
 ***Confidential
Treatment Requested 

 Table B-2 
 If
Sanofi terminates this Agreement pursuant to Section 10.2(b) hereof, or the License Agreement pursuant to Section 12.2(a) or (b) thereof, the applicable annual volume used in computation of the COGS Cap shall be equal to the actual
volume for such portion of the applicable Calendar Year divided by the number of days elapsed in the applicable Calendar Year prior to the effective date of such termination multiplied by 365. 

 

									
	 Annual volume (total cartridges for all dosages, in millions)*
	  	 Maximum cost, not including Insulin, in $US
per
thousand cartridges for all such cartridges

	  	 4U
	  	 8U
	  	 12U
	  	 16U

	 Less than [...***...] million
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  
 ***Confidential
Treatment Requested 

									
	 Equal to or greater than [...***...] but less than [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

  

	*	For the avoidance of doubt, any Product which is ordered by Sanofi in accordance with the terms of this Agreement but not delivered by MannKind in a timely fashion (for whatever reason) shall be included for purposes of
calculating the annual volume of cartridges. 

  
 ***Confidential
Treatment Requested 

 SCHEDULE C 

SAMPLE COGS CALCULATIONS 
 Example 1.
Determining Insulin cost 
  

																	
	 	  	Insulin cost per thousand cartridges for all such cartridges	 
	  	4U cartridges	 	  	8U cartridges	 	  	12U cartridges	 	  	16U cartridges	 
	 At all volumes
	  	 
 	Insulin Price x
[...***...]	  
  	  	 
 	Insulin Price x
[...***...]	  
  	  	 
 	Insulin Price x
[...***...]	  
  	  	 
 	Insulin Price x
[...***...]	  
  
	 Weighted average Insulin price of $[...***...] per gram
	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  
	 Weighted average Insulin price of $[...***...] per gram

(i.e., [...***...])
	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  
	 Weighted average Insulin price of $[...***...] per gram

(i.e., [...***...])
	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  	  	$	 [...***...]	  

 Example 2 Determining the COGS Cap for purposes of Paid Price: 

Estimated Annual Volume = [...***...] 
 Weighted average
Insulin price: $ [...***...] 
 For 4U cartridges: $ [...***...] (per thousand) 

For 8U cartridges: $ [...***...] (per thousand) 

  
 ***Confidential
Treatment Requested 

 Example 3. Determining the COGS Cap for purposes of Cumulative COGS 

Actual total volume = [...***...], of which [...***...] were 4U and [...***...] were 8U.

 Weighted average Insulin price: $ [...***...] 
  

			
	For 4U cartridges:	  	$ [...***...] (per thousand)
		  	$ [...***...]
		
	For 8U cartridges:	  	$[...***...] (per thousand)
		  	$ [...***...]

 Cumulative COGS cannot exceed $ [...***...]. 

Example 4. True-Up 
 Actual total volume =
[...***...], of which [...***...] were 4U and [...***...] were 8U. 
 Weighted average insulin price: $[...***...] 

Cumulative COGS Cap: $[...***...] (from Example 3) 
 A.
If Cumulative COGS < Cumulative Price Paid 
  

			
	For 4U Cartridges (per thousand):
	Price Paid:	  	$[...***...]
	Actual COGS:	  	$[...***...]
		
	For 8U Cartridges (per thousand):	  	
	Price Paid:	  	$[...***...]
	Actual COGS:	  	$[...***...]

 Cumulative Price Paid: $[...***...] 

Cumulative COGS = $[...***...] (< Cumulative COGS Cap of $[...***...]) 

MannKind True-Up Payment to Sanofi: $[...***...] 

B. Cumulative Price Paid < Cumulative COGS < COGS Cap 

For 4U Cartridges (per thousand): 
 Price Paid: $[...***...]

 Actual COGS: $[...***...] 

  
 ***Confidential
Treatment Requested 

			
	For 8U Cartridges (per thousand):
	Price Paid:	  	$[...***...]
	Actual COGS:	  	$[...***...]

 Cumulative Price Paid: $[...***...] 

Cumulative COGS = $[...***...] (< Cumulative COGS Cap of $[...***...]) 

Sanofi True-Up Payment to MannKind: $[...***...] 

C. Cumulative Price Paid < Cumulative COGS but Cumulative COGS > COGS Cap 

 

			
	For 4U Cartridges (per thousand):
	Price Paid:	  	$[...***...]
	Actual COGS:	  	$[...***...]
	
	For 8U Cartridges (per thousand):
	Price Paid:	  	$[...***...]
	Actual COGS:	  	$[...***...]

 Cumulative Price Paid: $[...***...] 

Cumulative COGS = $[...***...] (> Cumulative COGS Cap of $[...***...]) 

Sanofi True-Up Payment to MannKind: $[...***...] 

Example 5. Effect of inflation on calculation of COGS Cap 

CPI increase during 2015 – 4% 
 CPI increase during 2016
– 3% 
 Insulin ceiling price in Section 4.1(b)(i)(B) for 2017 = $[...***...] 

Insulin ceiling price in Section 4.1(b)(i)(C) for 2017 = $[...***...] 
  

									
	 Annual volume (total cartridges for all dosages, in millions)
	  	
Maximum cost, not including Insulin, in $US per thousand
cartridges for all such
cartridges

	  	 4U
	  	 8U
	  	 12U
	  	 16U

	 Equal to or greater than [...***...] but less than [...***...]
	  	$[...***...]	  	$[...***...]	  	$[...***...]	  	$[...***...]

  
 ***Confidential
Treatment Requested 

 Example 6 Calculation of Price per SKU 

If an SKU contains [...***...] cartridges of “4U” and [...***...] cartridges of “8U”, then the price applied during the
Calendar Year for that SKU shall be [...***...] times the Paid Price of one “4U’ cartridge plus [...***...] times the Paid Price of one “8U” cartridge. 

  
 ***Confidential
Treatment Requested 

 SCHEDULE D 

CAPA OBLIGATIONS 
 [...***...] 

  
 ***Confidential
Treatment Requested 

 SCHEDULE E 

INITIAL FORECAST 
 [...***...] 

  
 ***Confidential
Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]